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ABSTRACT

MODELING AND PREDICTION OF AMORPHOUS SOLID DISPERSION
FORMATION USING A MOLECULAR DESCRIPTOR

By
Kevin DeBoyace
May 2019

Dissertation supervised by: Peter L.D. Wildfong, Ph.D.
Poor aqueous solubility of an active pharmaceutical ingredient (API) is a significant
hurdle during drug development. Delivering a drug in its amorphous solid-state is a
potential method to overcome this issue, since the amorphous form has increased apparent
aqueous solubility. However, the amorphous state is only metastable, and is
thermodynamically driven to recrystallize. As a result, pure amorphous drugs are seldom
used in marketed products. Intimately mixing a drug in its amorphous form with a polymer,
known as an amorphous solid dispersion (ASD), has the potential to significantly extend
the physical stability of the amorphous form, while maintaining the benefit of increased
apparent solubility. However, ASDs remain poorly understood. As a result, ASDs are
primarily developed using a trial and error approach, resulting in increased costs and
extended time to market. A method for predicting the probability of successful formation

iv

of intimate mixtures of drug and polymer without recrystallization (a.k.a. dispersability)
has the potential to reduce costs, shorten development time, and advance scientific
understanding of ASDs.
The central hypothesis of this work is that there exists a combination of materials
properties that correlates with the probability that an ASD will form in PVPva. Since
molecular descriptors are mathematical representations of properties of a molecule, it is
hypothesized that they can be successfully applied to predict the formation of amorphous
solid dispersions. Specifically, the molecular descriptor R3m was investigated as a tool for
the prediction of ASD formation. The work presented herein addresses 3 primary aims: (1)
investigating the statistical validity of the model by expanding the model to include 2
preparation methods and 2 concentrations, (2) advancing the understanding of the
physicochemical meaning of the R3m descriptor to improve the interpretability of the
descriptor, and (3) investigating the relationship between R3m and solubility.
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Chapter 1. Introduction
1.1. Statement of Problem
Overcoming limitations associated with the poor aqueous solubility of an active
pharmaceutical ingredient (API) is a significant hurdle during drug development. Poor
aqueous solubility will result in drug dissolution limitations and, therefore, limitations to
bioavailability. Delivering a drug in its amorphous solid-state is a potential method to
ameliorate this issue, since the amorphous form increases the apparent aqueous solubility
of the drug. However, amorphous solids are metastable and thermodynamically driven to
recrystallize. As a result, pure amorphous drugs are seldom used in marketed products.
Intimately mixing a drug in its amorphous form with a polymer, known as an amorphous
solid dispersion (ASD), has the potential to significantly extend the physical stability of
the amorphous form, while maintaining the benefit of increased apparent solubility.
ASDs represent an important formulation strategy for addressing poor aqueous
solubility of API. It is estimated that approximately 40% of highly potent compounds fail
to reach clinical trials owing to their inability to dissolve well in aqueous media, 1 and
approximately 50% of new drug candidates require formulation help to improve solubility
and delivery.2 ASDs have the potential to increase the apparent solubility of a drug, while
also increasing the physical stability relative to the pure component amorphous drug
substance.
Although ASDs were introduced to pharmaceutical drug delivery more than 50 years
ago,3 their formation and physical stability remains poorly understood,4 with only a few
specific exceptions. Proposed stabilizing mechanisms include API crystallization
1

inhibition5 and anti-plasticization effects that reduce molecular mobility,6 while
dispersions are generally thought to form as the result of specific non-covalent bonding
interactions between drug and polymer carrier, such as hydrogen-bonds.7,

8

Presently,

reliable prediction of ASD formation and persistence is not possible, and, therefore,
requires experimental confirmation. As a result, ASD formulation development must often
be performed using trial-and-error, which can result in significantly increased development
costs and delays to market. The challenges imposed by this formulation strategy are evident
from the relatively few commercially available ASDs.9 Models that can assist with rational
selection of excipients for ASD formulations are desirable for improvement of formulation
development, reduction of costs, and reduced time to market.

1.2. Literature Review
1.2.1.

Methods for Improving Aqueous Solubility

A large portion of newly developed drug candidates have poor aqueous solubility, and
several formulation strategies (both chemical and physical) have been developed in an
attempt to increase solubility. These include the use of salt forms, particle size reduction,
higher energy polymorphs,10 co-crystallization,11 and amorphous solid molecular
dispersions. However, there is no universally applicable method for increasing solubility,
and each of these strategies has potential pitfalls.
Formulation of salt forms is not always practical, and if they are synthesized, they may
undergo reconversion to their acid or base forms, resulting in no significant benefit in
dissolution rate.12 Additionally, potassium and sodium salts may react with atmospheric

2

carbon dioxide and water to precipitate out as their original parent compounds, especially
in the outer layer of a dosage form, resulting in reduced rates of dissolution.13 Particle size
reduction will increase API solubility due to the increased surface area of the drug crystals.
However, improvement in apparent solubility via reducing particle size has practical
limitations, not the least of which is the minimum size to which a particle can be reduced
relative to the energy input from comminution equipment.14 Also, small particles can have
a negative impact on downstream unit operations (owing to their poor flow, poor
wettability, etc.). Additionally, mechanical force may induce solid state phase
transformations such as polymorphism (e.g., as seen in chlorpropamide15) or
amorphization,16 which may result in poor control over the final solid form of the API, and
subsequent undesirable batch-to-batch variability in dissolution rate and/or bioavailability.
High energy polymorphs of the API of interest will also yield solubility benefits due
to a reduction in the number of non-bonded interactions. However, the application of
metastable polymorphs is limited to those that are sufficiently kinetically stable over a
pharmaceutically relevant timescale.
Co-crystallization has the potential to yield increases in solubility while maintaining
thermodynamic stability and potentially avoiding issues associated with polymorphic
transformations. But, co-crystallization can also lead to deteriorated pharmaceutical
properties in some cases (e.g., further decrease in solubility) and may exhibit its own
polymorphism.11
Formulations that use the amorphous form of a drug have many challenges, but there
has been increased interest in this approach owing to the approval of several formulations
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by the FDA.17 In addition, solid dispersions may be beneficial over some other techniques
due to lower manufacturing costs and smaller pill burden.4

1.2.2.

Amorphous Solid Dispersions

1.2.2.1.

Brief History

Amorphous solid dispersions are intimate mixtures of polymer and API that increase
apparent aqueous solubility via inhibition of crystallization. The historical background of
solid dispersions is laid out well in the review article by Chiou and Riegelman.13 Briefly,
a unique technique for preparation of dispersions of small particles in an inert matrix was
demonstrated by Sekiguchi and Obi in 1961. They prepared eutectic mixtures by melting
and rapidly cooling binary mixtures.3 This resulted in a significant increase in drug delivery
from this mixture as compared to the crystalline form of the API alone. This premise was
later extended to the preparation of glasses due to the even greater increase in solubility
offered by the amorphous form.18

1.2.2.2.

Manufacturing Methods

Methods for preparation of amorphous solid dispersions include melting, solvent
evaporation, and the melting-solvent method.13 The melting-solvent method involves
dissolving the API in a suitable solvent followed by mixing with a molten polymer. This
method is less popular in the literature due to limitations in drug loading and concerns
about the inclusion of solvent in the final formulation. This approach will, therefore, not
be discussed further in this document.

4

The melting method is performed by co-melting the polymer and API at a temperature
above the API melting temperature and above the polymer glass transition temperature
and/or melting temperature (if applicable). After melting, the liquid mixture is rapidly
cooled so that the API is kinetically unable to nucleate and grow in its crystal form. In
contrast, the solvent method requires dissolution of the API and polymer in a common
solvent followed by rapid evaporation of that solvent. As with the melt quench method,
rapid evaporation and subsequent solidification reduces the likelihood of nucleation and
subsequent growth of crystals.
It is important to note that while both the solvent and melting methods may be used to
formulate an amorphous dispersion, there is evidence to suggest that the resulting
formulations are not completely molecularly similar. It has been proposed that thermal
history is an important determinant of the physical properties of the resulting amorphous
dispersion.19 Differences in experienced stresses are thought to result in different enthalpic
states. Additionally, it is reasonable to expect dissimilarity between preparation methods
due to the introduction of a ternary component in solvent evaporation. A change in the
number of molecular interactions occurring as a result of the presence of a solvent could
result in differences in the final state of the dispersion.
It has been shown that preparation method can have a significant impact on the
resulting solid.20-23 In addition to these concerns, certain small molecules may be more
amenable to certain manufacturing methods. For example, if the compound is thermally
labile, a solvent evaporation method would be more suitable. Conversely, if the compound
is not sufficiently soluble in preferred organic solvents, a melt method may be preferable.
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1.2.2.3.

Miscibility, Solubility, and Dispersability

Dispersability is defined herein as the successful formation of an ASD by intimate
mixing of API and polymer followed by co-solidification without crystallization.
Miscibility is defined as a mixture of drug and polymer “consisting of a single chemically
homogeneous phase where all of the components are intimately mixed at the molecular
level, and the properties of the blend are different from the properties of the pure
components.”
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The important distinction between dispersability and miscibility is a

consequence of: (1) the analytical limitations inherent to the detection of phase separation
and (2) the thermodynamics of the system (miscibility) versus the kinetics (dispersability).
The current analytical limitations make it difficult to definitively identify the presence
of a homogeneous system. For example, differential scanning calorimetry (DSC) is
commonly used to assess miscibility, but Utracki et al. point out that “a single Tg is not a
measure of miscibility, but only of the state of dispersion.”24 Phase separation may still
occur over time. Additionally, it may not be possible to detect phase separation for domains
<30 nm, or when the glass transitions of the pure components are within 10°C of each
other.25 Even heating the sample during DSC can result in changes to miscibility that may
be misinterpreted as representing the initial physical state of the sample (see Chapter 3).
Another example of an analytical limitation can be seen in powder x-ray diffraction
(PXRD). This method can be used to detect the lack of an ordered crystalline phase, but
will not be able to determine if a system is phase separated without more advanced data
analysis. One such advanced method is pair distribution function (PDF) analysis, which
can be applied to assess changes in the fingerprint of interatomic distances for co-solidified
mixtures compared to the amorphous pure components.26 However, this method will be
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more sensitive as higher energy x-rays are employed, such as a synchrotron source, which
is not routinely available to research labs. Copper anodes, which are most popular for
laboratory x-ray diffractometers, may not always generate PDF data that contain enough
information to be definitive.27 The application of a suite of analytical techniques will
increase the certainty of conclusions.28 However, there is currently no analytical method
which can definitively detect phase separation in every case.
The distinction between solubility and miscibility has been reviewed by Qian et al,4
and is illustrated in Figure 1 which is adapted from the same. The solid red line represents
the crystalline API solubility in the polymer, whereas the dashed blue line indicates the
amorphous API-polymer miscibility.
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Figure 1: Theoretical figure illustrating both drug-polymer solubility and miscibility.
(Adapted from the Journal of Pharmaceutical Sciences, Vol 99(7), F. Qian, J. Huang, M.
A. Hussain., Drug–Polymer Solubility and Miscibility: Stability Consideration and
Practical Challenges in Amorphous Solid Dispersion Development, Pages No. 2941-2947,
Copyright 2010, with permission from Elsevier).4 Zones I and II indicate
thermodynamically stable mixtures, Zones III and IV indicate meta-stable zones, and
Zones V and VI are unstable zones where recrystallization is certain within a timeframe
dictated by the molecular mobility of mixtures.

Solubility is defined as the analytical composition of a saturated solution, where the solid
and solubilized form of a molecule are in equilibrium.29 Solubility is perhaps most
commonly applied in pharmaceutical science to assess the amount of drug that will dissolve
in a particular volume of a solvent such as water. It is also possible for a polymer to dissolve
a drug to some extent when in the liquid state. The API is often considered the ‘solvent’ in
this case, merely because of its smaller size. This API-polymer solubility is indicated by
the red solid line in Figure 1. This line indicates a boundary between a thermodynamically
stable state and a thermodynamically metastable state.
8

The equilibrium associated with miscibility is given by Equation (1), and the
IUPAC definition for miscibility is given in Equation (2).29 Miscibility describes the
successful formation of a homogenous phase through liquid-liquid mixing;30 specifically
in this document the liquid-liquid mixing of polymer and amorphous API.
(1)

APIamorphous + Polymeramorphous ⇌ API/Polymeramorphous,homogenous phase
∂2 ΔGmix

(

(2)

∂ϕ2

)

>0

T,p

The blue dashed line boundary corresponding to the amorphous API-polymer miscibility
is a boundary between a thermodynamically metastable state and an unstable state, where
eventual recrystallization is certain.4 This boundary also represents conditions where
Equation (2) is equal to zero.
The application of miscibility in this context comes from polymer physics, where
the individual components are generally stable in the amorphous state. The application of
the concept to systems in which the thermodynamically stable state is crystalline (i.e., API),
results in added complexity.4 A thermodynamically stable state will be achieved in Zones
I and II shown in the figure, a meta-stable state occurs in Zones III and IV, and an unstable
or crystallized co-solidified mixture in Zones V and VI. It is important to note that this
figure is theoretical, and measurements of solubility and miscibility at temperatures below
the Tg cannot be obtained experimentally, and, therefore, can only be estimated through
extrapolation.4 Methods for such extrapolations will be discussed in more detail in Chapter
7.
As stated above, dispersability is defined here as the successful formation of an
amorphous solid dispersion by intimate mixing with a carrier polymer, followed by cosolidification without recrystallization. Both miscibility and solubility lack a clear physical
9

meaning below the glass transition temperature of the system because increasing viscosity
prohibits the system from reaching equilibrium.4 Also noted above, the extrapolation of
miscibility to lower temperatures is only theoretical. Dispersability differs from these
equilibrium states because it is expected to also encapsulate kinetic factors. While
miscibility and solubility refer to equilibrium states, dispersability may also capture
important factors that occur during formation of the solid binary mixtures. For example, a
system that is expected to phase separate and/or crystallize based on inferences about the
equilibrium state could remain dispersed due to rapid solidification.

1.2.2.4.

Predicting dispersability

Currently there is no proven, rapid, and cost-effective way to assess the dispersability
of API in polymers. As a result, determinations of dispersability have been primarily
performed by trial-and-error.
Some current research has been focused on streamlining component screening for
amorphous solid dispersions. Shanbhag et al. developed an automated screening method
using 96-well plates to screen an API against 6 polymers and 8 surfactants to identify leads
for solid dispersion formulations.31 However, screening was performed using the solvent
method while melt extrusion was the unit operation of interest for manufacturing at large
scale. As noted previously, potential differences in molecular interaction between these
methods would suggest that the solvent method may be inappropriate for predicting
performance of the melt method. Verma and Rudraraju developed a systematic four-phase
approach to formulation design of amorphous solid dispersions.32 They detail a stepwise
method for assessment of API, screening against polymers, prediction of miscibility, and
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confirmation of predictions. While their method is thorough and useful for development of
amorphous solid dispersions, it is time consuming and requires a significant amount of
drug for testing. Typically during early pre-formulation studies gram quantities of API are
often scarce, presenting a limitation to industrial application of this work.
Predictions related to what is defined herein as dispersability have been relatively
infrequent in the literature. Existing research tends to be more focused on the development
of models to assess and predict miscibility or solubility in amorphous solid dispersions,
with the goal of predicting the physical stability of dispersed mixtures. For example,
Marsac et al. used the Flory-Huggins theory (a lattice based solution model they applied to
amorphous solid dispersions) and interaction parameters to predict drug-polymer
miscibility.30 A thermodynamic model was developed to estimate solubility of API in
polymer. In a separate study, Vasanthavada et al. studied solid dispersions of trehalosedextran and trehalose-PVP. They used modulated DSC to observe the phase separation of
components over time until equilibrium was reached, based on the consistent glass
transition value. This equilibrium point was believed to indicate the extent of molecular
miscibility.33 Additional detail about the above methods, as well as other methods for
predicting dispersability, are discussed in more detail in Chapter 2.
These papers also focus mainly on the thermodynamic stability of amorphous
dispersions and, in general, do not consider kinetic stability. Kinetics may inhibit phase
separation and crystallization, since the molecular mobility in the solid state is greatly
reduced. As a result, it may be possible to maintain a homogeneous phase over
pharmaceutically relevant time scales without the need for a thermodynamically stable
system. As a result, predictions of the ability of drugs to disperse in polymer systems,
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regardless of solubility of API in polymer, may be more useful for formulation
development.
The research detailed in this dissertation describes the expansion of a previously
identified model for the prediction of dispersability in a specific polymer using a molecular
descriptor, including a detailed investigation into the meaning of that descriptor. This work
builds toward a broader research goal of building a formulation development tool for
ASDs. Such a tool is envisioned in Figure 2, where an appropriate polymer could be rapidly
identified for a new chemical entity (NCE), with material-sparing experimentation.
Additional molecular descriptors could be identified in the future that predict dispersability
in other polymers. Such a formulation development tool could aid ASD development by
reducing experimental burden, time to market, and development costs.

Figure 2: Envisioned formulation tool to speed development of ASDs. Future work could
also focus on applying molecular descriptors to create models for predicting long-term
physical stability of ASDs.

1.3. Molecular Descriptors
Molecular descriptors were developed as a tool enabling indirect association of
molecular structure with properties of interest,34 and are the basic means for transforming
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chemical information into a numerical code for application in quantitative structureproperty relationship (QSPR) modeling.35 A fundamental assumption of QSPR is that the
structure of a molecule is responsible for the physical, chemical, and biological properties
of that molecule.35 Since chemical and physical properties have been shown to be important
for the formation and stability of ASDs, it is herein posited that molecular descriptors may
be useful for prediction of dispersability. The potential usefulness of molecular descriptors
is supported by their application in other areas of pharmaceutical research, including drug
discovery,36-38 formulation screening,39-43 and amorphous systems.16,

44-47

These

applications are discussed in more detail in Chapter 2.
The application of molecular descriptors to aid formulation development of ASDs
was proposed in 2011, where Moore and Wildfong48 showed that a single molecular
descriptor (R3m) was predictive of dispersability for a 15-member API library in poly(1vinylpyrrolidone-co-vinyl acetate) (also known as PVPva or copovidone49) prepared by
melt-quenching (M/Q) at a fixed drug loading (75% w/w). While these initial results were
promising (see Figure 3), there remained uncertainty with respect to the general
applicability and limitations of the model. The original model was built by screening over
1400 molecular descriptors using a relatively small dataset, potentially leading to a type 1
error owing to multiple comparisons.50 Further model testing was necessary to strengthen
the statistical power. Additionally, specific questions related to how changes in API
concentration and changes in manufacturing method could impact the model led to the
experiments proposed in this dissertation. For example, decreasing the API concentration
in a co-solidified mixture may result in a reduction in the degree of supersaturation, or
perhaps even result in a miscible system. This would decrease the thermodynamic driving
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force of the API to recrystallize, and thereby increase the likelihood that it would be
dispersable in PVPva. These changes have the potential to impact the model, and therefore,
are of interest.

Figure 3: Logistic regression model showing that R3m is predictive of API (75%w/w)
dispersability in PVPva.48 Red triangles indicate data used to build the model, while yellow
squares indicate 3 compounds used to test the model.

R3m is a member of the GETAWAY (GEometry Topology and Atom Weights
AssemblY) class of descriptors, whose calculation utilizes three-dimensional molecular
geometry, topology, and chemical information.51 Equation (3), below, describes the
calculation of R3m, where A is the number of atoms in the molecule of interest, i and j
refer to two atoms in the molecule, h is the leverage, m is the atomic mass, r is the geometric
distance between atoms, and δ(3;dij) is a Dirac-delta function. For this descriptor, the Diracdelta function results in the consideration of only pairs of atoms where the topological
distance is equal to 3. The descriptor is explained in more detail in Chapter 5.
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R3m = ∑A−1
i=1 ∑j>i

(3)

√hii ∙hjj
rij

∙ mi ∙ mj ∙ δ(3: dij )

Moore & Wildfong noted that increases in R3m corresponded with an increasing
number of electronegative atoms, larger atoms more distant from the geometric center,
and/or intramolecular interactions between atoms having a topological distance equal to
three.48 However, a clear physicochemical relationship between the R3m descriptor and
dispersability was not readily apparent from the 2011 work. Uncertainty about the
physicochemical meaning of the R3m descriptor is, therefore, also a primary driving force
for the experiments proposed herein.

1.4. Hypothesis & Research Objectives
The central hypothesis of this research is that there exists a combination of materials
properties that correlates with the probability that an amorphous dispersion will
form in PVPva. Molecular descriptors, which are mathematical representations of
properties of a molecule, can be used to predict the formation of amorphous solid
dispersions.
The following specific aims are proposed to investigate this hypothesis:
1. Confirm the usefulness of the R3m descriptor.
While the results of the study described by Moore and Wildfong48 were promising,
there remained uncertainty with respect to the model’s general applicability and
limitations. The original model was built by screening over 1400 molecular descriptors
using a relatively small dataset, potentially leading to a type 1 error due to multiple
15

comparisons.50 Further testing is necessary to strengthen the model’s statistical power.
Additionally, specific questions related to how changes in API concentration and changes
in manufacturing method could impact the model led to the experiments proposed herein.
The goal of specific aim I is to confirm or refute the general applicability of this molecular
descriptor toward the prediction of ASD formation. This specific aim will be primarily
covered in Chapter 4.

2. Improve the interpretability of the model.
It has been argued that the usefulness of molecular descriptors is not limited to cases
for which they are easily interpretable.35 However, a model which is both interpretable and
effective is preferable. The goal of this specific aim was to confirm that no simpler, more
interpretable model predicting dispersability of API in PVPva exists, and to advance the
understanding of why the R3m descriptor does predict dispersability.
Molecular descriptors are derived from a representation of a molecule, where it is
assumed that similar molecular structures have similar physical and chemical properties.
Therefore, molecular descriptors that can successfully predict dispersability may point
toward a physical and/or chemical property that is of importance for dispersability. While
a molecular descriptor may allow for rapid assessment of dispersability potential of an API
with a particular polymer, identification of a specific physical and/or chemical property
that is important for dispersability will advance scientific understanding of useful APIpolymer interactions. Data analysis and results associated with this specific aim will be
covered in Chapter 5 and Chapter 6.
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3. Investigate the relationship between R3m and the experimentally determined solubility
of select API in PVPva.
Ultimately, the formation of ASDs can be attributed to the thermodynamic stability
and/or the kinetic stability of the mixture. For a soluble system, the API and polymer can
form a solid solution that will remain stable indefinitely. Likewise, a miscible system can
remain stable barring nucleation, or changes in temperature or pressure.
However, it is also possible that the mixture may remain stable for pharmaceutically
relevant timescales owing to kinetic effects such as anti-plasticization and/or physical
barriers to API nucleation and crystallization due to the presence of polymer. The goal of
specific aim III is to experimentally determine if the usefulness of the R3m descriptor is
specifically associated with the solubility of the API in PVPva. This specific aim will be
discussed in Chapter 7.
As briefly discussed earlier in this chapter, there has been much interest in predicting
the solubility and/or miscibility of ASD systems to aid drug development. Before
investigating a new method for predicting dispersability, it is necessary to review the
literature to understand the strengths and weaknesses of existing methods. The existing
methods for modeling and prediction of the formation of ASDs will be discussed in more
detail in the next chapter (Chapter 2).
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Chapter 2. Review: The Application of Modeling
& Prediction to the Formation of Amorphous
Solid Dispersions
As discussed in Chapter 1, the goal of the research described in this dissertation is
to further develop and refine the understanding of a model that predicts ASD formation in
PVPva. It is, therefore, important to review the scientific literature for existing methods of
prediction. This chapter will review the existing methods for modeling and prediction of
ASD formation, describe and discuss literature important to the field, and convey the
limitations of each method of prediction.

2.1. Introduction
Amorphous solid dispersion (ASD) formulation development is frequently difficult
owing to the inherent physical instability of the amorphous form, and limited understanding
of the specific physical and chemical interactions that enable the initial formation of
dispersions, setting up their long-term physical stability. ASD formulation development
has been historically accomplished through trial-and-error or experience with extant
systems; however, rational selection of appropriate excipients is preferred to reduce time
to market and decrease costs associated with development. Current efforts to develop
thermodynamic and computational models attempt to rationally direct formulation and
show promise. This chapter describes and evaluates important methods used to predict
ASD formation and physical stability, which include recent applications of solubility
parameters (SP) and the Flory-Huggins interaction parameter (FHIP) to amorphous and
18

ASD formulations. Additionally, newly emerging computational techniques and their
applications to ASD formulation development are examined. Recent literature in which
these methods are applied is also reviewed, and limitations of each method are discussed.

2.2. Solubility Parameter
2.2.1.

Theory

2.2.1.1.

Hildebrand Solubility Parameter

The solubility of components in a mixture is favorable if the thermodynamic free
energy of mixing (Δ𝐺𝑚𝑖𝑥 ) is negative.52

(4)

ΔGmix = ΔHmix − TΔSmix

In liquid mixtures, the entropy of mixing (Δ𝑆𝑚𝑖𝑥 ) is generally positive due to increasing
system disorder brought about by the increased numbers of available interactions. The
system enthalpy can have the greatest impact on solubility, since a large positive value
makes mixing unfavorable. In an ideal solution, the enthalpy of mixing (Δ𝐻𝑚𝑖𝑥 ) is zero
since the adhesive interactions equal the cohesive interactions. This assumption requires
that the solvent and solute molecules have essentially the same size, shape and chemical
nature,53 and can be mathematically represented by the geometric mean assumption:

(5)

U12 = √U11 U22
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where 𝑈 is the potential energy of the cohesive (𝑈11 , 𝑈22 ) and adhesive forces (𝑈12 ).
Cohesive forces are required for a condensed phase, and the presence of interactions such
as London dispersion forces, polar interactions, and hydrogen-bonds results in a decrease
in the potential energy of molecules relative to the vapor phase.54 Enthalpic deviations from
ideality are captured by the solubility parameter, the detailed derivation of which is found
elsewhere.54-56
The solubility parameter was defined by Hildebrand57 as the square root of the
cohesive energy density (CED), often referred to as the ‘Hildebrand solubility parameter’
or ‘total solubility parameter.’ The enthalpy of mixing is related to the solubility parameter
using the equation proposed by Hildebrand and Scott,58

ΔE

ΔHv −RT

δ = √CED = √ M v = √

(6)

v

ΔHmix

(7)

Mv

Mv

= ϕ1 ϕ2 (δ1 − δ2 )2

where subscripts 1 and 2 refer to the components of the mixture, ϕ is the volume fraction,
R is the gas constant, T is the absolute temperature, δ is the solubility parameter, Ev and
Hv are respectively the free energy and enthalpy of vaporization, and Mv is the molar
volume. A slightly positive or negative Δ𝐻𝑚𝑖𝑥 is required for solubility, where an upper
limit is imposed by a positive Δ𝑆𝑚𝑖𝑥 . Equation (7) suggests that two liquids having similar
δ will have a low Δ𝐻𝑚𝑖𝑥 , and therefore, form a miscible system. Several assumptions
regarding the relationship between Δ𝐻𝑚𝑖𝑥 and the Hildebrand solubility parameters are
required, and discussed in detail elsewhere.52, 54, 58 Perhaps most deleterious for application
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to pharmaceutically relevant materials is the geometric mean assumption, in which polar
and specific interactions are neglected,54 limiting the usefulness of the Hildebrand
solubility parameter to nonpolar systems. Nevertheless, extension of solubility parameter
theory has received considerable interest in pharmaceutical development, and applications
specific to ASDs are reviewed herein.

2.2.1.2.

Hansen Solubility Parameters

Three-dimensional solubility parameters (also known as Hansen or partial
solubility parameters) separate the total solubility parameter into parts that describe
dispersion forces (𝛿𝑑 ), polar forces (𝛿𝑝 ), and hydrogen-bonding forces (𝛿ℎ ).59

δ2t = δ2d + δ2p + δ2h

(8)

The Hansen solubility parameter more practically estimates solvent miscibility because of
its explicit inclusion of different interactions. These values can be visualized as a point in
three-dimensional space enclosed by a sphere containing miscible solvents, where each
axis corresponds to one of the partial solubility parameters (𝛿𝑑 , 𝛿𝑝 , 𝛿ℎ ).60 As the balanced
values of the partial solubility parameters of two liquids approach each other in this threedimensional space, their miscibility is expected to increase because of their increasing
similarity. However, since this sphere is obtained from experimental data, and not
thermodynamic considerations, there is no rule-of-thumb for a radius having a particular
magnitude that universally identifies liquids that will be miscible and those which will
not.56, 60
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A common two-dimensional visualization plots the hydrogen-bonding term against
the polar term, owing to the relatively low significance of the term describing dispersion
forces.60 A combination of dispersion and polar terms has also been proposed based on
their similarity, and is known as the volume dependent solubility parameter (𝛿𝑣 ).61

δv = √δ2d + δ2p

(9)

A two-dimensional Bagley plot considers 𝛿ℎ versus 𝛿𝑣 , which approximately delimits
miscible solvents by a circle52 rather than a sphere. Additional extensions or expansions of
both the Hildebrand and Hansen SPs have been proposed,62-64 but are less often applied in
pharmaceutical systems, and therefore, beyond the scope of this chapter.

2.2.1.3.

Group Contribution Methods

Miscibility assessment based on the chemical structures of the compounds of interest
avoids time consuming, and potentially imprecise experimental determination of the SP.56,
61, 65, 66

Group contribution (GC) methods for estimating 𝛿 were first proposed by Small,67

and allow estimations of the solubility parameter by summing molar attraction constants
based on an atomic or constitutive basis. GC methods used to calculate solubility parameter
values are relatively easy to use, and a number of approaches have been developed. The
most frequently used are those by Fedors,66 which either predicts the total solubility
parameter or the molar volume, and those by Hoy68 and Hoftyzer and Van Krevelen52, 69 to
predict either the Hansen or total solubility parameters.
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2.2.2.

Application to Amorphous Solid Dispersions

The application of solubility parameters in the pharmaceutical industry was reviewed
nearly two decades ago by Hancock et al.,65 and described their use in aiding dosage form
design via the prediction of relevant properties. Since 1997, the application of solubility
parameters to identify a thermodynamically stable mixture of drug and polymer has
continued.
In a study by Greenhalgh et al.,70 GC methods were applied to determine Hildebrand
solubility parameters, and miscibility predictions were compared with experimental results
compiled from several other studies. The authors noted a strong link between larger
differences in solubility parameters and incompatibility of API and carriers,70 and
suggested categorizations to aid miscibility predictions. A Δ𝛿 ≤ 7√𝑀𝑃𝑎 was identified as
a cutoff for miscibility, while Δ𝛿 > 10√𝑀𝑃𝑎 was expected to indicate immiscibility.
These conclusions were supported by Mohammad et al.71 when applied to co-crystal
formation, wherein it was observed that the value of Δ𝛿 for compounds that formed cocrystals with piroxicam and carbamazepine was generally below 7 √𝑀𝑃𝑎.71 Greenhalgh
and colleagues did note that Hildebrand parameters do not inform specific types of
interactions between mixture components.70 In particular, the exclusion of hydrogenbonding from Hildebrand parameters may limit the applicability of proposed
categorizations for pharmaceutically relevant systems. The authors also identified the lack
of a clear relationship between phase diagrams and Δ𝛿,70 suggesting that the method fails
to be predictive of solubility over all concentrations.
Although it was noted that Hansen parameters may be better for ASD predictions,
Greenhalgh et al. suggested that their practical application may be constrained by limited
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data for many pharmaceutically relevant structural groups.70 Expanding interest in ASDs
has resulted in some further development of GC tables, including prediction of Hansen
parameters for pharmaceutically relevant compounds.72 Because of current limitations,
however, Greenhalgh et al. used different GC methods to calculate the total solubility
parameters. In some instances, there were insufficient data for specific functional groups
using the Fedors GC method (e.g., amide and sulfone groups70), so the authors applied the
method of Hoftyzer and Van Krevelen,69 and in some cases Martin.73 While this was
necessary to complete the calculations using available data, this combination of methods
may yield inconsistent results, since values from different sources can vary significantly.54,
74

Specifically, the group contributions published by Fedors have been reported as being

less accurate for the prediction of the cohesive energy.52, 70 Such variation in the calculation
of the solubility parameter could potentially increase the uncertainty in the boundaries
proposed in their work. Nonetheless, this study showed the potential usefulness of the
solubility parameter as a rapid screening method for the selection of carriers in solid
dispersions.70 Although there may be uncertainty in predictions at the boundaries between
miscible and immiscible, solubility parameters could be applied to narrow potential
formulation by rapidly identifying API:polymer combinations having largely different
solubility parameter values.
Forster et al.75 used solubility parameters to predict particular excipient-drug
mixtures suitable for hot melt extrusion (HME), and found that the calculated Δ𝛿 values
could be predictive of miscibility, but recommended a different categorization than
Greenhalgh et al. (see Figure 4).

In their work, Forster et al. used the Hoy and

Hoftyzer/Van Krevelen method to determine the total solubility parameter, but did not
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analyze the Hansen partial solubility parameters (i.e., Δ𝛿𝑑 , Δ𝛿𝑝 , Δ𝛿ℎ ). These individual
differences could potentially be more informative than their total Euclidean distance, since
a one-dimensional comparison is inherently less descriptive than a three-dimensional
comparison. Mohammad et al. applied the Hansen solubility parameters in this way in an
attempt to predict the formation of co-crystals.71 These authors generated a threedimensional plot as well as a Bagley plot, to allow for the independent consideration of the
relative contributions of various types of forces.71 The location of compounds relative to
the reference API (indomethacin) correlated well with experimentally determined
miscibility. A more complete description of the various types of forces may give an
improved description of component similarity, and therefore, improved miscibility
predictions.

Figure 4: Categorizations of miscibility based on differences in Hildebrand solubility
parameter between components, as proposed by Hoftyzer and Van Krevelen,52 Greenhalgh
et al.,70 and Forster et al.75

2.2.3.

Limitations of the Solubility Parameter

Approach
While the solubility parameter can be a useful screening tool for potential carrier
polymers, there are limitations, perhaps the most significant of which is the purely
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thermodynamic foundation of the theory. Solid dispersions are not limited to
thermodynamically stable API:polymer mixtures, as kinetically stable mixtures can be
equally useful for the improvement of apparent aqueous solubility. As such, other attributes
of the dispersion may be important, which may not be captured in a solubility parameter.
For example, the impact of polyvinylpyrrolidone viscosity was shown to reduce the
diffusion of ketoconazole molecules, resulting in increased kinetic stability, even in the
absence of strong specific interactions between the drug and the carrier polymer.6 Failure
to consider such kinetically stable mixtures when making drug development decisions may
inadvertently exclude potentially viable formulations. Likewise, overlooking interactions
not considered by the solubility parameter, such as ionic interactions,9 can also exclude
important excipients.
Despite the original thermodynamic basis of the solubility parameter, few studies
have investigated it as a predictor for long-term physical stability of ASDs. Since a binary
mixture with low Δ𝛿 indicates a favorable free energy of mixing, it is reasonable to expect
that such a mixture would remain stable owing to a reduced thermodynamic drive toward
recrystallization. Yoo et al.76 evaluated the Hildebrand solubility parameter, among other
properties, as a predictor for physical stability of ASDs. While Δ𝛿 correlated well with
initial observations of miscibility, it was not successful for predicting which compounds
remained amorphous after 50 days of storage at 25°C/ 60%RH.76 It is, however, important
to note that the presence of moisture during storage will likely complicate interpretation
owing to the impact of water content on molecular mobility. An assessment of stability in
the absence of moisture may prove to be an important future study to determine if the
solubility parameter can predict the long-term stability of ASDs.
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The solubility parameter method also neglects the entropy of mixing term, which
becomes more important with more complex molecules such as polymers.61 Hansen noted
that entropy factors could affect visualized data in an undetermined manner,60 likely
changing the radius of miscibility, depending on the compounds under consideration. The
impact of temperature is also generally neglected, the importance of which increases as the
melting point of drugs increases, if for example, molten mixtures are created to prepare
ASDs. These terms should be included for a truly ab initio thermodynamic model for the
prediction of API-polymer miscibility.
Hydrogen-bonding forces associated with the Hansen solubility parameter have been
of great interest to the pharmaceutical industry. Alhalaweh et al.77 found a high correlation
between the total solubility parameter and the difference in hydrogen-bonding partial
solubility parameters when comparing indomethacin with 33 other compounds. Likewise,
Albers et al.78 observed that Δ𝛿 was mainly influenced by the difference in hydrogenbonding forces for a set of 15 drug-carrier pairs. However, Hansen solubility parameters
are only semi-empirical,79 having no thermodynamic justification for the separation of the
total solubility parameter into Δ𝛿𝑑 , Δ𝛿𝑝 , and Δ𝛿ℎ . For example, hydrogen-bonding between
API and carrier requires the presence of both hydrogen-bond donors and acceptors,
indicating a requirement for different structural moieties. This is not captured by the Δ𝛿ℎ
term, and was first addressed by Karger et al.,62 where the hydrogen-bonding term was
split into acidic (𝛿𝑎 ) and basic (𝛿𝑏 ) terms based on Lewis acid-base theory, and further
pursued by Beerbower et al.80 and Martin et al.64, 73, 81 Unfortunately, this method is less
often applied due to limited data for relevant functional groups.78

27

It appears that the largest hurdle to the broader application of the solubility parameter
in understanding ASD formulation is the lack of available data for GC methods.
Experimental data is difficult to obtain,52, 54 and performing such experiments for each new
API and excipient is impractical. Nevertheless, the application of solubility parameters to
ASDs has continued. For example, Verma et al.32 more recently recommended using
solubility parameters as part of a systematic approach to ASD formulation design. While
solubility parameters can be useful for the rapid screening of potential excipients for ASD
formulations, inadequacies in the theory often require additional experimental work to
confirm inferences. These shortcomings have led to the development of more complex
models.

2.3. Flory-Huggins Interaction Parameter
2.3.1.

Theory

The Flory-Huggins interaction parameter (FHIP) was developed independently by
Flory82 and Huggins83 for polymer applications, and considers deviations of polymer
solutions from ideality thought to result from the underlying assumptions of entropy in the
ideal case. In a mixture of small molecules, the environment can be approximated by a
lattice, where it is assumed the molecules are interchangeable (i.e., molecules are identical
in size, spatial configuration, and external force field84). As shown in Figure 5, the
connectedness of polymer long-chain molecules invalidates this assumption.84
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Figure 5: Visualization of the liquid lattice theory. (a) Solute and solvent molecules are
assumed virtually identical in size, spatial configuration, and external force field. (b) A
chain polymer occupies the liquid lattice, resulting in changes to configuration entropy.
Adapted from Principles of Polymer Chemistry, by Paul J. Flory. Copyright 1953. Cornell
University and Copyright 1981 Paul J. Flory. Used by permission of the publisher, Cornell
University Press.84

Flory and Huggins adjusted the entropy equation, using the volume fraction in place
of mole fraction to account for the significant size discrepancy between molecules.85
Additionally, the probability that a given lattice point was occupied by a polymer segment
was adjusted (via the enthalpy equation) to account for the connectivity of the chain.86 The
first two terms on the right side of the resulting equation (Equation (10)) are the entropic
component, while the final term is the enthalpic component.

ΔGmix

(10)

RT

= n1 ln ϕ1 + n2 ln ϕ2 + n1 ϕ2 χ

Above, subscript 1 is the solvent, subscript 2 is the solute, ϕ is the volume fraction, n is
the number of moles, R is the gas constant, T is the absolute temperature, and χ is the FHIP.
The interaction parameter is dimensionless, and characterizes the interaction between
polymer segments and solvent molecules.84 The entropic portion of Equation (10) is
relatively fixed due to the high molecular weight of the polymer,85 and thus the FHIP can
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be used to estimate the miscibility. The critical value for 𝜒 is 0.5 when the ratio of polymer
to API volume is large due to the high molar mass of the polymer.56 Miscibility is expected
at values of 𝜒 lower than 0.5, whereas immiscibility is expected above this value.
The FHIP has been experimentally determined using a number of methods including
freezing point depression, boiling point elevation, viscosity, and polymer equilibrium
swelling,56 however, these methods are often difficult to apply for pharmaceutical
materials. As a result, the FHIP method was not widely applied to ASDs until a new method
was proposed by Marsac et al.30

2.3.2.

Application to Amorphous Solid Dispersions

The Flory-Huggins lattice theory is important to ASD systems since it specifically
considers the entropic effect of the polymer. The FHIP also reflects the relative strength of
the cohesive and adhesive interactions of the system, thereby capturing the enthalpic
interactions.30 Although the application of the Flory-Huggins lattice theory to ASDs had
been limited due to experimental challenges, recent advances have aided in the
determination of FHIP, and are discussed below.

2.3.2.1.

Solubility Parameters to Calculate the Flory-Huggins Interaction

Parameter
Approximation of the FHIP using solubility parameters results in Equation (11),
when the previously described geometric mean assumption is applied,56 where Vi is the
volume of the hypothetical lattice site:

30

V

χ = RTi (δi − δj )

(11) Using Hildebrand 𝛿:
Using Hansen 𝛿:

2

V

2

2

2

χ = RTi [(δdi − δdj ) + (δpi − δpj ) + (δhi − δhj ) ]

This method for determining 𝜒 is limited, as described in section 2.3. , but benefits relative
to the solubility parameter alone by including assessment of the entropic contribution and
the effect of temperature on miscibility.
Thakral and Thakral87 investigated a screening tool for ASD formulation
development by determining the Hansen solubility parameter-based FHIP for 83 drugs with
polyethylene glycol (PEG) 6000 and using values of 𝜒 to predict the free energy phase
diagrams for each API. Generally, completely miscible API could not be experimentally
distinguished by thermal analysis from those that were partially miscible,87 however,
immiscible API were differentiable, indicating that the method could be used to rapidly
exclude certain API-excipient combinations (Figure 6).
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Figure 6: (a) Hansen solubility based interaction parameters and their predicted miscibility
with PEG 6000, where 𝜒 < 0.98 was classified as ‘Type I’, 𝜒 = 5.19-28.27 was classified
as ‘Type II’, and 𝜒 = 1.09-4.19 was classified as ‘Type III’. (b) Example free energy phase
diagrams for API which are ‘Type I’ or miscible (green dot-dash line), ‘Type II’ or
immiscible (red dotted line), and ‘Type III’ or partially miscible (yellow solid line) with
PEG. Adapted from the Journal of Pharmaceutical Sciences, Vol 102(7), S. Thakral, N.K.
Thakral, Prediction of drug-polymer miscibility through the use of solubility parameter
based Flory-Huggins interaction parameter and the experimental validation: PEG as model
polymer, Pages No. 2254-2263, Copyright 2013, with permission from Elsevier.87
Although the proposed model is promising, the authors’ experimental investigation
of only 3 compounds suggests that further studies are necessary, particularly in an effort to
better distinguish between partially and fully miscible mixtures. It is also possible that the
use of a 10 °C/min ramp rate for Tm depression analysis, may have contributed to difficulty
in distinguishing between partially and fully miscible mixtures by differential scanning
calorimetry (DSC), owing to the kinetic effects of the polymer on mixing (see section
2.2.3. ). The authors also generated a Bagley plot, which reasonably approximated the
miscibility behavior of the compounds tested,87 and appeared to better separate between
drugs that were partially miscible versus those that were immiscible in PEG 6000 (Figure
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7). While the FHIP allowed the free energy phase diagram to be determined, the results did
not appear to offer significant benefit over the solubility parameter alone, since, at least
with the data presented, the Bagley plot appeared to be equally effective at separating
predictions of partially miscible from fully miscible compounds.

Figure 7: Bagley plot of PEG 6000 with a series of drugs. PEG 6000 is located at the center
of the black dotted circle, and compounds within the radius of the circle are expected to be
miscible with the polymer. The key refers to predictions made using the FHIP. The Bagley
plot appears to offer a better separation between predicted immiscible and partially
miscible compounds. Adapted from the Journal of Pharmaceutical Sciences, Vol 102(7),
S. Thakral, N.K. Thakral, Prediction of drug-polymer miscibility through the use of
solubility parameter based Flory-Huggins interaction parameter and the experimental
validation: PEG as model polymer, Pages No. 2254-2263, Copyright 2013, with
permission from Elsevier.87

2.3.2.2.

Melting Point Depression

Marsac et al. used two methods to investigate application of the Flory-Huggins
lattice theory to the prediction of miscibility for ASDs.30 The first was the solubility
parameter approach described by Equation (11). The second was the melting point
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depression method, which was extended from the polymer literature88 and applied to APIpolymer systems, resulting in Equation (12):

(12)

1

1

R

(Tmix − Tpure ) = − ΔH
m

m

1

fus

[lnϕdrug + (1 − m) ϕpoly + χϕ2poly ]

Above, Tm is the melting point (of the mixture and pure API), R is the gas constant, ΔHfus
is the enthalpy of fusion, ϕ is the volume fraction, and m is the ratio of the volume of
polymer to that of the lattice site.30 Favorable drug-polymer interactions were manifest as
a depression in Tm due to reduced thermodynamic activity of the drug in the presence of
polymer, relative to its pure form. Depression of Tm was experimentally determined for
mixtures of polymer and API at different ratios, using a low ramp rate (1 °C/min) and
controlled particle size (45-75 μm) to reduce kinetic effects. At low polymer volume
fractions, a linear relationship was identified:

(13)

1

1

(Tmix − Tpure ) ∗
m

m

ΔHfus
−R

1

− lnϕdrug − (1 − m) ϕpoly vs. ϕ2poly

Linearity was lost with increasing polymer concentrations owing to the composition
dependence of 𝜒 and the increasingly unfavorable mixing kinetics as the Tm approached Tg
of the polymer.30 Despite this, the method resulted in more reasonable values of 𝜒 relative
to those predicted from the solubility parameter method, when compared to experimental
solubility data for nifedipine in polyvinylpyrrolidone (PVP) monomer solution,30 and
reflects the cohesion from specific interactions such as hydrogen-bonding.
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While this method estimates the FHIP quite well, its application is not without
limitations. The method assumes that thermodynamic mixing occurs over the timescale of
the experiment,85 however, caution may be necessary when evaluating high polymer
concentrations where the increased viscosity can negatively impact mixing kinetics.
Particle size may also have an impact since the intimate contact afforded by increased
specific surface area of smaller particles can decrease Tm. The authors were careful to use
slow DSC heating rates to approximate equilibrium. The most appropriate method for
approaching ‘pseudo-equilibrium’ using DSC remains a topic of debate, and Tm has been
determined using both onset30,

87, 89

and offset30,

90, 91

values. Offset temperatures are

believed to represent more complete molecular mixing, and therefore, may better estimate
Tm of the final mixture.85, 92 With that said, the experimental time required to approximate
equilibrium may be prohibitive for large studies, and an underestimation of Tm depression
is expected. Marsac et al.85 demonstrated kinetic effects on experimental data by showing
a further decrease in Tm when analyzing crystalline felodipine in contact with a molecularlevel dispersion of felodipine:PVP. Since the dispersion had a plasticized Tg relative to the
pure polymer, there was a greater increase in mobility at a lower temperature, allowing
more thorough mixing of crystalline felodipine with the dispersion, compared to polymer
alone. Consequently, this method is most applicable for systems where Tg of the mixture
is sufficiently different from Tm of the drug, with a difference of 20 °C recommended to
facilitate mixing.92
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2.3.2.3.

Recrystallization method

Mahieu et al.93 proposed a method to reduce the time needed to determine the FHIP.
The equilibrium solubility was determined via de-mixing (i.e., induced phase separation),
the kinetics of which were expected to occur more rapidly than dissolution.93 Mixtures
were milled to form supersaturated glass solutions, which were annealed above Tg, causing
supersaturated API to phase separate from the polymer and recrystallize. Samples were
then cooled and reheated to determine Tg, which was subsequently used to predict the
equilibrium solubility via the Gordon-Taylor equation. Experiments at different
concentrations allowed generation of a solubility curve at an estimated ten times faster than
by using the Tm depression method,93 however, this may overestimate method efficiency
since selection of an appropriate annealing temperature required additional experiments.
Figure 8, below, compares this method with the Tm depression method.

Figure 8: Comparison of the (a) melting point depression30 and (b) recrystallization
methods93 for approximating the equilibrium solubility, and subsequently, the interaction
parameter (𝜒).
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It is also important to note that this method assumed that the experimental Tg
accurately predicted the concentration via the Gordon-Taylor equation; yet, the GordonTaylor equation assumes ideal mixing of polymer and API. Deviations can occur, therefore,
if the adhesive and cohesive interactions vary greatly from one another.94, 95 Furthermore,
Knopp et al.95 showed that preparation of supersaturated glass solutions using three
different methods (ball milling, film casting, and spray drying) resulted in methoddependent inconsistencies in predicted equilibrium solubility and variable fit to the FloryHuggins model.
The experimental efficiency offered by this method is appealing, however, it should
be noted that, in order to be quantitative, complete crystallization of the phase-separated
drug is required. If the supersaturated portion of the drug does not fully separate from the
sample, the resulting Tg will be plasticized, and therefore, inexact. In addition, the
recrystallization rate is expected to slow as the concentration of phase separated amorphous
drug molecules decreases, making determination of its end point difficult. If this reduced
rate of crystallization falls below the detection limit of DSC, the equilibrium solubility will
likely be overestimated.92 Moreover, the crystallization tendency of an API (as described
by Baird et al.96 and Van Eerdenbrugh et al.97) may also influence the kinetics of
recrystallization during annealing, making API with a greater tendency to remain
amorphous, less suited to this method.

2.3.2.4.

Solubility in liquid polymer analog

Marsac et al. also investigated the use of a low molecular weight analog of PVP, 1ethyl-2-pyrrolidone, to estimate the solubility of API in that polymer.85 This method
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allowed estimation of 𝜒 at room temperature, while the Tm depression method gave an
estimate of 𝜒 at Tm (Equation (12)). The authors suggested that this solubility value may
be useful since it was less affected by inhibited mixing kinetics, and by the variation in
activity coefficient with temperature and concentration.85 Perhaps the main limitation to
wider adoption of this approach is the availability of liquid polymer analogs. PVP is an
ideal polymer in this respect, since 1-ethyl-2-pyrrolidone is chemically equivalent to the
polymer repeat unit, and the analog is readily available. In contrast, hypromellose acetate
succinate, another common ASD carrier, has heterogeneous chemical substitutions on its
cellulose rings, making it difficult to identify monomers that appropriately emulate the
polymer. Nonetheless, where liquid analogs are available, representative estimates of
thermodynamic solubility in that polymer are possible. For example, Paudel et al.98 used
multiple methods to determine the solubility of naproxen in PVP, ultimately concluding
that the liquid polymer analog method resulted in the most realistic values, since this
method gave the FHIP at room temperature,98 and included specific interactions between
drug and carrier. More recently, Rask et al.99 also applied this method to determine the
solubility of celecoxib in polyvinylpyrrolidone-vinyl acetate copolymer (PVPva) using Nvinylpyrrolidone and vinyl acetate. In this study, the authors noted the potential for this
method to overestimate the solubility when interactions are expected between API and
repeat units since in the polymeric form, the drug may be sterically hindered from
interacting with each repeat unit.99
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2.3.2.5.

Temperature-Composition Phase Diagrams

A method allowing calculation of the complete temperature-composition phase
diagram for binary ASDs was proposed by Lin and Huang using Tm depression
experiments.91 A relationship between temperature and the FHIP was determined using
Equation (14).

B

χ = A + Tmix

(14)

m

where 𝑇𝑚𝑚𝑖𝑥 is the melting point of the mixture, A is a constant reflecting the noncombinatorial entropic contribution, and B/T is a constant reflecting the enthalpic
contribution.91, 100 The linear relationship between 𝜒 and 1/T is used to solve for A and B,
allowing a phase diagram relating temperature and volume fraction of the drug to be
constructed. This diagram predicts the solubility of API in polymer at any temperature, and
was previously difficult to complete owing to experimental limitations resulting from
increased polymer viscosity at lower temperatures.91 A curve separating a metastable
system from an unstable system (known as the spinodal curve100) can also be generated by
′′
setting Δ𝐺𝑚𝑖𝑥
= 0 (Figure 9).91
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Figure 9: Theoretical Drug-Polymer Phase Diagram. Adapted with permission from Y.
Tian, J. Booth, E. Meehan, D.S. Jones, S. Li, G.P. Andrews, Construction of Drug–Polymer
Thermodynamic Phase Diagrams Using Flory–Huggins Interaction Theory: Identifying the
Relevance of Temperature and Drug Weight Fraction to Phase Separation within Solid
Dispersions, Mol. Pharm. 10(1) (2013) 236-248. Copyright 2013 American Chemical
Society.101 The area above the drug-polymer solubility curve will be a stable, one phase
system. Co-solidified mixtures at drug fractions and temperatures below the spinodal curve
are predicted to phase separate. Between the spinodal and solubility curve, the system is
expected to be metastable.
Several studies using experimentally determined phase diagrams89, 91, 102-104 have
shown promising results. For example, Tian et al.101 generated temperature-composition
diagrams, selected drug-compositions representing both the unstable and metastable areas,
and ultimately found that the predictions matched experimental observations. In a separate
paper, Tian et al.104 concluded that the Flory-Huggins phase diagram was useful for ranking
suitable polymer candidates for ASD formulations.
Despite their usefulness89, 91, 95, 101-105 the phase diagrams for very few API (e.g.,
indomethacin, felodipine, ketoconazole, and aceclofenac) have been published to date. One
potential limitation to their more widespread use could stem from the exclusion of
considerations of experimental and prediction error. In their paper describing the method,
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Lin et al.91 acknowledged that the possible dependence of 𝜒 on drug concentration and
higher temperatures was neglected. A separate publication by Zhao et al.89 also expressed
some concern regarding the oversimplified correlation in Equation (14).
Continued development of the phase diagram method as a formulation tool would
benefit from including predictions applicable to long-term storage to better facilitate
understanding of ASD physical stability. Lu et al.102 found that phase diagrams for
dispersions of ketoconazole and felodipine in Soluplus® successfully predicted physical
stability for up to 3 months of storage at accelerated conditions. However, sorption of water
at high relative humidity could introduce a third component to these systems, complicating
interpretation of the data. At the completion of the writing of this chapter, no studies were
found that compared phase diagrams to experimental data beyond 3 months. Additionally,
use of this method should also consider how the accuracy and precision of predictions may
be impacted by issues such as sample preparation method (known to affect the FHIP95), or
experimental error owing to kinetic effects in the Tm depression method. Knopp et al.106
recently performed a statistical analysis of this method, and concluded that the predicted
miscibility curve could not be trusted as a result of poor statistical confidence.106 This
conclusion was based on identification of a violation of the assumptions of regression
resulting from the linear transformation used in Equation (14) (specifically, the reciprocal
transformation of temperature). The impact of bias introduced by this transformation is
shown in Figure 10.

41

Figure 10: Visualization of the impact of the reciprocal transformation to linearity used in
equation (14) on the statistical validity of Flory-Huggins phase diagrams.106 (a) The
extrapolated confidence intervals are shown, indicating poor confidence in the predicted
interaction parameter at lower, pharmaceutically relevant temperatures. (b) Comparison of
the least squares estimate of equation (14) using raw data and (c) using average values. The
best fit line varies significantly, ultimately resulting in opposite inferences regarding
miscibility. Adapted from the Journal of Pharmaceutical Sciences, 105(1), M.M. Knopp,
N.E. Olesen, Y. Huang, R. Holm, T. Rades, Statistical Analysis of a Method to Predict
Drug–Polymer Miscibility, Pages No. 362-367, Copyright 2015, with permission from
Elsevier.106

Finally, it has been suggested that current DSC instruments may be insufficiently
precise for the generation of reliable phase diagrams,106 as the prediction accuracy is
dependent on the accuracy of the experimental data.91 Additional work is needed to assess
the underlying physical assumptions of the Tm depression method to ensure that extensions
of this method (e.g., to generate phase diagrams) are valid.106

2.3.2.6.

Polymer in Solution Method

A new method proposed by Knopp et al.107 hypothesizes that drug-polymer solubility
can be determined from the increase in drug solubility due to concomitant presence of
dissolved polymer in an inert solvent,107 where a linear increase in drug solubility with
increasing polymer concentration was observed for all mixtures tested. Additionally, for
the majority of the samples tested, the prediction intervals were narrower than those
determined using the Tm depression method. It was also expected that more realistic
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interactions were likely compared to the liquid monomer method, since factors such as
steric hindrance were not overlooked. The method may also perform better than the Tm
depression method since there is no need to extrapolate results to room temperature.107 It
is notable that this method assumes the dissolved polymer and API remain representative
of their solid form, which may be problematic for polymethacrylic and cellulosic polymers
that ionize in solution. While this method shows promise, the recent development of this
approach necessitates further research to identify other potential limitations.

2.3.3.

Limitations of Flory-Huggins Interaction

Parameter
The FHIP offers insight into the thermodynamics of binary ASD systems. Both the
entropic and enthalpic effects are considered and, in general, the effect of specific
interactions is included. However, application of this approach (and its derivative methods)
requires caution under certain circumstances. For example, the assumption that
concentration has a negligible impact on the FHIP is not always true. Saturable interactions
are not considered by the Flory-Huggins lattice theory,98 and concentration dependence
will be significantly important for a drug and polymer whose mixing is enhanced by
hydrogen-bonding. As the concentration of drug increases, the number of potential
hydrogen-bonds that it can form with the polymer may plateau, thereby affecting its
solubility in that carrier. Additionally, as discussed in the introduction to Section 2.3,
system kinetics, which are important for understanding ASD stabilization, are also not
considered by the Flory-Huggins theory. For example, an increase in polymer chain length
will increase the entropic contribution to mixing, which will be reflected in the FHIP. The
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commensurate increase in viscosity, however, which will inhibit API crystallization in
longer chain polymers, will not contribute to the FHIP calculation, potentially making
predictions incomplete.
The methods for determining the FHIP may also suffer from experimental
limitations. It is difficult to accomplish molecular mixing in situ (e.g., using DSC), and
may be prohibitive as the drug concentration drops below approximately 70% w/w.89
Additionally, these thermal methods are only applicable for compounds that are thermally
stable, particularly in the recrystallization method, which requires lengthy annealing times
during which the drug must remain stable.95

2.4. Molecular Descriptors
The methods discussed thus far have largely ignored the effect of system kinetics on
the miscibility of drug and polymer in ASD formulations. Since molecular mobility in the
solid state is greatly reduced, ASDs can remain kinetically stable for pharmaceutically
relevant time periods, even in formulations where the miscibility limit may have been
exceeded. Predicting the ability of drugs to disperse in polymer, including the formation of
supersaturated systems, may also be useful for formulation development, although no first
principles model for kinetic stability currently exists.
Quantitative structure-activity relationships (QSAR) and quantitative structureproperty relationships (QSPR) have been explored since a model for molecular structure
was developed in the late 1800s. The history of chemoinformatics, QSAR, and molecular
descriptors is described elsewhere, and the reader is directed to the cited literature for more
information.34-36, 108, 109 The fundamental assumption of QSAR/QSPR is that the structure
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of a molecule is responsible for its physical, chemical, and biological properties.35 If the
chemical structure is related to these properties, it follows that these properties can be
predicted using structure alone; however, the relationships between specific properties and
chemical structure are too complex to discern using first principles models, necessitating
an indirect process.34

Figure 11: The QSAR/QSPR approach. Figure adapted from Gasteiger.34

Molecular descriptors were developed as a tool enabling indirect association of
molecular structure with properties of interest (Figure 11). Molecular descriptors are
defined by Todeschini and Consonni108 as “the final result of a logical and mathematical
procedure which transforms chemical information encoded within a symbolic
representation of a molecule, into a useful number, or the result of some standardized
experiment.” They are the basic tool for transforming chemical information into a
numerical code for application in QSAR modeling.35 Molecular descriptors may represent
the physiochemical properties of a molecule, or may be derived from molecular structures
using algorithmic techniques.109 For completeness, some of the discussions in this section
also include easily determined physiochemical properties (e.g., Tg and Tm). While these
properties are not considered molecular descriptors by definition, they are included owing
to their general availability during early method development. In some cases, these
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properties can also be accurately predicted and, therefore, applied as molecular descriptors
without the need for experimentation. For example, in many cases, T g has been shown to
be highly correlated with, and, therefore, easily predicted from Tm.110 It may also be
possible to predict Tg using other molecular descriptors.111
Historically, the application of molecular descriptors in the pharmaceutical industry
has been applied most commonly to drug discovery.35-37 Tian et al.38 reviewed the
application of drug-likeness modeling to pharmaceutical science. The following sections
will discuss the application of molecular descriptors to formulation screening, amorphous
systems (glass forming ability and physical stability), and their application toward ASDs.

2.4.1.

Formulation Screening

Following drug discovery, an appropriate formulation is selected to enable drug
delivery. This task can be exceedingly challenging, owing to the number of potential
delivery methods, and the large number of formulation and process variables that can
interact in complex ways.39 High-throughput screening has led to an increasing number of
poorly water-soluble drug candidates, and identification of the most suitable formulation
is often challenging. Methods that apply molecular descriptors are commonly used to aid
scientists in these areas. For example, Amidon et al.40 proposed the well-known
biopharmaceutics classification system (BCS), which allows rapid categorization of new
chemical entities and aids the selection of appropriate formulations strategies. The ‘Rule
of 5’ proposed by Lipinski et al.41 uses descriptors to identify the ‘drugability’ of new
chemical entities and can be applied to screen compounds most likely to reach the market
based on their similarity to existing drugs. As recently as 2015, an assessment of the
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DrugBank database112 showed that 85.4% of the 1543 uploaded FDA approved drugs met
the Rule of 5 criteria.38
Application of molecular descriptors in product development may help scientists
make informed formulation decisions, especially as a potential means of addressing the
‘combinatorial explosion’ of poorly water-soluble compounds. As the number of potential
formulation methods has increased, the number of possible combinations to reach a suitable
product has become exceedingly large.42 Branchu et al.42 identified several key decision
points in the development process, the first of which was the selection of either
‘conventional’ or ‘non-conventional’ (e.g., solid dispersion, lipid/surfactant system,
crystalline nanoparticle) formulations. If a non-conventional formulation was deemed most
appropriate, a second decision regarding the formulation strategy was required, and made
based on the physicochemical properties of the molecule of interest. The authors generated
11 statistical models and 11 decision trees to aid this decision process (Figure 12).
Unfortunately, the complete model is proprietary and very few performance statistics were
divulged, making it difficult to assess or apply the model. Nevertheless, the study illustrates
the potential for application of molecular descriptors to speed formulation development.
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Figure 12: Example decision tree process. Adapted from the European Journal of
Pharmaceutical Sciences, S. Branchu, P.G. Rogueda, A.P. Plumb, W.G. Cook, A decisionsupport tool for the formulation of orally active, poorly soluble compounds, 32(2), Pages
No. 128-139, Copyright 2007, with permission from Elsevier.42
In a separate study, Kuentz & Imanidis43 ranked drug candidates using molecular
descriptors, based on the solubility advantage that their amorphous form offered over the
crystalline form. By applying this method, the authors hoped to use molecular descriptors
to identify compounds most likely to benefit from formulation approaches such as ASDs.
Two models were developed to predict the ideal solubility advantage using partial least
square (PLS) modeling. The first consisted of 9 terms, while the second included additional
quadratic terms for the 5 most important variables, although inclusion of these terms
resulted in only a minor increase in model fit (R2 increased from 0.803 to 0.820), and a
decrease in predictive performance (Q2 from 0.792 to 0.729) for the second model relative
to the first. Nonetheless, the authors identified 4 descriptors as potentially useful for
identifying compounds that could benefit from amorphous formulations (Table 1).
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Formulation Screening

Table 1: Compilation of molecular descriptors used for prediction related to amorphous API or ASDs. Variables which require
experimental work to determine are bolded.
Molecular Descriptors
(correlation direction and/or
cutoff value, if reported)
MW(≤500), ClogP (≤5), HDon(≤5),
HAcc(≤10)
An, Dn, Do
Dissociation constants, HDon, PSA,
%PSA, Lipinski score, Distribution
coeff, Dose, Do (see Figure 12)
MW(+), #RoBo(+), HAcc(+),
PSA(+), Tm(+), logS(-), logP(+),
HLB(+), HDon(+)
Mv(+), Tg(+)

Amorphous – GFA
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XMOD(+), VAR(+), Whete(+), #
benzene rings(-)
MW(+), #RoBo(+), ∆Hfus(-), ∆Sfus(), Tm(-), Tg, ∆Gv(+)

MW(+, 300 g/mol)
T_Grav3_3D(+, 15.5)

MW(+, 200-300 g/mol), pi Fukui
index(-, 14), presence of ring
structures excluding benzene(+,
Y/N)

Description
Lipinski’s rule of 5
Biopharmaceutics Classification System
11 PLS models or decision trees.

PLS model to guide formulation selection for poorly
soluble compounds.
MV and Tg found to correlate with disordering
potential. Mv indicates geometric constraint and T g
believed to indicate resistance to recrystallization
Branching of carbon skeleton, molecular symmetry,
distribution of electronegative elements, number of
benzene rings
Parameters investigated showed no strong correlation
with GFA or glass stability, suggesting that they may
not be ideal for prediction purposes. The GFA
classifications were made using experimental
techniques, and ultimately, no model using
descriptors was built.
MW alone predicted GFA with 84% accuracy
T_Grav3_3D reflects size, shape, and bulk properties
of molecule and allowed prediction of GFA with 86%
accuracy.
MW from 200-300 g/mol showed decreased
prediction accuracy. A decision tree was developed
using molecular descriptors to improve predictions in
this range. Fukui index indicates tendency of an atom
to lose electron.

# of compounds
(train/ test/ validation)

Reference

2245

Lipinski et al.41

N/A
73 (73/0/0)
Cross-Validation (CV)
performed

Amidon et al.40
Branchu et al.42

56 (56/0/0)
CV performed

Kuentz et al.43

17 (17/0/0)

Lin et al.16

32 (16/16a/0)

Mahlin et al.44

51 (N/A)

Baird et al.96

101 (33/17/51a)
CV performed

Mahlin et al.45

131 (100/31/0)

Alhalaweh et al.46

Amorphous – Physical Stability

Table 1 (continued)
Molecular Descriptors
(correlation direction and/or
cutoff value, if reported)
∆Sconfig(+)
MW(+), Tg(+), Tcr(+)
MW(+, 200 g/mol): Class I
∑Hückel_pi_C(+), HAcc(+): Class
II & III
MW(+), ∆Hfus(-)

MW(+), #RoBo(+), ∆Hfus(-),
∆Sfus(-), Tg(+), ∆Gv(+)
Tg(+), Molecular flexibility(+),
HDon(-)

50
R3m(+)

Description

Stability of glass above Tg may not be related to stability below T g.
Sigmoidal relationships were identified between these descriptors and
stability after 1 month in dry conditions.
PCA model applying a SVM algorithm used to classify between
crystallization tendency classes II and III.
Several models were developed (e.g., see equation (15)). Model 6 used
the descriptors indicated to the left, and showed the best correlation with
physical stability using more easily acquired variables.
PCA models were developed in an attempt to predict classifications of
crystallization tendency.
General rules deduced from models constructed from stability data
(40°C/75%RH) for ASDs created using multiple polymers and
preparation methods.
May give an indication of electronegative atoms along periphery and
their separation distance.
Descriptors helped to identify molecule polarity, shape, size,
eccentricity, and atomic mass distribution as being potentially important
for solubility in lipid excipients.

# of compounds
(train/ test/
validation)
12 (12/0/0)

Graeser et al.113

24 (24/0/0)

Mahlin et al.45

77 (61/16/0)
CV performed

Alhalaweh et al.46

25 (25/11a/0)

Nurzyńska et al.47

96 (93/3/0)
CV performed

Van Eerdenbrugh
et al.97

10 (10/0/0)
CV performed

Fridgeirsdottir et
al.114

15 (12/3/0)
CV performed

Moore et al.48

Reference

ASD

PSA(-), DECC(-), MOR21v(-),
DP06(-), MATS6m(-)
30 (20/10/0)
ICR(-), JG16(+), MOR21v(-),
Persson et al.115
CV performed
PSA(-)
Tm(-), nN(-), nDB(-)
Abbreviations: An (absorption number), ClogP (calculated logarithm of the partition coefficient), CV (cross-validation), DECC (eccentric), Dn (dissolution
number), Do (dose number), DP06 (molecular profile no. 06), ∆Gv (free energy difference between the crystalline and amorphous states), HAcc (hydrogen
bond acceptors), HDon (hydrogen bond donors), ∆H fus (enthalpy of fusion), HLB (hydrophilic-lipophilic balance), ∑Hückel_pi_C (sum of the absolute values
of the Hückel pi atomic charges for only carbon atoms), ICR (radial centric information index), JG16 (mean topological charge index of order 6), logP
(logarithm of the partition coefficient), logS (log of the aqueous solubility), MATS6m (Moran autocorrelation lag 6 weighted by atomic masses), Mor21v
(3D-MoRSE signal 21 weighted by atomic van der Waals volumes), nDB (number of double bonds), nN (number of nitrogen atoms), PSA (polar surface
area), R3m (R autocorrelation of lag 3 weighted by atomic masses), #RoBo (number of rotatable bonds), ∆Sconfig (configurational entropy), ∆Sfus (entropy of
fusion), Tcr (crystallization temperature), T_Grav3_3D (topological equivalent of cube root gravitational index), VAR (variation), Whete (Wiener-type index
from electronegativity weighted distance matrix), XMOD (modified Randic connectivity index).
Bolded descriptors/properties indicate those which may require experiments to determine.
(a) Indicates test or validation data sets which were obtained from the literature.

2.4.2.

Amorphous Systems

2.4.2.1.

Glass Forming Ability

Glass forming ability (GFA) is defined as “the ease of vitrification of a liquid on cooling.”96
Poor glass formers rapidly recrystallize on cooling, while good glass formers will persist in the
amorphous form through the cooling process, and beyond. GFA can give an indication of the
physical stability of a drug during processing, and for example, inform the likelihood of
recrystallization during melt-extrusion. Prediction of this property may, therefore, be useful in
identifying materials most suitable for ASD formulations.96
Mahlin et al.44 developed a model to predict GFA using a PLS discriminant analysis model.
Sixteen compounds were classified as either glass formers or non-glass formers based on
experimental inferences made after processing using 3 different methods. The final model
contained 4 molecular descriptors (see Table 1), which the authors related to the size, symmetry,
branching, distribution of electronegative atoms, and the number of aromatic rings. The training
set performed quite well with a misclassification rate of approximately 6%. The test set was
obtained from literature and resulted in 25% misclassification of GFA. It is important to note that
the test set used a different technique to generate amorphous samples. The source of the test set
was Lin et al.,16 who investigated amorphization potential using cryomilling. In contrast, Mahlin
et al.44 used spray drying, melt quenching, and repeated compression cycles in a tableting machine
to induce glass formation for the training set. Although the authors generally found similar
outcomes for all of the methods applied, comparing the outcome of these different processes could
be detrimental. Even for the two amorphization processes involving mechanical activation, it is
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possible that the different stress states inherent to cryomilling, versus compaction (e.g., impaction
force, extent of normal and shear stresses, sample size, thermal effects, etc.), were not captured in
the PLS model. This may account for the increased misclassification rate for the test set, since PLS
models are unsuited for extrapolation.116 Nevertheless, the model appears to perform relatively
well for the prediction of GFA, and may have identified some properties important for GFA. For
example, the Whete descriptor is related to distribution of electronegative atoms, and may reflect
the role of hydrogen-bonding pattern in glass formation.44
Molecular descriptors have also aided the identification of molecular size as important
factors for GFA. Lin et al.16 previously showed that a combination of molar volume (Mv) and Tg
could be used to predict amorphization caused by high-shear mechanical processing. In other
studies, GFA was also found to be more likely for compounds having high molecular weight (MW)
and complex molecular structure,96, 97 and Mahlin et al.45 noted that MW alone was a significant
predictor of GFA. Alhalaweh et al.46 extended this work by showing that MW was generally an
excellent predictor of GFA except in the 200-300 g/mol range. Figure 13 gives a visual
representation of the relationship of Mv and MW with GFA.
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Figure 13: The relationship of GFA with Mv and MW. (a) A logistic regression model predicting
amorphization by mechanical activation. Adapted from the Journal of Pharmaceutical Sciences,
Vol 98(8), Y. Lin, R.P. Cogdill, P.L.D. Wildfong, Informatic Calibration of a Materials Properties
Database for Predictive Assessment of Mechanically Activated Disordering Potential for Small
Molecule Organic Solids, Pages No. 2696-2708, Copyright 2009, with permission from Elsevier.16
Error bars are included where Tg was predicted from Tm. (b) Relationship between MW and GFA.
A cutoff of 300 g/mol is indicated by the red dotted line. 50 compounds are shown with 90%
correctly sorted using MW alone. Reprinted from the European Journal of Pharmaceutical
Sciences, Vol 49(2), D. Mahlin, C.A.S. Bergstrӧm, Early drug development predictions of glassforming ability and physical stability of drugs, Pages No. 323-332, Copyright 2013, with
permission from Elsevier.45 (c) MW is a good predictor of GFA except in the 200-300 g/mol range
(based on data obtained from Alhalaweh et al.46).
Alhalaweh et al.46 attempted to further improve the GFA prediction accuracy for
compounds having MW ranging between 200-300 g/mol using molecular descriptors. Through the
application of support vector machines (SVM), the authors found that several descriptors helped
to improve prediction accuracy (Table 1). The authors also attempted to use molecular descriptors
to predict GFA when excluding MW from the model to avoid bias. A single descriptor, the
topological equivalent of the cube root of the gravitation index (T_Grav3_3D), was able to classify
GFA with 86% accuracy. Like MW, T_Grav3_3D is also related to the size and shape of the
molecule; however, it appeared to achieve better prediction accuracy than MW, suggesting that it
may have captured additional information about the molecule related to GFA. Notably, the authors
did not evaluate the correlation between MW and T_Grav3_3D. As shown in Figure 14, these
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variables appear to be highly correlated, making the true benefit of T_Grav3_3D over MW unclear,
as it is possible that the improved model performance occurred by chance. Additional data,
especially for compounds within the 200-300 g/mol range, as well as those having lower MW
should be examined to ensure that the improved prediction using T_Grav3_3D is not the result of
random chance.

Figure 14: High correlation observed between MW and T_Grav3_3D. (a) The linear and
logarithmic relationship between MW and T_Grav3_3D indicates that the improved prediction of
GFA using T_Grav3_3D may have occurred only by chance. (b) The residuals vs. predicted plot
shows a potential violation of the assumption of linearity. (c) Logarithmic transformation of MW
appears to correct this. These figures were based on data obtained from Alhalaweh et al.46

2.4.2.2.

Physical Stability

The physical stability of glasses is equally important to the development of amorphousbased formulations as GFA. In this case, physical stability refers to the persistence of the formed
glass with respect to time, beyond its initial formation. Accurate prediction of physical stability
would allow formulators to take a more informed approach, with the potential to significantly
reduce financial and time investment.
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Previous studies investigated relationships between thermodynamic parameters and
stability. For example, Graeser et al.113 argued for a deviation from the more common case-study
approach of formulation development, and attempted to identify general thermodynamic and
kinetic parameters important to physical stability. In this case, configurational entropy was found
to correlate best with physical stability for samples stored above Tg.113 It is notable, however, that
physical stability is multifactorial, and Laitinen et al.117 compiled a useful table of factors and
relevant references for many of these factors, including molecular mobility, entropic barrier to
crystallization, enthalpic driving force, hydrogen-bonding, etc. Readers are also directed to
reviews by Bhugra et al.118, Janssens et al.,119 and Baird et al.120 for additional information
regarding kinetic and thermodynamic factors that have been considered with respect to glass
physical stability. Unfortunately, many of these terms require determination using rigorous and
precise experimentation; even then, conflicting results indicate no clear correlation between these
parameters and physical stability. For example, Graeser et al.113 found that conformational entropy
correlated well with physical stability (r=0.83), while Nurzyńska et al.47 observed essentially no
correlation (r=-0.05). Nurzyńska et al.47 also noted a positive correlation between physical
stability and the number of aromatic and aliphatic rings, whereas Mahlin et al.44 observed a
negative correlation. Molecular descriptors may offer a method for rapid prediction of physical
stability in the amorphous state without the need for more complex and time-consuming
experiments, which may lead to such variable conclusions.
Baird et al.96 and Van Eerdenbrugh et al.97 classified the crystallization tendency of many
APIs, designating class I, II, and III respectively for rapid, intermediate, and slow crystallization
tendencies. Crystallization tendency was also investigated as an indicator for physical stability of
the amorphous form, suggesting that class III compounds were more likely to remain physically
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stable (and, therefore, be more suitable for ASD formulations) than class I compounds.97
Crystallization tendency from undercooled melts can be experimentally determined using DSC as
described by Baird et al.,96 but descriptors were also investigated in an attempt to identify
physiochemical properties important to crystallization tendency . In their study, Baird et al. built
a PCA model for predicting crystallization tendency using seven physiochemical properties (Table
1). Some differentiation in crystallization tendency was observed, indicating that multiple
physiochemical properties played a role in crystallization tendency96 (Figure 15a). Class I
molecules tended to have lower MW and fewer rotatable bonds compared to class III molecules.96
Additionally, class I molecules had higher Δ𝑆𝑓𝑢𝑠 , Δ𝐻𝑓𝑢𝑠 , and lower Δ𝐺𝑣 values on average than
class III molecules.96 However, the model could not sufficiently separate classifications of
crystallization tendency to justify its application for prediction.
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Figure 15: Principal component analysis model scores plots colored according to crystallization
tendency: (a) From undercooled melts (Adapted from the Journal of Pharmaceutical Sciences, Vol
99(9), J.A. Baird, B. Van Eerdenbrugh, L.S. Taylor, A Classification System to Assess the
Crystallization Tendency of Organic Molecules from Undercooled Melts, Pages No. 3783-3806,
Copyright 2010, with permission from Elsevier).96 (b) From rapid solvent evaporation (Adapted
from the Journal of Pharmaceutical Sciences, Vol 99(9), B. Van Eerdenbrugh, J.A. Baird, L.S.
Taylor, Crystallization Tendency of Active Pharmaceutical Ingredients Following Rapid Solvent
Evaporation—Classification and Comparison with Crystallization Tendency from Under cooled
Melts, Pages No. 3826-3838, Copyright 2010, with permission from Elsevier).97 Class I (red), class
II (blue), class III (green). Diamonds represent individual molecules and triangles represent
averages of each class. Note: 3 principal components were used to generate both models, but the
3rd principal component is not shown since it did not contribute to discrimination.96
Van Eerdenbrugh et al.97 continued this research by investigating crystallization tendency
during rapid solvent evaporation. In general, classifications of crystallization tendency were
consistent between preparation methods.97 The PCA model generated in this case showed some
additional separation of classes, especially between classes I and III (see Figure 15b). The authors
then built an individual three-component PCA model for each class (i.e., soft independent
modeling of class analogues, ‘SIMCA’), which showed greater potential for discrimination of class
I from class II, indicating that easily accessible descriptors could be applied to predict
crystallization tendency.97 It is possible, however, that the individual PCA models were negatively
influenced by the size and distribution of their datasets. For example, the class II PCA model was
generated using data from only 11 compounds and, if by chance these compounds were not
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representative of the population of class II compounds, the resulting PCA model might not be as
useful for prediction. For example, Nurzyńska et al.47 examined data for 1327 poorly water-soluble
drugs, which were obtained from the DrugBank112 database. Data for each available property was
entered into a PCA model and subsequently clustered. One drug from each cluster was selected
for the test set, and finally, the distribution of the test set was compared to the population to ensure
the test set had a representative distribution. A PCA model using data confirmed to be
representative of the broader population will be less likely to suffer from insufficient variability.
Alhalaweh et al.46 also attempted to predict crystallization tendency to make inferences
about physical stability. The authors found that class I molecules could be identified using MW
alone (<200 g/mol), however, MW was not useful for distinguishing between class II and III
compounds. In this case, a model was developed using two descriptors (see Table 1) and SVM
was applied to identify a classification boundary in the principal component space. This model
may be useful for future predictions, but again, this is true only if the data included in the training
set are representative of the population. This concern is illustrated by the misclassifications of class
II compounds (4/6) in the test set, which appears to be poorly predicted using the current model.
Incorporation of the test data into the calibration set would likely result in a significant change to
the SVM boundary. Nevertheless, the potential application of this type of model was well
illustrated by the authors, and addition of more poorly soluble compounds could result in a more
stable model boundary.
Mahlin et al.45 also found a strong relationship between physical stability and
crystallization temperature for amorphous compounds stored below Tg. Glass transition
temperature and MW also resulted in a reasonable prediction, having 78% accuracy.
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Unfortunately, these models were not tested using an independent data set, so further research is
necessary to confirm their broader application.
These studies have shown the potential for the application of molecular descriptors for
prediction of physical stability, where Table 1 summarizes the molecular descriptors used to this
end. MW appears to be a very useful descriptor for physical stability, due to its recurring presence
across several models. Descriptors that may indicate the number or strength of hydrogen bond
interactions (e.g., HAcc, Δ𝐻𝑓𝑢𝑠 ) and molecular mobility (e.g., Tg) also appear in these models with
some frequency.

2.4.3.

Amorphous Solid Dispersions

A method for reliably predicting the dispersability and stability of amorphous dispersions
would be very beneficial to drug development efforts. Application of molecular descriptors may
also advance scientific understanding of binary ASDs.
Moore and Wildfong48 investigated the use of molecular descriptors for the prediction of
solid dispersion potential of twelve API with PVPva prepared by melt-quenching. A single
molecular descriptor, R3m (the atomic mass weighted 3rd order autocorrelation index), was found
to correlate well with dispersion potential, and a logistic regression model applying this descriptor
correctly predicted the dispersability for all compounds, including 3 additional test compounds.
Unfortunately, the physical reasons for the predictive accuracy of the R3m descriptor were not
obvious.48 It is also important to note that the applicability of the R3m model was restricted to the
design space of the existing model. For example, the molecular descriptors were calculated only
for the API molecules, so the properties of the polymer were not considered. If R3m describes
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some combination of complex interactions between the API and polymer, these will likely change
if a different polymer is selected. Finally, caution is necessary when screening a large number of
independent variables. Moore et al.48 used the E-Dragon software containing 1602 descriptors to
screen against observations of dispersion formation. As the number of independent variables tested
against the dependent variable increases, the probability of incorrectly rejecting the null hypothesis
(i.e., that no correlation exists) is much larger than the initial level of significance, and continues
to grow with each test made.50 An adjustment of the significance level using multiple comparison
corrections (e.g., Bonferroni method) is advised to avoid selecting an erroneous independent
variable by chance.50

While the R3m descriptor appears promising for the prediction of

dispersability in PVPva using the melt-quench technique, model expansion is necessary to confirm
its statistical validity.
Persson et al.115 investigated the solubility of API in lipid-based formulations. While this
research did not examine ASDs specifically, the work illustrates the potential benefit of molecular
descriptors for predictions of solubility in binary systems. The authors experimentally determined
the solubility of 30 API in four commonly used lipid carriers. PLS models, as well as multiple
linear regression (MLR) models, were successfully generated for two of the lipids (soybean oil
and Captex355) using molecular descriptors and API Tm. These models indicated that size, shape,
topological charge, polar surface area, number of double bonds, and number of nitrogen atoms
contributed to API solubility (see Table 1). Unfortunately, models were successfully built for only
two of the four lipids. The authors cite the low variability in the API solubility in these two
lipids,115 illustrating the importance of carefully selecting compounds for the calibration data set.
Consideration of the studies above suggests certain emerging patterns. The R3m descriptor
used to model API dispersability in PVPva is expected to increase in magnitude when a molecule
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has peripheral electronegative atoms positioned such that their interatomic distances are
minimized.48 Additionally, the Whete descriptor, useful for predicting GFA, was also related to
the distribution of electronegative atoms in a molecule.44 There are some additional parallels
between the models, specifically with respect to molecule shape, eccentricity, and polar surface
area, illustrating the potential usefulness of molecular descriptors.

2.4.4.

Limitations of Molecular Descriptors

Modeling physical phenomena using molecular descriptors is not without limitations. A
common criticism of these models is often made when the descriptors are applied in circumstances
where a connection to well understood physical properties is unclear. However, Todeschini and
Consonni argue that the usefulness of molecular descriptors is not limited to cases for which they
are easily interpretable,35 rather the inability to understand descriptors using well-established
chemical concepts might instead help to reveal new concepts.35 Even so, it is prudent to apply
descriptors with caution when no clear understanding of their meaning can be found, and models
should only be accepted once their usefulness for prediction has been well established. This can
be accomplished through appropriate model testing and validation to avoid issues such as
overfitting, and to increase statistical certainty. Model validation is essential to confirm its
applicability for prediction.116 At a minimum, cross-validation should be performed; even then, a
useful descriptor should be further investigated to elucidate the underlying reason for its efficacy.
Development of molecular descriptor models requires careful consideration of the
assumptions inherent to the applied model to avoid inadvertent incorporation of errors.
Additionally, inclusion of practically unimportant, but statistically significant predictors can
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negatively impact both model interpretation and prediction accuracy.50 For example, MLR is
commonly used in an attempt to better describe the response variable by using additional
explanatory variables,121 but should be accompanied by examination of variable multicollinearity
to prevent generation of highly unstable regression coefficients, and, consequently, inaccurate
predictions.50 In recent work by Nurzyńska et al.47 several different models were developed using
MLR, and the model that was expected to have the greatest prediction accuracy is shown in
Equation (15):

(15)

log(Solubility) = −0.02Tm − 0.05Hfus + 0.03Tg + 0.28Gconfig −
0.01τ + 0.03HDon − 0.28ClogP + 0.17 CHA + 6.42

Above, Tm is the melting temperature, Hfus is the entalpy of fusion, Tg is the glass transistion
temperature, Gconfig is the configurational free energy, τ is the relaxation time, HDon is the number
of hydrogen bond donors, ClogP is the calculated logarithm of the partition coefficient, and CHA
is the ratio of carbon atoms to heteroatoms. The model included melting temperature and glass
transition temperature as separate parameters, however, these two terms are correlated to the extent
that Tm can be used to predict Tg.110, 111 Although the results of this work predicted solubility
reasonably well, inclusion of collinear terms in the model may negatively impact predictions due
to unstable regression coefficients.
Modeling of the physical stability of amorphous solids is also common.47, 113 Some caution
is warranted with respect to linear regression approaches in that both the dependent and
independent variables are assumed to be continuous. Typically, physical stability is assessed by
analyzing samples at specific time points (e.g., 1 week, 1 month, 2 months, etc.), which bins the
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data in such a way that the independent variable (stability) is no longer truly continuous. Likewise,
the common means of measuring physical stability is to report amorphous content as percentages
with respect to time. Since the variable is bounded (i.e., between 0% and 100%) a linear model
may result in difficult to interpret values (e.g., <0% or >100%).
Despite some limitations, application of molecular descriptors may help to elucidate
properties that are important for the formulation of ASDs. Future work might involve the
expansion of existing models to strengthen their validity, investigation of model applicability for
different polymers, and advancement of the understanding of relevant descriptors via correlation
with physical properties. Ultimately, application of molecular descriptors may be limited until they
can be associated with specific physical and/or chemical properties.

2.5. Molecular Modeling
Molecular modeling is the study of “molecular structure and function through modelbuilding and computation.”122 Molecular systems are most often modeled using molecular
mechanics, which assumes that cumulative physical forces can be used to describe molecule
geometries and energies.98 Molecular energy is assumed to be expressed as the sum of potentials
derived from physical forces, and these potentials are described using force fields (FFs).122 FFs
estimate forces between interacting atoms, considerably increasing the speed of calculations
relative to quantum mechanical models.123 Molecular dynamics (MD) is the application of
molecular mechanics to observe system behavior over time. For additional details of molecular
modeling and MD, readers are referred to the cited literature.122-124 Modeling and simulation can
help connect microscopic mechanisms with the collective properties of a system.124 Ultimately,
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the goal of applying molecular modeling to ASDs is to observe the microscopic interactions of a
system in an attempt to explain what is experimentally observed at macroscopic scales, such as
physical stability or phase separation. For this reason, molecular simulations are expected to be an
important tool for the future of ASD development.

2.5.1.

Molecular Modeling and Dynamics to Aid Existing

Prediction Methods
Many of the methods described above for predicting compatibility of API and excipients
for ASD formulations can be enhanced using molecular modeling. For example, estimates of
solubility parameters have been made using molecular modeling and MD. Huynh et al.125
calculated the solubility parameter using MD simulations, since it was expected that these would
result in more accurate values owing to the consideration of specific interactions between atoms.
The authors concluded that MD was a useful method for ranking excipients by their potential to
stabilize specific API. Langer et al.126 applied MD simulations to aid prediction of miscibility in
order to address regions of low confidence for solubility parameter predictions (i.e., the Δ𝛿 8-15
√𝑀𝑃𝑎 range). MD simulations led to the identification of a new potentially useful parameter; the
polar interaction term (Pi).126 Gupta et al.127 also applied MD simulations to calculate solubility
parameter values, which agreed well with GC methods, and are potentially applicable in the
absence of GC values.
Molecular modeling and MD have also been used to improve calculations of the FHIP.
Pajula et al.128 applied Monte Carlo simulations to rapidly determine the temperature-dependent
FHIP for 1122 compound pairs, an approach that was extended in a later article where the authors
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predicted phase separation in binary mixtures using a computational approach to calculate the
FHIP.129 The method correctly predicted immiscibility in 7/8 compounds. Patel et al.130 later
applied MD to calculate both solubility parameter and FHIPs, leading to the suggestion that the
MD-FHIP approach was superior owing to its consideration of the local packing environment of
API and polymer, with predictions that were consistent with experimentally determined solubility
for both of the drug-polymer systems examined. This assertion was supported in a later study by
Xiang and Bradley where the authors showed that the experimental data available for
indomethacin:PVP dispersions were best predicted using FHIPs calculated from MD simulations,
since the strong interactions between the polymer and API were captured.131
Perhaps the most important benefit of molecular modeling is its ability to include
directional interactions into the Flory-Huggins and solubility parameter values.127 In addition, MD
can be used to calculate these parameters at different temperatures, and the calculations are not
limited by availability of GC values.127 Variability due to changes in molecule conformation can
also be accounted for using molecular modeling.129 It is expected that inclusion of these additional
complexities will result in more reliable predictions of miscibility.
The limitations of molecular modeling and dynamics are also apparent in the combinations
of molecules studied in the cited literature. In general, these reports examined only binary mixtures
of small molecules, with the exception of a few publications, such as those of Gupta et al.127 and
Xiang et al.132, 133 This was a result of the increased complexity of large molecules (e.g., polymers),
and the subsequent requirement for extended simulations. These limitations currently prevent the
application of MD for screening large numbers of small molecules against realistic representations
of polymers.
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2.5.2.

Molecular Modeling of Binary Systems – Novel

Approaches
While MD involving large molecules such as polymers requires extensive computation
time, use of small molecule analogues, characteristic of the polymer (e.g., monomers or dimers),
can enable much more complex modeling. Docking has been proposed as a method for rapidly
screening molecules for crystallization inhibition of API, a method most often applied in the
pharmaceutical industry to aid virtual screening. For more information on docking, readers are
referred to the cited review.134
Pajula et al.135 hypothesized that small molecule additives (or ‘inhibitors’) having
computationally determined high binding affinity on crystal API surfaces would slow nucleation
and crystal growth, resulting in increased amorphous stability. The authors assumed that
complicating effects of steric forces and anti-plasticization were not possible since the compounds
examined had low molecular weight, relative to well-known inhibitors such as polymers.135
However, this assumption could be violated if the presence of inhibitor molecules impacts the
availability of free API molecules for crystal growth, since the relative concentration of inhibitor
molecules in the melt will increase as the API continues to crystalize. Additionally, the authors
measured the crystallization rate by polarized light microscopy, which may have proven
quantitatively challenging in this case due to the speed of crystallization. The potential for both
components in the mixture to simultaneously crystallize could also complicate the assessment of
crystallization rate for a single phase. Nonetheless, application of docking to ASD formulation
development is novel, and may aid rapid identification of potential interactions between polymer
and API without the need for more computationally intensive methods.
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Density functional theory (DFT) uses a quantum mechanical approach, and, therefore,
includes representations of electron density with a balance of accuracy and computational
requirements.122 Maniruzzaman et al.136 applied DFT to identify possible non-covalent bonding
interactions between API and monomers of potential polymers. Their predictions were confirmed
using X-ray photoelectron spectroscopy, demonstrating that this modeling technique could be used
to predict both the presence of non-covalent interactions, and their strength. Nie et al.137 also
successfully applied DFT modeling to support understanding of clofazimine:hypromellose
phthalate interactions, ultimately identifying the most probable conformation of interactions
between the species. The use of simplified molecular substitutes for the polymer (e.g., monomers),
however, may not completely capture API:polymer interactions. For example, long chain polymers
will have the ability to take on many conformations, and steric effects could reduce the amount of
sites available for hydrogen bonding. A long-term study would be useful to identify if the
calculated strength of interactions translates into extended physical stability.

2.5.3.

Limitations of Molecular Modeling & Dynamics

Molecular modeling and dynamics are expected to become an increasingly important tool
for ASD formulation development; however, there are several limitations to these techniques that
must be recognized. The first of these is the steep learning curve that accompanies their use, and
the resulting potential for their misuse. For example, appropriate application of MD simulations
can require extensive experience to avoid erroneous conclusions. Starting conditions such as the
number of molecules and system dimensions must be carefully selected to balance real-world
systems and computational complexity. The importance of starting conditions is illustrated in the
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study by Patel et al.130 The authors noted that for systems containing large molecules such as
polymers, there is insufficient time to undergo very drastic reorientation and relaxation. 130 It was
necessary, in this case, to have the starting conditions be as representative of the equilibrium state
as possible, since equilibrium could not be computationally achieved within a reasonable time.
Correspondingly, the authors selected the starting conditions of their system using well accepted
approximations and experimental evidence.130 Additionally, constraints may need to be applied to
certain degrees-of-freedom to reduce computational requirements, and system conditions can be
maintained using several algorithmic thermodynamic ensembles. Appropriate selection of these
conditions is necessary to generate meaningful data.
Perhaps the most important consideration that must be taken into account is appropriate FF
parameterization, which requires a thorough understanding of the underlying chemistry,
thermodynamics, statistical mechanics, and the computational tools and algorithms currently
available. FFs are of utmost importance to MD since they are the only input information
representing the specific physical properties of the molecules, and result in the simulation of
physiochemical properties for different systems.124 While empirical FFs have been developed, and
are continually improved (e.g., CHARMM138, AMBER139), the structural variability of small
organic molecules often requires time consuming manual parameterization, which is subject to
errors.123 Crystal structure data can be used to aid this parameterization, as demonstrated for
indomethacin by Xiang et al.,140 however, solved crystal structures are not always available, so
parameterization may rely even more heavily on the experience of the scientist. Tools such as the
CHARMM general FF (CGenFF)141 and FF tool kit (fftk)142 have been developed to facilitate
parameterization, but the process remains complex.
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Another consideration of modeling and MD addresses limitations inherent to FFs, even
after appropriate parameterization. These include inability to describe reactions involving
electronic rearrangements, such as polarization, bond formation, and bond cleavage.122 Perhaps
the most restrictive of these with respect to pharmaceutical applications is the exclusion of
polarization effects. Some FFs, which include polarizability have been developed,143 but these are
generally focused on biomolecules, and are even more computationally intensive.123 Other
methods have been proposed that attempt to incorporate polarization, such as DFT (see section
2.5.2. ), and the conductor-like screening model for real solvents (COSMO-RS).144 COSMO-RS
has shown reasonable prediction of API solubility in excipients in one study,145 but is beyond the
scope of this review.
Finally, while simulation of increasingly complex systems has become possible with
computational advances, interpretations must be made with caution. A simulation will always
provide a result, so it is necessary to consider the limitations of the computation and to compare
results with other physical models, where available, to ensure that each output is meaningful. For
example, MD simulations were used to investigate the molecular structure of ibuprofen ASD
formulations prepared by HME,146 which suggested a new model describing polymer
conformation in ASDs. This model proposed that polymers formed random coils and API
interacted on the outside surfaces of these coils, seemingly contrasting the previously established
theory of polymer entanglement in melts, which is reviewed elsewhere.100, 147, 148 The authors used
polymer representations containing 20 or fewer monomers to generate their model, which may not
adequately capture steric effects anticipated to be a driving force behind the entanglement model.
It is possible that by performing the same simulations using longer polymer chains, the simulation
results may have more closely aligned with the polymer entanglement model; however, it can be
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difficult to balance realistic representations of polymer chains with reasonable computation times.
In the end, new models predicted by MD simulation may be real, or they may be limited by input
parameters. Ultimately, it is necessary to not only apply computational tools correctly, but also to
support computational results with experimental evidence, whenever possible.
Despite current limitations, molecular modeling and MD can aid exploration of both
thermodynamic and kinetic interactions important to ASD formation and stability. As
computational speed increases and new computational methods are developed, modeling and MD
are expected to become an increasingly important aspect of ASD formulation development.

2.6. Conclusions
ASD formulations continue to show significant promise as a strategy to improve the apparent
aqueous solubility of poorly soluble APIs. Despite this potential, significant barriers to more
widespread adoption of ASD formulations are extant, owing to the complexity associated with
predicting whether new chemical entities can form dispersions in suitable polymeric carriers, and
further estimation of physical destabilization of these materials. Several approaches have been
established to assist in predicting API:polymer mixtures that form viable ASDs at meaningful drug
loads, in an attempt to reduce experimental burden, decrease time-to-market, and moderate risks
assumed with pursuing metastable formulations. Successful future development of ASD
approaches rests in continued research to better understand the applicability of these predictive
methods, as replacements for the experimental trial-and-error methods of the past. Ultimately,
methods that can rapidly direct scientists toward formulations having greater probability of success
will prove beneficial to both pharmaceutical development and human health.
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Throughout this chapter, efforts to make predictions about ASD formation and stability were
discussed, including the use of solubility parameters, Flory-Huggins interaction parameters,
molecular descriptors, and molecular modeling. Experimental results and predictive methods have
been described, and limitations addressed, with the intent of reinforcing that no model should be
used indiscriminately. Although each approach suggests progress in predicting ASD behavior,
simplifying assumptions, limitations in current analytical methods, lack of diverse supporting data,
and/or computational limitations indicate that further studies are needed. As research in this
particular area grows, and as computational modeling capabilities continue to improve, it is
projected that scientific understanding of the complexities of ASDs will advance as a result,
leading to improved predictions of ASD formation and physical stability.
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Chapter 3. Differential Scanning Calorimetry
Isothermal Hold Times Can Impact Interpretations of
Drug-Polymer Dispersability in Amorphous Solid
Dispersions
As described in the previous chapter, there are many existing methods for the modeling
and prediction of ASD formation. For models based on experimental data, it is certainly necessary
to have a good understanding of the analytical methods applied. It is arguably even more important
to know the limitations of each analytical method. In this chapter some of the potential pitfalls in
the application of differential scanning calorimetry (DSC) are discussed. DSC is a commonly
employed analytical technique for the analysis and characterization of ASDs, however, steps
typical of standard temperature programs can alter the material in situ. It is important that the
analyst not misinterpret changes that occur in situ during heating as indicative of the original state
of the sample. In this chapter data for two active pharmaceutical ingredients are detailed, wherein
isothermal hold times, traditionally employed to remove thermal history and/or residual solvent,
were observed to impact the observed dispersability of the compounds in polyvinylpyrrolidone
vinyl-acetate copolymer (PVPva). Re-crystallized tolbutamide was observed to re-dissolve in
PVPva, while terfenadine was observed to crystallize during the isothermal hold period. Exposing
co-solidified drug-polymer mixtures to temperature changes and experimental hold times can
potentially confound correct categorization of dispersability, particularly when DSC is used as the
lone characterization technique. This chapter further illustrates the importance of using a suite of
characterization techniques to improve the certainty of conclusions made with respect to the true,
initial physical state of a co-solidified mixture,28 while taking care to understand the impact that
each has on complex analytical data.
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3.1. Introduction
Amorphous solid dispersions (ASDs) provide a promising formulation strategy for
improving the apparent aqueous solubility of poorly water soluble drugs.9,

12, 149

Many

characterization techniques are commonly applied to assess the physical state of ASDs.
Differential scanning calorimetry (DSC) is one of the most commonly employed, however, this
method is not without its limitations with respect to characterizing drug-polymer behavior.120 In
general, the presence of a single glass transition temperature (𝑇𝑔 ) and the absence of API melting
is interpreted as evidence of a dispersed system. However, when a drug and polymer have similar
𝑇𝑔 values, these transitions may overlap merely as a result of the relative proximity of their pure
component values.120 Additionally, different materials can have variations in the magnitude of heat
capacity changes (∆𝐶𝑝 ) and widths associated with glass transition events, potentially exacerbating
this issue.120 DSC is also known be limited with respect to the domain size of separated phases,
with estimates that phase separation at domain sizes smaller than approximately 50 nm may go
undetected.24
The impact of thermal history may also be detrimental to interpretation of ASD
characterization data, particularly when applying relationships such as the Gordon-Taylor150 or
Couchman-Karasz151 equations, where the location of the glass transition temperature for the
mixture (𝑇𝑔,𝑚𝑖𝑥 ) relative to the pure components is central to subsequent inferences. As a result,
it is recommended that the thermal history of co-solidified mixtures be erased prior to thermal
characterization,110 since the position of 𝑇𝑔,𝑚𝑖𝑥 is dependent on the thermal history of the
sample.152, 153 Likewise, residual water or other solvents has the potential to plasticize 𝑇𝑔,𝑚𝑖𝑥 ,
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and/or obscure important thermal events as a result of evaporation, and should be removed from
samples.
Thermal history erasure and solvent removal can be accomplished in DSC experiments by
preliminarily ramping to an elevated temperature, e.g., 105 °C,48 which is isothermally maintained
for a period of time (herein referred to as the “hold time”). The potential negative impact of such
a heat treatment was identified by Kerč and Srčič, who advised that care should be taken to avoid
inadvertently eradicating transitions of interest.110
For the present work, it was hypothesized that increasing isothermal hold times prior to
DSC characterization could impact the experimentally observed dispersability of the drug in
polymer, where dispersability was defined in Chapter 1 as the observation of a homogeneous
mixture of API and polymer at the time of characterization, and does not necessarily indicate
thermodynamic stability of that mixture. The goal of this chapter was to demonstrate that DSC
hold times, which are often used to erase thermal history and remove moisture or other solvents
from samples, can lead to erroneous conclusions regarding the initial state of a co-solidified
mixture. Two API were selected based on their previously established dispersability in
polyvinylpyrrolidone vinyl acetate copolymer (PVPva). Increasing isothermal holds were shown
to have the potential to obscure the initial state of the co-solidified mixture by either inducing
crystallization of the API, or re-dissolution of the API into the polymer.
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3.2. Materials & Methods
3.2.1.

Materials

Tolbutamide was purchased from MP Biomedicals (Solon, OH). Terfenadine was
purchased from Sigma-Aldrich (St. Louis, MO). Kollidon VA64 (PVPva) was a gift from BASF
(Ludwigshafen, Germany).

3.2.2.

Preparation of Co-Solidified Mixtures

Co-solidified mixtures were prepared using a standard in-house melt-quench method,
which has been previously described.48 Briefly, polymer and API were weighed and combined in
a scintillation vial where they were manually dry blended for a period of approximately 5 min to
form mixtures reported as w/w ratios. The contents were then transferred to a crucible, which was
immersed in a silicone oil bath that was held at a preparation temperature (𝑇𝑝𝑟𝑒𝑝 ) of approximately
165 °C. This temperature was above the respective melting temperatures of both API, and high
enough to sufficiently lower the viscosity of PVPva to permit mixing. Molten mixtures of drug
and polymer were manually stirred approximately every 5 min, and after 30 min, each mixture was
quenched by immersion of the crucible into an ice water bath under dry nitrogen purge. The
resulting co-solidified mixture was transferred to a disposable petri dish and stored in a desiccator
over P2O5 (approximately 0% RH) for at least 18 h. Prior to sample preparation, thermogravimetric
analysis (TGA) was used to confirm the thermal stability of the API over the planned duration of
heating (i.e., 30 min at 165 °C) as indicated by weight loss <2%.
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3.3. Characterization
3.3.1.

Differential Scanning Calorimetry (DSC)

A model Q100 DSC (TA instruments, New Castle, DE) was used with a 50 mL/min
nitrogen purge. Samples weighing ~3-7 mg were placed into Al hermetic pans with punctured lids.
Enthalpy calibration was performed using In, and temperature calibration was performed using Sn,
In, and o-terphenyl. The initial DSC method is shown in Figure 16a, in which Step 2 was adjusted
to investigate the impact of hold time duration on inferences made with respect to the state of the
co-solidified mixture. As such, further references to ‘hold time’ in this chapter refers specifically
to the duration of the isothermal hold during Step 2. The ‘pre-heat’ step refers to Steps 1 and 2,
during which the samples were heated to 105 °C to remove residual moisture and erase thermal
history (see Figure 16b). In experiments where ‘no pre-heat’ is indicated, Steps 1 and 2 were
excluded, and the sample was immediately cooled from the instrument standby temperature (40
°C) to low temperature (𝑇𝑙𝑜𝑤 ). At a minimum, 2 replicate samples were tested for each hold time.
Inferences made with respect to the dispersability of the API in PVPva were based on the presence
of a single glass transition temperature, and the absence of a melting endotherm.
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Figure 16: (a) General DSC method, (b) A plot visualizing example DSC methods where
Tlow = -60°C, c) representative DSC thermograms for tolbutamide:PVPva (3:1 w/w) and d)
terfenadine:PVPva (3:1 w/w) subject to increasing isothermal holds (105°C) prior to initiation of
temperature program.

3.3.2.

Powder X-Ray Diffraction (PXRD)

PXRD patterns were collected using an X’Pert Pro MPD system (PANalytical B.V.,
Almelo, Netherlands) in transmission mode, with an operating voltage of 45 kV and amperage of
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40 mA. The instrument was equipped with an elliptical mirror, Cu anode (λ= 1.5406° Å), and
X’Celerator™ detector. Co-solidified mixtures were placed between two Kapton® films in a ring
holder and rotated to permit full volume interrogation. Diffractograms were collected using an
angular step size of 0.017° 2θ over a range of 2 to 100° 2θ, with an irradiation time of 51.04 s per
step.

3.3.3.

Polarized Light Microscopy (PLM)

An Olympus BX-51 optical microscope with dual polarizing filters was used to inspect
samples for birefringence and to collect photomicrographs. The presence of crystallinity was
informed by observations of birefringence in prepared co-solidified mixtures. Hot-stage polarized
light microscopy (HSM) was performed using an Instec HCS 302 Pelletier temperature-adjustable
stage with an STC 200 temperature controller (Instec, Boulder, CO) to observe the behavior of the
binary mixtures when exposed to increases in temperature and during isothermal holds at elevated
temperature (105 °C).

3.4. Results & Discussion
Tolbutamide and terfenadine were selected as model compounds owing to their observed
differences in dispersability with PVPva the day after preparation.48 These conclusions were
confirmed via repeat preparation and characterization using DSC, PLM, HSM, and PXRD.
Crystallization of terfenadine in 3:1 w/w terfenadine:PVPva preparations was indicated by
birefringence observed in the co-solidified solid (see Figure 17a). A small endotherm consistent
with the melting temperature of terfenadine was also sometimes observed by DSC. In contrast,
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tolbutamide was dispersable in PVPva one day after preparation as indicated by a single 𝑇𝑔,𝑚𝑖𝑥 ,
absence of characteristic diffraction peaks in PXRD diffractograms, and no observable
birefringence consistent with the melting point of the drug, as informed by PLM and HSM.
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Figure 17: Characterization of terfenadine:PVPva following 24 h of storage at room temperature
over P2O5 and with an additional 1 hour storage at 105 °C; (a) PLM image showing small
crystallites after 24 h over P2O5. (b) PLM image showing significant crystal growth after an
additional 1 h storage period in an oven at 105°C. (c) DSC thermogram showing a significant
increase in melting enthalpy after storage at 105°C for 1 h. (d) PXRD diffractograms show no
detectable crystallinity in the co-solidified mixture after 24 h over P2O5 (green diffractogram), but
characteristic peaks are apparent after the 1 h storage period at 105°C (orange diffractogram) when
compared to the diffractogram of crystalline, as received terfenadine (black diffractogram).
80

3.4.1.

Isothermal hold times may induce sample

crystallization
Co-solidified samples of 3:1 w/w terfenadine:PVPva mixtures were characterized by DSC
as described in section 2.3.1. Repeat preparations consistently resulted in the formation of small
crystallites throughout the co-solidified mixture, whose birefringence was observed by PLM. DSC
results were less consistent, with up to 3 distinct 𝑇𝑔 values appearing, sometimes accompanied by
an endotherm consistent with the melting point of the drug. Regular observation of the melting of
recrystallized drug was expected to be a limitation of sample size, and the relative amount of
crystalline API sampled from the whole. Nonetheless, as isothermal hold times were increased
(105 oC for up to 30 min) terfenadine also appeared to recrystallize in situ, with endotherms
attributable to melting appearing more consistently from sample-to-sample. Figure 16d shows
representative DSC thermograms of the terfenadine:PVPva samples, demonstrating that increasing
the DSC experimental hold time resulted in a commensurate increase in the degree of terfenadine
crystallization. The presence of distinct endothermic peaks may be the result of varying crystallite
sizes, or the crystallization of multiple polymorphs during sample storage. The likely presence of
distinct polymorphs of terfenadine was more evident when the experimental ramp rate was reduced
to 0.5 °C/min, as previously described by Leităo et al.154 (see Figure 54 in the Appendix).
The recrystallization of terfenadine induced by holding at 105 °C for different durations
was further supported by dividing a co-solidified mixture of terfenadine:PVPva in half after
overnight storage over P2O5. One half was returned to the P2O5 desiccator at room temperature,
while the other half was placed in an oven maintained at 105 °C for 1 h, after which it was allowed
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to cool back to room temperature. Figure 17a and Figure 17b respectively show representative
PLM images of the samples maintained continuously at room temperature and those heated in the
oven. The sample heated to 105 °C for 1 h shows that this exposure resulted in substantial
terfenadine crystallization. DSC analysis (Figure 17c) also showed a significantly larger
endotherm for the oven-stored sample, relative to the half that was continuously maintained at
room temperature. PXRD patterns of each subsample are shown in Figure 17d, showing that the
oven-heated sample contains several diffraction peaks characteristic of terfenadine.
HSM was used to visually observe a portion of each co-solidified mixture at 105 °C, in real
time. Figure 19 shows a series of images depicting the increasing amount of recrystallized
terfenadine over time, which becomes visually evident after 15 min at 105 °C on the hot stage
(Figure 19c) and continues to increase over time. These results show that the co-solidified mixture
of 3:1 w/w terfenadine:PVPva has the potential to crystallize during isothermal DSC periods
typically used for the removal of solvent and thermal history. In this case, the crystallization
appeared to occur slowly enough to avoid detection by DSC, but could be detected using PLM.
Further characterization of these samples by HSM (Figure 19) revealed that the crystallization of
terfenadine occurred quite slowly during the hold time, resulting in changes in heat flow over time
that were apparently below the detection limit of DSC. While the kinetics of terfenadine
crystallization at 105 °C may be slow enough to prevent significant deviation from the original
state of the sample at reasonable hold times in this case, this example demonstrates the potential
for inadvertent crystallization to occur during thermal analysis, particularly if erasing the thermal
history is standard protocol, as it often is. It is possible that such a thermal treatment could
significantly change the physical state of the sample, causing an analyst to come to conclusions
about the physical state which are inconsistent with its true state at room temperature.
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3.4.2.

Isothermal hold times may induce dissolution of API

in polymer
Co-solidified samples of 3:1 w/w tolbutamide:PVPva mixtures were characterized by DSC
and consistently showed a single 𝑇𝑔 , indicating that the tolbutamide was dispersed in PVPva.
Increasing the durations of isothermal hold time (105 °C for up to 30 min) showed no detectable
change in the state of the sample, as shown in Figure 16a. Only the thermogram for the sample to
which no isothermal hold was applied (i.e., the ‘no pre-heat’ sample) was observably different
from the others, showing an endothermic event between approximately 60-100 °C, which was
most likely the result of water loss from the sample.
A subsample of the tolubtamide:PVPva co-solidified mixture was subjected to the oven
experiment as described in the previous section. No birefringence was observed when examined
using PLM after exposure to 105 °C for 1 h (Figure 18b), consistent with observations for the
sample of the same mixture continuously maintainted at room temperature (Figure 18a),
suggesting that tolbutamide did not recrystallize when held at elevated temperatures in the oven.
This conclusion was supported by both DSC and PXRD analyses, from which representative
thermograms and diffractograms are respectively shown in Figure 18c and Figure 18d.
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Figure 18: Characterization of tolbutamide:PVPva following 24 h of storage at room temperature
over P2O5 and with an additional 1 h storage at 105 °C; (a) PLM image showing no birefringence
after 24 h over P2O5. (b) PLM image showing no change after an additional 1 h storage period in
an oven at 105°C. (c) DSC thermogram showing no significant difference after storage at 105°C
for 1 h. (d) PXRD diffractograms show no detectable crystallinity in the co-solidified mixture after
24 h over P2O5 (yellow diffractogram), or after the 1 h storage period at 105°C (blue diffractogram)
as compared to the crystalline, as received tolbutamide (black diffractogram). As received
tolbutamide was determined to be polymorph I (see Figure 55a in the Appendix, CSDZZZPUS02)155, 156).
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Figure 19: HSM of terfenadine:PVPva (3:1 w/w) stored at room temperature over P2O5 for 24 h.
A heating ramp of 10°C/min was applied. (a) 25°C (b) 105°C (c) Isotherm at 105°C for 15 min (d)
Isothermal at 105°C for 30 min (e) Isothermal at 105°C for 60 min. Crystallization of terfenadine
is observed.

Tolbutamide:PVPva co-solidified mixtures were stored in a desiccator over P2O5 for
approximately 9 months and re-analyzed by PLM, where significant recrystallization of the drug
was observed (Figure 21a). However, initial re-characterization of aged samples by DSC using a
2 min hold time at 105 °C appeared to show no evidence of crystallinity in the sample. Elimination
of the hold time in DSC experiments revealed the rapid dissolution of the tolbutamide crystals into
the polymer, as evidenced by the endotherm ranging from approximately 40-110 °C in Figure 20,
which was confirmed by HSM images (Figure 21). During HSM, as the temperature was increased,
the viscosity of the sample was reduced, and the sample flowed more easily (Figure 21c).
Dissolution of the crystals was immediately apparent, and after only 1 min at 105 °C (Figure 21e),
birefringence was no longer observed in the aged samples. Although tolbutamide is known to have
a low melting temperature polymorph (Form V, Tm ≈ 102 °C157), it was confirmed by PXRD that
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the endotherm observed in DSC analysis of aged samples was the result of dissolution into the
PVPva during heating and not melting of a different solid form. The polymorphic form of
tolbutamide as received, was Form I, while the recrystallized tolbutamide in the aged samples was
determined to be Form II (Tm ≈ 117 °C158). PXRD data can be found in Figure 55 in the Appendix.

Figure 20: 9 month aged Tolbutamide:PVPva (3:1 w/w) DSC analysis
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Figure 21: HSM of tolbutamide:PVPva (3:1 w/w) aged at room temperature over P2O5 for 9
months. A heating ramp of 10 °C/min was applied. (a) 25 °C (b) 80 °C (c) 90 °C (d) 100 °C (e)
isothermal at 105 °C for 1 min. Re-dissolution of the tolbutamide into the polymer is observed.

In this case, the initial inferences about the dispersability of the tolbutamide:PVPva
dispersions remain unchanged, owing to the application of a suite of analytical techniques.28
Characterization of the aged 3:1 w/w tolbutamide:PVPva co-solidified mixtures illustrates the
potential for DSC hold times to result in rapid re-dissolution of crystalline API into the polymer,
potentially leading to erroneous conclusions about the initial dispersability of the sample. Similar
events have been described previously, such as the re-dissolution of felodipine and hesperetin into
poly(ethylene glcyol) observed by Bikiaris et. al.159 These results suggest that when developing a
DSC method, each step should be carefully considered with respect to its potential to physically
influence the sample.
Perhaps most importantly, these data also confirm that relying on a single analytical
method to characterize an ASD is ill-advised, and classification of ASD phase behavior is more
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appropriately confirmed by multiple analytical techniques.28, 160 As demonstrated here, important
thermal events can potentially be obfuscated as the sample is subjected to changing temperatures.
This can result in in situ phase changes such as crystallization or dissolution of crystalline API into
the polymer, subsequently resulting in erroneous conclusions regarding the true initial physical
state of an amorphous solid dispersion.

3.5. Conclusions
Exposing co-solidified drug-polymer mixtures to temperature changes and experimental
hold times typical of post-manufacturing solvent removal and pre-DSC thermal history erasure
can potentially confound correct categorization of dispersability behavior, particularly when DSC
is used as the lone characterization technique. DSC hold times impacted dispersability conclusions
by either inducing crystallization of the API (e.g., in the case of terfenadine in PVPva) or by
causing dissolution of the API into the polymer (e.g., in the case of aged tolbutamide in PVPva).
The former example illustrates a situation in which a co-solidified mixture might be categorized
as partially dispersable in PVPva as a result of the DSC method imposed during categorization. In
the latter example, tolbutamide might be categorized as fully dispersed in PVPva even after
extended storage, if the absence of melting in the thermogram was assumed to be from complete
persistent dispersion in the polymer during preparation, rather than dissolution of residual crystals
in the polymer at elevated temperatures during the DSC experiment. Relying on any one technique
will increase the likelihood of erroneous inferences with respect to the true state of the system due
to the inherent limitations of each analytical technique. The present work illustrates the importance
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of using a combination of techniques (e.g., DSC, PXRD, PLM, HSM) to improve the certainty of
conclusions made with respect to the true physical state of a co-solidified mixture.
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Chapter 4. Modeling and Prediction of Drug
Dispersability in Polyvinylpyrrolidone-Vinyl Acetate
Copolymer using a Molecular Descriptor
Having reviewed the literature for methods for the prediction of ASD dispersion, and
having discussed the limitations and pitfalls of a particular analytical method, this chapter will
describe the expansion of a model for the prediction of ASD dispersability using a molecular
descriptor. This chapter will describe the experiments and data analysis associated with specific
aim I (confirm the usefulness of the R3m model), and touch briefly on specific aim II (improve
the interpretability of the model).
This chapter describes the expansion of a novel in silico model that predicts the
dispersability of 18 small organic molecule drug substances in PVPva. The molecular descriptor
R3m (atomic mass weighted 3rd order autocorrelation index) is shown to be predictive of the
formation of amorphous solid dispersions at two drug loadings (15% and 75% w/w), using two
preparation methods (melt-quenching and solvent evaporation using a rotary evaporator). Cosolidified samples were characterized using a suite of analytical techniques, which included
differential scanning calorimetry, powder X-ray diffraction, pair distribution function analysis,
polarized light microscopy, and hot stage microscopy. Logistic regression was applied, where
appropriate, to model the success and failure of compound dispersability in the water soluble
dispersion platform copolymer PVPva. R3m had a combined prediction accuracy greater than 90%
for tested samples. The usefulness of this descriptor appears to be associated with the presence of
relatively heavy atoms on molecules in the API library (e.g., Cl) in the molecular structure of the
API, and their location with respect to the geometric center of the molecule. Given the higher
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electronegativity and atomic volume of these types of atoms, it is hypothesized that they may
impact the molecular mobility of the API, or increase the likelihood of forming non-covalent
bonding interactions with the carrier polymer.

4.1. Introduction
Amorphous solid dispersions (ASDs) are a proven formulation strategy for improving
dissolution of poorly water soluble drug substances. This approach has received substantial
attention owing to the prevalence of water insoluble molecules in current pipelines of the
pharmaceutical industry.161 There are, however, significant challenges with respect to the
successful development of ASDs, as evidenced by the relatively few formulations that have been
approved for human use, since potential benefits to absorption were first observed,3 and the
pharmaceutical application of solid solutions was first proposed.162 More recently, the number of
ASDs that have successfully reached the market has increased, nevertheless, limited fundamental
understanding remains, particularly with respect to issues surrounding their formation and physical
stability.4
Several specific and non-specific interactions have been proposed to be of importance with
respect to successful formation and persistence of ASDs, including crystallization inhibition due
to a kinetic barrier for nucleation,5 antiplasticization effects that reduce molecular mobility,6 and
specific non-bonded interactions, such as hydrogen bonding.7,

8

Reliable prediction of ASD

dispersability, however, remains difficult, particularly with new chemical entities for which
limited quantities are available during early development. It is ultimately necessary to perform
extensive experimental studies to confirm that an API can successfully form an amorphous solid
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dispersion by intimate mixing with a carrier polymer, followed by co-solidification without
recrystallization (herein referred to as ‘dispersability’). Additionally, confirmation that the
formulation remains physically stable for pharmaceutically relevant periods of time is important
for dispersable API in order to estimate product viability. Assessment of dispersability and
physical stability by trial-and-error is costly, and may not be feasible, depending on the quantities
of API available. Improved prediction of dispersability has the potential to reduce development
costs by preemptively identifying promising binary mixtures, thereby reducing the experimental
burden. If such a ‘go/no-go’ decision can be made before experiments are necessary by identifying
attributes of an API essential for dispersability in a given polymer, it is expected that development
costs and time-to-market will decrease.
Successful dispersability of an API molecule in a polymer matrix likely depends on a
complex combination of materials properties that facilitate the interactions necessary to form an
ASD. Molecular descriptors are being investigated to help elucidate those properties that are most
important for dispersability. It is hypothesized that molecular descriptors most highly correlated
with ASD formation are reflective of the combined attributes of the API molecule necessary for
dispersion in a given carrier polymer, in this case, polyvinylpyrrolidone-vinyl acetate copolymer
(a.k.a. PVPva or copovidone). Previous work showed that a single molecular descriptor (R3m)
was predictive of solid dispersion potential for a 12-member API library in PVPva48 prepared by
melt-quenching (M/Q) at a fixed drug loading (75% w/w). Although these initial results were
promising, it remained uncertain if predictions made using R3m were more broadly applicable.
The objective of this work was to further examine the usefulness of the R3m molecular descriptor
as a predictive tool for dispersability of API in PVPva at different concentrations, prepared using
different manufacturing processes.
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4.2. Materials and Methods
4.2.1.

Materials

Bicalutamide (90357-06-5) was purchased from Enzo Life Sciences (Farmingdale, NY).
Ketoconazole (65277-42-1) was purchased from Spectrum Chemicals (Gardena, CA).
Sulfanilamide (63-74-1) was purchased from Acros Organics (Geel, Belgium). Chlorpropamide
(94-20-2) and Tolbutamide (64-77-7) were purchased from MP Biomedicals (Solon, OH).
Cloperastine HCl (14984-68-0), Indomethacin (53-86-1), Quinidine (56-54-2), and Terfenadine
(50679-08-8) were purchased from Sigma-Aldrich (St. Louis, MO). Cimetidine (51481-61-9),
Felodipine (72509-76-3), Itraconazole (84625-61-6), Nifedipine (21829-25-4), and Propranolol
HCl (3506-09-0) were purchased from TCI Chemicals (Tokyo, Japan). Melatonin (73-31-4) was
purchased from Alfa Aesar (Ward Hill, MA). ABT-072 (1132936-00-5), ABT-102 (808756-710), ABT-348 (1227939-82-3) and PVPva (25086-89-9, BASF, Kollidon VA 64 Fine) were
obtained from AbbVie Inc. (North Chicago, IL). The molecular structures of APIs used in the
present work are shown in Figure 22.
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Figure 22: Molecular structures of API in the compound library.
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4.2.2.

Dispersion Preparation

4.2.2.1.

Melt-Quench (M/Q) Method

API and PVPva were separately weighed and transferred to a scintillation vial in the desired
weight percent proportions. The powders were physically mixed for 5 min by manual agitation.
The entire sample was then transferred to a crucible, which was heated by immersion in a silicone
oil bath for 25-30 min at a temperature 10°C-15°C above the melting temperature of the API
(Tm,API). In the event that Tm,API was less than 150°C (for example, melatonin with a Tm,API =
118°C), the mixture was held isothermally at 165°C to ensure polymer viscosity conducive to
liquid mixing. Hold times between 25-30 min (as determined by thermogravimetry) were used so
that no API lost more than 2% weight at the preparation temperature, due to thermal degradation.
Based on this criterion, no API:PVPva mixture was maintained at temperature for less than 25
min, during which the molten mixtures were mixed periodically. Finally, the liquid mixtures were
immersed in an ice water bath under nitrogen purge until hardened (1-2 min). Samples were
transferred to a 0% RH desiccator containing P2O5 to remove any residual water, as well as to
prevent moisture uptake and consequent plasticization. All co-solidified mixtures were prepared
in triplicate and characterized after 24 h.

4.2.2.2.

Solvent-Evaporation (S/E) Method

A single solvent (methanol) was used to prepare all of the co-solidified mixtures, to avoid
complicating factors that would result from using a variety of different solvents. These factors
include variable evaporation kinetics (a longer drying time can promote undesired API
recrystallization), and changes in molecular-level interactions of solvent with the polymer and/or
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API. API solubility in methanol was obtained using literature values, where available, or estimated
by visual inspection. Solids were weighed and transferred to 500 mL evaporating flasks to which
methanol was added, followed by sonication to aid in dissolution. The flask was then attached to
a Büchi rotavapor R-210 equipped with a vacuum pump (KNF Laboport, Model N820). The flask
was immersed in a water bath set to maintain an experimental temperature of 50°C, and oriented
at an immersion angle that was generally 21°. For samples in which the solubility of the API in
methanol was comparatively lower, larger volumes of methanol were required, and the immersion
angle was adjusted to 28°. Samples were left on the rotary evaporator for at least 1 h after the
appearance of solid inside the flask. The flask was then stored in a vacuum (approximately -14
psi) at room temperature with P2O5 to remove residual solvent and moisture. All co-solidified
mixtures were prepared in triplicate and characterized after 24 h.

4.2.3.

Characterization

Previous work demonstrated the necessity of using multiple complementary
characterization techniques to appropriately classify phase behavior of amorphous solid
dispersions.28, 163, 164 When used independently, the inherent limitations of each method can lead
to erroneous inferences regarding the true state of the system.165 In the present work, a combination
of techniques including DSC, PXRD, polarized light and hot stage microscopy, and PDF analysis
of PXRD data were collectively used for these experiments, to improve the certainty of
dispersability classifications. The use of this particular suite of analytical techniques to accurately
categorize solid dispersion behavior was discussed in detail in a previous publication.28
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4.2.3.1.

Powder X-ray Diffraction (PXRD)

PXRD patterns were generated consistent with previous work with these systems, to allow
comparison.48 Diffraction data were collected using an X’Pert Pro MPD system (PANalytical
B.V., Almelo, Netherlands) in transmission mode, equipped with a Cu anode (λ = 1.5406° Å),
elliptical mirror, and X’Celerator™ detector. The operating voltage and amperage were set to 45
kV and 40 mA, respectively. Samples were held between two Kapton® films, mounted in a ring
holder and rotated throughout experimentation, to allow for full volume interrogation. Irradiation
time was set to 51.04 s per step with an angular step size of 0.017° 2θ over a range of 2 to 100°
2θ. A total of three PXRD patterns were collected for each preparation.

4.2.3.2.

Differential Scanning Calorimetry (DSC)

A model Q100 DSC (TA instruments, New Castle, DE) was regularly calibrated using
o-terphenyl, In, and Sn to perform a three-point temperature calibration. Enthalpy calibration was
performed using In. N2 was used as the purge gas during all experiments, at a rate of 50 mL/min.
Solid samples were weighed (3-7 mg) into Al hermetic pans with pin-holed lids, which were
subsequently crimped. The experiments began with a 20°C/min heating ramp to 105°C, followed
by a 2 min isothermal hold to expel residual moisture and erase thermal history. The sample was
then cooled at a rate of 20°C/min to -20°C, or a temperature at least 20°C below the glass transition
temperature of the API to allow baseline equilibration. The sample was then heated at 20°C/min
to Tm,API + 10°C, and all thermal events were identified and interpreted. At least three separate
DSC measurements were performed on samples from each solid preparation.
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4.2.3.3.

Microscopy

An Olympus BX-51 optical microscope with dual polarizing filters was used to observe
samples and collect photomicrographs. Birefringence informed the presence of crystalline API in
prepared samples. To confirm that the crystallinity was associated with the API, a portion of each
sample was also heated at 10°C/min to a temperature above Tm,API using an Instec HCS 302
Pelletier hot stage with an STC 200 temperature controller (Instec, Boulder, CO). Hot-stage
microscopy was also used to corroborate DSC data, as it allowed visual observations of the samples
during non-isothermal experiments.

4.2.3.4.

Pair Distribution Function (PDF)

The pair distribution function is a total scattering technique which is well described
elsewhere.26 Its application in the pharmaceutical sciences has also been previously described,166,
167

and its usefulness to help differentiate between phase-separated and fully disperse systems has

been previously shown.48, 166, 168 PDF transforms of PXRD data were performed for each individual
amorphous component, as well as for the co-solidified mixtures. Diffraction patterns having
crystalline peaks were excluded from PDF analysis. Where pure component amorphous API solids
could not be prepared, usually owing to very rapid recrystallization, PDF analysis could not be
performed. The PDF transforms for the independent components were linearly combined and
compared to the PDF transform of the co-solidified mixture. When a system is fully dispersed, it
is expected that the short range order would change relative to that of a physical mixture of the
same individual components, owing to the well distributed, intimate intermingling of polymer and
API molecules in the disperse system. PDF data suggestive of dispersions are, therefore, expected
to show significant deviations from simulated PDFs that result from the weighted linear
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combination of independent amorphous components. In contrast, the PDF data suggestive of a
phase separated system are expected to have similar PDF patterns to the weighted linear
combination of independent amorphous components. PDF analysis was performed using in-house
software developed using MATLAB (v.2012b, MathWorks®, Natick, MA).

4.2.3.5.

Classification

Figure 23 shows representative characterization data. A scheme for the classification
process used for each preparation is shown in Figure 24. Analytical observations (PXRD and PDFtransformed diffraction data, DSC, PLM, and HSM) were combined to categorize the
dispersability (or not) of the binary systems, at a specific concentration, 1 day after each was
prepared. Co-solidified mixtures characterized as non-crystalline and/or disperse systems by all
methods were classified as containing API that ‘successfully dispersed’ in PVPva, while solids for
which one or more techniques revealed either crystallinity or phase separation, were classified as
having API that ‘failed to disperse’ in PVPva. This dichotomous classification was applied to
enable logistic regression of the phenomenology for the purposes of screening correlations with
molecular descriptors.
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Figure 23: Representative characterization data for several compounds in the library. (a) PXRD
data confirm crystallinity in quinidine 15% (S/E) co-solidified mixtures. Note: Quinidine
recrystallized as a methanolate (CSD ID: MUHZUM18). Cimetidine 15% (M/Q) is X-ray
amorphous, as indicated by the absence of diffraction peaks. (b) DSC data representing three
potential outcomes: Ketoconazole 15% (M/Q) appears to be dispersed, based on the appearance of
a single Tg. Melatonin 15% (M/Q) is phase separated, as indicated by the presence of 2 distinct
Tg’s. Quinidine 15% (S/E) is partially crystalline, as indicated by the appearance of an endotherm.
(c) PLM data representing two possible outcomes: Chlorpropamide 15% (M/Q) appears
amorphous, as indicated by the lack of birefringence. Quinidine 15% (S/E) is birefringent,
indicating crystallinity. (d) PDF data representing two possible outcomes: The melatonin 75%
(M/Q) co-solidified mixture does not significantly deviate from the linear combination of the
individual components, suggesting phase separation. The felodipine 15% (S/E) co-solidified
mixture does (deviations shown in green), suggesting molecular dispersion.166
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Figure 24: Dispersion classification decision tree. A suite of analytical techniques is necessary to
reduce the likelihood of incorrect inferences that can result from the limitations of any individual
technique.10 The applied analytical techniques include powder X-ray diffraction (PXRD),
differential scanning calorimetry (DSC), polarized light microscopy (PLM), hot-stage microscopy
(HSM), and analysis of pair distribution function (PDF) transformed X-ray data.

4.2.4.

Calculation of Molecular Descriptors

Chemical structures were converted into SMILES format169 for entry into the
E-DRAGON170, 171 software. Within E-DRAGON, three-dimensional coordinates were generated
using the CORINA172 algorithm. The R3m descriptor was previously found to have statistically
significant correlation with successful dispersability of API in PVPva when prepared using the
M/Q method at 75%w/w loading. Dispersability under these conditions was modeled for a 12 API
library, and successfully confirmed using 3 extra-library test compounds.48 Continued
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investigation of R3m has, therefore, been of primary interest in this work under expanded
preparation conditions. R3m (the atomic mass weighted 3rd order autocorrelation index) is a
geometric molecular descriptor of the R-GETAWAY family, which are described in detail
elsewhere.35,
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The equation for the calculation of R3m is reprinted below for convenience

(Equation (16)):
R3m = ∑A−1
i=1 ∑j>i

(16)

√hii ∙hjj
rij

∙ mi ∙ mj ∙ δ(3; dij )

Above, h is the leverage (obtained from the diagonal of the molecular influence matrix), r is the
geometric distance between atoms i and j (obtained from the geometry matrix), m is the atomic
mass (for atoms i and j), d is the topological distance between atoms i and j, and δ(3;dij) is a Dirac
delta function. For the descriptor R3m, this Dirac delta function results in the consideration of only
pairs of atoms where the topological distance is equal to 3.

4.2.5.

Statistical Modeling

Characterization of each co-solidified sample culminated in a final dichotomous inference
of either successfully dispersed (coded as 1), or failure to completely disperse, as informed by the
presence of phase separation and/or crystallinity (coded as 0). Logistic regression was performed
using JMP (SAS Institute Inc., Cary, NC) and/or MATLAB. Regression coefficients were
calculated using maximum likelihood estimation, while significance was tested using the
likelihood ratio, which follows a χ2 distribution. The likelihood ratio was determined by calculating
the change in deviance between the reduced model (containing only the intercept) and the full
model. Where multiple logistic regression was performed, statistical significance of the full model
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relative to the reduced model was assessed using drop-in-deviance tests (a.k.a. nested likelihood
ratio tests).

4.3. Results
4.3.1.

Data Summary

4.3.1.1.

Melt-Quench (M/Q) Preparations

Summaries of individual experimental observations and the subsequent inferences made
regarding dispersability for co-solidified mixtures prepared using the M/Q method can be found
in the Appendix (Table 12 and Table 13). Table 2 shows the final inferences made based on the
analytical data from the combined techniques described in the Methods section. Figure 24 shows
a schematic for classification decisions.
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Table 2: Final dispersability inferences based on interpretations of data from the suite of analytical
techniques outlined in Figure 23. A value of 1 indicates successful dispersion of the API in PVPva,
while a 0 indicates failure to disperse in PVPva. R3m values listed for each compound were
calculated as outlined in the Methods section, using Equation (16).
Melt Quench
Solvent Evaporation
15% API 75% API 15% API 75% API R3m
Propranolol HCl
0
0
0
0
0.342
Cimetidine
0
0
0
0
0.403
Melatonin
0
0
0
0
0.407
ABT-102
N/A
N/A
1
0
0.547
Terfenadine
0
0
1
1
0.561
Cloperastine HCl
0
0
0
0
0.562
Nifedipine
0
0
1
0
0.568
Quinidine
0
0
0
0
0.593
Sulfanilamide
0
0
0
0
0.595
ABT-072
N/A
N/A
1
0
0.614
Tolbutamide
1
1
1
0
0.687
ABT-348
N/A
N/A
0
N/A
0.703
Indomethacin
1
1
1
1
0.737
Ketoconazole
1
1
1
1
0.814
Itraconazole
1
1
0
N/A
0.872
Chlorpropamide
1
1
1
1
0.927
Felodipine
1
1
1
1
0.964
Bicalutamide
1
1
1
1
1.001
N/A (S/E) Insufficient Solubility in Methanol – Not Applicable
N/A (M/Q) Thermal Degradation – Not Applicable

Figure 23 shows typical examples of characterization data, which inform the final classifications
shown in Table 2. Compounds received from AbbVie (ABT-102, ABT-072, and ABT-348)
underwent significant degradation above their respective melting temperatures, indicated by
extreme discoloration during preparation and significant weight loss observed during
thermogravimetric analysis. Additionally, these compounds had much higher Tm,API, thereby
requiring much higher preparation temperatures to achieve melting, relative to those used for any
other materials in the library. Attempts to assess dispersability of AbbVie compounds in PVPva
via M/Q, therefore, required preparation at temperatures above those recommended for working
with the polymer.173 For these compounds, the M/Q preparation method was deemed inappropriate
for dispersing API in copovidone.
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Attempts were also made to co-solidify mixtures involving ABT-102, ABT-072, and ABT348 at temperatures below the Tm,API, but discoloration due to thermal degradation persisted. Even
so, it was expected that this deviation from the M/Q method used for all other compounds may
have negatively impacted the potential to consistently prepare amorphous dispersions, as it relied
on dissolution of API crystals into molten polymer, a process that was expected to occur more
slowly relative to compounds in which molten API was mixed with liquid polymer prior to
solidification. As such, ABT-102, ABT-072, and ABT-348 were excluded from the M/Q analyses.

4.3.1.2.

Solvent-Evaporation (S/E) Preparations

A summary of the final dispersability inferences for each co-solidified mixture prepared
by the S/E method can also be found in Table 2. Summaries of individual experimental
observations and the subsequent inferences made regarding co-solidified mixtures prepared using
the solvent evaporation method can be found in the Appendix (Table 14 and Table 15). Two
compounds (itraconazole and ABT-348) were poorly soluble in methanol, making preparation of
the 75% w/w API mixtures impractical. At this targeted drug concentration for an eventual
dispersion, preparations involving both API required using a significantly higher starting volume
of methanol during the solidification process in order to yield enough solid for characterization. In
fact, the amount of solvent required for these S/E experiments would have necessitated the use of
much larger round-bottom flasks capable of holding a much greater volume of API-polymermethanol solution, making the duration of solvent evaporation much longer, with kinetics that
would have been substantially different from the other solidifications performed using this method.
Correspondingly, these compounds were not included in the S/E model at this concentration.
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Thermogravimetry indicated that the volatile content (residual water and methanol) in
samples prepared by S/E ranged from 1.6-4.8% w/w. Residual solvent can change the
characteristics of the dispersion significantly, reducing the Tg and increasing molecular mobility
of this ternary system. These changes can impact dispersability, potentially leading to less
predictability with S/E than M/Q. It may be possible to reduce the residual solvent by using a
more efficient preparation method that allows for rapid solvent removal (e.g., spray drying), or by
using more intense secondary drying. As neither option was available for the present work,
operating parameters and storage conditions were controlled to make the final mixtures as
consistent as possible.

4.3.2.

Data Modeling

Figure 25a shows the originally published R3m model (red triangles), which resulted in a
boundary value of approximately 0.65 and 100% prediction accuracy of dispersability in PVPva.48
Expansion of this model to investigate predictions of dispersability at lower API concentrations
(15% w/w) resulted in identical experimental observations for all API in PVPva (orange circles),
and therefore, the same model boundary (R3m = 0.65) persisted. The perfect separation that was
observed made the application of logistic regression inappropriate, since this would result in
unstable estimations of the coefficients. For the library studied, a decision boundary of R3m = 0.65
resulted in 100% accurate predictions regarding API dispersability in PVPva, when prepared using
the M/Q method, regardless of drug loading, the value of which was determined based on the
midpoint of the interval between the R3m values for compounds across which the change in
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dispersability was observed. This means that the exact location of this boundary is subject to some
uncertainty and could change as more compounds across this R3m interval are evaluated.
Unlike the compounds prepared using M/Q, perfect separation of dispersability results on
either side of a single value of R3m was not observed for S/E preparations, allowing the use of
logistic regression for modeling. While very good prediction (90.6% overall success rate) was
achieved, R3m was less predictive of dispersability for S/E prepared samples relative to M/Q
prepared samples. Despite this, increasing R3m values for individual API continued to correlate
well with increasing probability of dispersability in PVPva. Figure 25b shows the logistic
regression models for co-solidified API:PVPva mixtures prepared by S/E at both API
concentrations studied. Compared to 15% w/w API, the 75% w/w API solvent evaporation model
showed better separation between API that were dispersable in PVPva and those that were not.
Each model did, however, show statistical significance, indicating that the R3m molecular
descriptor is a useful tool for predictions of dispersability in PVPva, even when mixtures are
prepared using S/E. Table 3 summarizes the modeling statistics for each of the models.
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Figure 25: Modeling of dichotomous classifications of API dispersability in PVPva for cosolidified mixtures prepared by (a) melt quenching and (b) solvent evaporation, against the
molecular descriptor R3m. Separation is observed in the melt quench models; all API having R3m
> 0.65 were dispersable in PVPva. Logistic regression was used to model solvent evaporation
behavior. Increasing values of R3m are still well correlated with dispersability in PVPva.
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Table 3: Modeling statistics for R3m models of dispersability in PVPva prepared by either the
M/Q or S/E methods. The abbreviation LR refers to the likelihood ratio.
Method

LR
(χ²)

Regression Equation

MQ (15% API)
MQ (75% API)

N/A - Critical dividing value
N/A - Critical dividing value

N/A
N/A

SE (15% API)

logit P(Y) = -3.96 + 6.48(R3m)

4.65*

SE (75% API)

logit P(Y) = -12.47 + 18.16(R3m)

12.36†

Standard
Error
N/A
N/A
Intercept: 2.31
Slope: 3.58
Intercept: 6.31
Slope: 9.68

Misclassification
Rate
0% (n = 15)
0% (n = 15)
27.8% (n = 18)
6.3% (n=16)

†

* p-value < 0.05
p-value < 0.0005

Attempts to improve model performance for dispersability predictions of S/E preparations
were considered. API solubility in methanol was categorized according to the USP 34 table for
approximate solubility of a compendial substance (see Table 16 of the Appendix), which was
included as a covariate in the R3m dispersability model. This resulted in a drop in deviance (χ2
test statistic) of 1.56 for the 15% API S/E model, and 2.65 for the 75% API S/E model (see Table
17 and Table 18 in the Appendix), indicating no statistically significant improvement over the
models containing R3m alone.

4.4. Discussion
Molecular descriptors are the final result of a logical and mathematical procedure that
transforms chemical information encoded within a symbolic representation of a molecule, into a
useful number.108 A fundamental assumption of quantitative structure-property relationships
(QSPR) is that the structure of a molecule is responsible for the physical, chemical, and biological
properties of that molecule.35 Both chemical and physical properties have been shown to be
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important for the formation and stability of ASDs (e.g., hydrogen-bonding influences
crystallization kinetics,7 higher molecular weight increases glass forming ability,45 polymers
increase the kinetic barrier to API crystallization or re-crystallization5). However, the extent to
which each of these properties contributes to the dispersability of API in a given polymer remains
uncertain. Additionally, the presence of such interactions does not automatically ensure
dispersability. The application of molecular descriptors could be related to the aforementioned
properties, and thereby simplify predictions. Such a model (if established) could significantly
reduce costs associated with ASD development programs by aiding ‘go/no-go’ decisions, and
helping to identify polymers of interest before performing any experimental work. Although the
current model, based on correlating the R3m descriptor of an API with its dispersability behavior
in PVPva, is only applicable for that particular polymer, expansion of this work could aid ASD
development by identifying a series of relevant molecular descriptors that relate to manufacturing
methods and polymers that have the highest probability of resulting in a successful ASD
formulation. Such a rapid formulation development tool would reduce experimental costs, and
speed time to market.
The results presented in this work indicate that the R3m molecular descriptor is predictive
of API dispersability in PVPva over a wide concentration range, and for two preparation methods.
In the case of solids prepared using M/Q routines, the R3m model was 100% accurate, correctly
predicting dispersability in PVPva for all API having an R3m value >0.65, at either 15% w/w or
75% w/w drug loading (Figure 25a). Excellent model performance with M/Q preparations seems
most likely to have been the result of the relative simplicity in the physical and processing
environments. As binary mixtures, the interactions between the API and PVPva that enable or
prevent dispersability are dominant.

Consistent with the hypothesis, the strong correlation
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between the value of R3m and the dispersability in PVPva, suggests that the complex combination
of physical and chemical attributes reflected in values of R3m >0.65 are necessary for dispersion
in PVPva. In contrast, API having R3m < 0.65 suggests that these molecules are missing some
essential contribution from the physical and chemical attributes needed to facilitate dispersion in
PVPva, and, therefore, these API failed to disperse in all experiments.
These data also indicate that the R3m descriptor predicts dispersability of a series of
molecularly diverse API in PVPva, when prepared using a S/E method, at a rate that is much better
than random chance. As shown in Table 2 the dispersability of this library of API in PVPva was
less predictable in S/E solidifications containing 15% w/w drug, where the R3m model had a
prediction accuracy of 72.2%. In contrast, at 75% w/w concentration, the R3m model performed
better, with approximately 93.8% probability of correctly predicting dispersability. Strictly
speaking, direct comparison between the performance of the 15% w/w and 75% w/w S/E models
is complicated because the model at 15% w/w had two more observations than the model at 75%
w/w. It should be noted that the exclusion of itraconazole and ABT-348 from the 75% w/w S/E
model was made for physically valid reasons, discussed below.
When considered against the relative clarity of the M/Q models, at either concentration,
the S/E data suggested that the solvent may contribute to the variability in observations for the S/E
preparations, by adding to the complexity of molecular-level interactions introduced by the
solvent, while the dispersion is forming. R3m appears to be more representative of the physical
and chemical attributes necessary for dispersability in binary systems of API and PVPva, such as
those that result from the M/Q method. In contrast, the S/E method required dissolution in
methanol during processing, and residual methanol was retained following drying. Although the
presence of an additional component (residual methanol) in S/E prepared systems does not prevent
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modeling, correlation of a molecular descriptor with dispersability is expected to be contingent on
that descriptor capturing the attributes of the API that are most important for its interaction with
the carrier polymer. However, the R3m model may not be able to completely account for the added
complexity introduced by the presence of solvent molecules as the dispersion forms and/or during
storage.
As described above, the performance of the 75% w/w S/E model benefited from the
exclusion of itraconazole and ABT-348, because their solubilities in methanol did not allow
sufficient mass of drug to be dissolved, even with the maximum volume of solvent allowed by the
flasks used for this method. In other words, correct predictions of dispersability of API in PVPva
became more probable when compounds not physically suited to preparation under the conditions
established

for

consistent

S/E

were

excluded.

Similarly,

when

itraconazole

and

ABT-348 were excluded from the 15% w/w S/E logistic regression model, a more pronounced
boundary between successful and unsuccessful dispersability resulted, as illustrated by the
steepening of the slope in Figure 26. Although the 15% w/w S/E model improves by the exclusion
of itraconazole and ABT-348, their exclusion from the model could not be similarly justified since
their preparation was not limited by methanol solubility, as was the case at the higher drug loading.
As a result, they were retained to minimize the potential to inadvertently induce bias into the
model.
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Figure 26: The logistic regression model for dispersability predictions of 15% w/w API in PVPva
improved when itraconazole and ABT-348 are excluded (indicated with x symbols), relative to the
original model at this drug loading.

In an attempt to encompass the potential effect of API solubility in methanol on
dispersability, this factor was investigated as a possible covariate with dispersability predictions
for the more complex solvent-based preparations. The solubility ranking was categorized
according to the USP 34 table for approximate solubility of a compendial substance (Table 16),
and was included as a continuous variable in the model to avoid further reductions in the degrees
of freedom. Table 17 and Table 18, as well as Figure 56 and Figure 57 in the Appendix show the
changes in model performance that resulted from inclusion of the solubility ranking. Ultimately,
drop in deviance tests showed that there was no statistically significant improvement over the
univariate model for either of the API concentrations. This may be the consequence of an
insufficiently balanced model, with respect to solubility. Capturing the impact of API solubility in
methanol warrants further investigation to better understand S/E systems.
113

It is important to note that the S/E model prediction accuracies, discussed above, reflect
shifting R3m classification boundaries for each model corresponding to a probability equal to 50%.
These shifts were caused by different conclusions for the respective calibration data sets (i.e., R3m
≈ 0.61 for the 15% w/w API model and R3m ≈ 0.69 for the 75% w/w model). It is hypothesized
that this shift is partially due to the library containing fewer compounds that were dispersable at
the higher drug concentration. This was anticipated, since the dispersability in PVPva was
expected to vary with concentration, owing to increasing levels of supersaturation in the polymer.
For example, tolbutamide and ABT-072 successfully dispersed at 15% w/w, but failed to disperse
at 75% w/w. These compounds have R3m values that border the initial decision boundary, and the
change in dispersability with concentration contributes to the shift in probability. A similar shift
was initially hypothesized for the M/Q model, where it was expected that reducing the amount of
API in the binary mixture would result in more compounds being dispersable in the PVPva.
However, observations of dispersability remained consistent between concentrations for cosolidified mixtures prepared by M/Q.
For completeness, the accuracies of the logistic regression models generated for the
15 % w/w S/E preparations (classification boundary of R3m ≈ 0.61) and 75% w/w S/E preparations
(classification boundary of R3m ≈ 0.69) were compared to the accuracy of the original
dispersability

boundary

determined

from

M/Q

data

(classification

boundary

of

R3m ≈ 0.65). The accuracy of the models were between 5 and 6 % better than the predictions based
on the original 0.65 boundary. These differences were due to one additional compound being
misclassified at each concentration by the original boundary compared to the predictions of the 15
% w/w and 75 % w/w S/E models. Expanding the compound libraries will help clarify the
boundary locations.
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It should also be noted that not all of the co-solidified mixtures prepared using S/E that
successfully dispersed at 15% w/w drug loading fell at the decision boundary. For example, two
compounds having lower values of R3m (nifedipine and ABT-102) successfully dispersed at 15%
w/w when prepared by S/E. The behavior of terfenadine also appeared to be an outlier, in that it
was dispersable at both concentrations when prepared using S/E, while it failed to disperse at both
concentrations when prepared using M/Q. In contrast, the itraconazole at both concentrations was
dispersable in PVPva when prepared by the M/Q, while it failed to disperse at 15% w/w and could
not be prepared using S/E at 75% w/w (see Figure 58 for a version of Figure 25 with relevant
compounds labeled). These results are all thought to be the result of the differences inherent to the
M/Q and S/E methods, specifically, the presence or absence of methanol as the dispersions are
forming. The facilitated dispersability of terfenadine in PVPva during S/E may be the result of
unique interactions with the methanol during preparation that were not present during M/Q
preparation. Likewise, the failure of itraconazole to disperse in PVPva during S/E suggests that
the methanol negatively impacted the drug-polymer interactions that were capable of forming and
persisting during co-solidification during M/Q. Ultimately, there were no immediately apparent
differences in the physical or chemical properties of any of these compounds that clearly identified
a cause for these outcomes, so further investigation is necessary.
Considering all these data, the molecular descriptor R3m clearly correlates with API
dispersability in PVPva, suggesting that it numerically represents a complex combination of
critical chemical and physical attributes of the API. It has been argued that the usefulness of
molecular descriptors is not limited to cases for which they are easily interpretable,35 and that the
inability to understand a descriptor using well-established chemical concepts may not necessarily
eliminate descriptor usefulness, rather, it could help reveal new concepts.35 A model that can
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predict the dispersability of an API in a specific polymer would undoubtedly be useful for
formulation development, but a convincing argument for the broader application of this descriptor
can only be expected once the physical and chemical meaning of R3m becomes more apparent.
As shown in equation (16), R3m is weighted by the mass of the atoms, relative to carbon.
For the library of compounds used to build the models (Figure 22), the heaviest atoms were
nitrogen, oxygen, fluorine, sulfur, and chlorine; all of which also have a higher electronegativity
and atomic volume relative to any other intramolecular atoms studied. As such, further references
to heavy atoms in this chapter refer specifically to N, O, F, S, and Cl, and not all atoms with high
atomic mass. These atoms are ‘heavy’ only with respect to the atoms in the molecules used to build
the R3m model. Their importance in the model of the extant library is, however, thought to be
because these relatively heavy atoms may reduce the molecular mobility of the API, or increase
the likelihood of forming non-covalent bonding interactions with the polymer, either of which
would reduce the potential for API recrystallization, and allow for persistence of a metastable
dispersion.
Notably, R3m encompasses more information than provided by atomic weight alone. This
is demonstrated by Figure 27, where the relationship between R3m and both molecular weight
(MW) and average molecular weight (AMW) are shown. While MW gives the total weight of
atoms, AMW gives a representation of the distribution of atomic weight for the atoms in the
molecule. Library molecules having more of the relatively heavy atoms will have a higher AMW.
Similarly, molecules comprised of heavier atoms will result in a larger value of R3m, particularly
when those heavy atoms are close to each other in three-dimensional space. However, investigation
of both MW and AMW as predictors of dispersability showed inferior performance compared to
R3m. This suggests that other molecular attributes encoded into the R3m descriptor, but absent
116

from average molecular weight must be important for dispersability in PVPva. Further research is
underway to evaluate the physical meaning of R3m.

Figure 27: Scatter plot showing the relationship between R3m and both molecular weight (circles)
and average molecular weight (triangles). The solid blue and dotted orange lines show the linear
regression of both molecular weight and average molecular weight against R3m, respectively.

4.4.1.

Model Limitations

As with all models, dispersability predictions involving these R3m models are limited to
the modeling-space established by the compounds from which they are calculated. Further
investigation is necessary to expand the models so that dispersability predictions can be made
without the need for extrapolation. As an example, the current model applies only to binary
mixtures of an API with the polymer PVPva. Extrapolation of the R3m molecular descriptor for
the prediction of dispersability in any other polymer is not recommended without further study.
As hypothesized, the strong correlation between R3m and API dispersability in PVPva reflects a
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complex combination of chemical and physical attributes of each compound, which are
collectively necessary for dispersion in the polymer. Changing the carrier to a different polymer
will change the physical environment in which the API is dispersed as well as the potential to form
specific, non-covalent chemical interactions between the API and polymer that contribute to its
ability to form a dispersion. This makes it likely that a different molecular descriptor (or
combination of descriptors) is needed to reflect those changes. Furthermore, the R3m model is not
necessarily expected to be applicable to a formulation that contains surfactants, commonly used in
ASD formulations.

In fact, new and perhaps multiple descriptors may be required when

surfactants are added to the formulation, as the additional components contribute to a different
physical and chemical environment into which the API is being dispersed.
Another limitation imposed by the current modeling space is that the R3m model consists
primarily of molecules having melting and glass transition temperatures within the respective
ranges of approximately 118-193°C and 13-69°C. Three of the compounds, ABT-102, ABT-072,
and ABT-348, constituted outliers with respect to these properties. This is illustrated in Figure 28,
in which the glass transition temperatures and melting temperatures of ABT-102, ABT-072, and
ABT-348 are much higher relative to the rest of the library API. Further expansion of the models
will focus on filling in these gaps in order to ensure that meaningful predictions can be made using
R3m for compounds having a wider range of properties.
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Figure 28: Histograms and outlier boxplots (shown above the histograms) for the distribution of
(a) glass transition temperatures and (b) melting temperatures for model compounds (in Kelvin).
The blue box indicates the interquartile range. The red line within the box indicates the median.
Whiskers indicate the largest and smallest value in the distribution, excluding outliers. The red
cross marks indicate outliers from a normal distribution. ABT-102, ABT-072, and ABT-348 all
have higher glass transition and melting temperatures than the other library compounds. The
boxplot indicates that in either case ABT-102, ABT-072, and ABT-348 were considered outliers
in the model.

Finally, it is important to note that the observed correlation between R3m and
dispersability, while statistically significant, is based on a relatively small experimental dataset.
This is reflected in the standard error of the coefficients in Table 3, where the relatively high values
result from the small sample size. Future work will focus on validation of the model with an
external dataset, and continued expansion of the model to increase the sample size.

4.5. Conclusions
R3m was shown to predict the dispersability of a library of up to 18 API in PVPva, prepared
at two different concentrations, using two different preparation methods. Dispersability predictions
using the R3m model were 100% accurate for dispersions prepared by melt-quenching. All API
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having an R3m > 0.65 were dispersable in PVPva, at concentrations of both 15% w/w and 75%
w/w, while API having an R3m < 0.65 failed to disperse in this polymer.
R3m predictions were less accurate for dispersions prepared using a solvent-evaporation
method, however, the prediction accuracy remained high and performed much better than random
chance alone. At a concentration of 15% w/w, it was 72.2% probable to correctly predict API
dispersability in PVPva for molecules having an R3m > 0.61. The S/E model accuracy improved
at a drug concentration of 75% w/w, at which it was 93.8% probable to correctly predict API
dispersability in PVPva when R3m > 0.69. If the R3m boundary was kept consistent across
preparation methods (i.e., R3m = 0.65 for both M/Q and S/E), the overall prediction accuracy
decreased from 90.6% to 87.5%. The slight changes in prediction accuracy for preparations
involving S/E were likely the result of additional interactions encountered during processing,
between the API, polymer and methanol. Additionally, the slow kinetics of dispersion formation
that occurred during rotary evaporation of methanol and the potential for differences in API
mobility caused by the presence of residual solvent in samples solidified according to the S/E
scheme are also likely to have created differences between the M/Q and S/E samples, and the
inferences that can be made about dispersability. These results warrant further investigation of
R3m to potentially aid in ASD formulation development, especially the physical interpretation of
the R3m descriptor.
The results described in this chapter have significantly strengthened the R3m model and
its interpretation. These data suggest that R3m is useful for the prediction of ASD formation,
however, the physical meaning of the molecular descriptor remains relatively uninterpretable. It is
necessary, therefore, to decipher a clearer meaning for R3m to obtain a more interpretable model,
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and to advance scientific understanding of the formation of ASDs. The next chapter will describe
the investigation into the meaning of the R3m descriptor.
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Chapter 5. Examining the Physicochemical Meaning
of a Molecular Descriptor which is Predictive of
Amorphous Solid Dispersion Formation for API in
Polyvinylpyrrolidone Vinyl Acetate
The previous chapter significantly strengthened the R3m model by expanding the dataset
and showing continued statistically significant predictive performance for ASD formation with
PVPva. However, the physical meaning of the molecular descriptor remained relatively
uninterpretable. It is necessary, therefore, to decipher the physicochemical meaning of R3m to
obtain a more interpretable model. The goal of the research described in this chapter is to elucidate
the physicochemical meaning of R3m and connect these properties to ASD formation.

5.1. Introduction
The utility of the R3m descriptor was supported by expanding the model to include
additional API concentrations and ASD preparation methods (Chapter 4).174 While the value of
R3m>0.65 for an API was predictive of dispersability in PVPva, direct physical interpretation of
this molecular descriptor remained nebulous. It has been argued that the usefulness of molecular
descriptors is not limited to cases for which they are easily interpretable, and that the inability to
interpret descriptors may ultimately lead to new concepts.35 Nevertheless, it is prudent to
cautiously apply models based on descriptors when no clear understanding of their meaning can
be found. Ultimately, a model that is both predictive and interpretable is more useful than a model
that is not as clearly related to well understood properties.36
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Since molecular descriptors are derived from a representation of a molecule, and it is
assumed that similar molecular structures have similar physical and chemical properties,35
interpreting the R3m descriptor in terms of API physicochemical properties most useful for
promoting dispersion formation in PVPva is expected to enhance the scientific understanding of
its utility as a formulation tool. The formation of ASDs is complex, and dependent on combinations
of thermodynamic and kinetic factors. For example, the presence of specific non-covalent
interactions has been shown to be important for the formation of ASDs, as has been demonstrated
for indomethacin and polyvinylpyrrolidone (PVP).7 However, the presence of these interactions is
not always necessary, and in some cases ASDs can be formed in the absence of such interactions,
as has been demonstrated with PVP and ketoconazole.6 This complexity makes it much more
difficult to make a priori predictions of ASD formation. The application of a simple model for the
prediction of ASD formation based on individual studies, such as the number of hydrogen bond
donors an API possesses, would be an oversimplification, and therefore, would often fail when
applied to API which are the exception to the presumed rule (e.g., in this example, ketoconazole
and PVP). Given the complexity of ASD formation, its a priori prediction was assumed to require
a model constructed from a more complicated combination of properties than those usually
reported. It was, therefore, hypothesized that R3m would better predict dispersability in PVPva for
the extant library of API (Figure 22) relative to any other descriptor or physicochemical property,
because it captures more physical and chemical information that is relevant to ASD formation in
this polymer.
To investigate this hypothesis, first, inferences were made from the R3m equation. Next,
the matrices which are used to calculate R3m were investigated in more detail, including the
specific impact of these matrices on library API. Other more interpretable descriptors were
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investigated for improved prediction for the formation of ASDs, but no other descriptor performed
as well across multiple preparation methods and concentrations. Finally, multiple linear regression
modeling of other descriptors against R3m was attempted to support inferences. In general, large
molecules, having increased topological connectivity (reflective of increased branching),
molecules having more of the relatively heavy atoms common to the extant API library (higher
molecular density), and having those intramolecular heavy atoms positioned furthest from the
geometric center (on the periphery of the 3D conformation of the molecule) have higher R3m
values, suggesting these attributes conform to R3m>0.65, which corresponds to API which are
dispersable in PVPva.

5.2. Experimental Section
5.2.1.

Preparation of Co-solidified Mixtures

Co-solidified mixtures were prepared using 2 preparation methods at 2 concentrations
(75% and 15% API). The preparation of co-solidified mixtures by either melt-quenching or solvent
evaporation is described in Chapter 4. Briefly, the melt-quench method involved dry blending the
polymer and API at specific weight ratios and transferring to a crucible. Mixtures were then heated
to 10 °C above the melting temperature of the API, and isothermally held for approximately 30
min with intermittent stirring. The molten mass was then quenched by immersion of the crucible
in ice water over which a dry N2 (g) purge was applied. The resulting solids were then stored
overnight in a P2O5 desiccator.
The solvent evaporation method required dissolution of API and polymer in methanol at
specific weight ratios in a round bottom flask. The flask was then attached to a rotary evaporator

124

and methanol was evaporated under vacuum, using a water bath to maintain a consistent
temperature at 50 °C. The resulting solids were then stored overnight in a P2O5 desiccator under
vacuum.
As described in Chapter 4, all resulting solids were characterized using powder X-ray
diffraction (PXRD), differential scanning calorimetry (DSC), and hot-stage polarized light
microscopy to categorize experiments as either dispersed or not in the PVPva. The resulting
phenomenology was regressed against a database of molecular descriptors, from which R3m
emerged as the only significant descriptor capable of accurately separating the API library shown
in Figure 22 into groups of dispersable and not dispersable in this polymer. The models are shown
in Figure 29, each of which showed statistically significant performance (p<0.05), indicating that
R3m was a useful descriptor for the prediction of ASD formation over 2 concentrations and 2
preparation methods. The reader is referred to the relevant literature for additional details.174
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Figure 29: Modeling of dichotomous classifications of API dispersability in PVPva for cosolidified mixtures prepared by (a) melt-quenching and (b) solvent evaporation, against the
molecular descriptor R3m. Separation is observed in the melt-quench models; all API having R3m
>0.65 were dispersible in PVPva. Logistic regression was used to model solvent evaporation
behavior. Increasing values of R3m are still well correlated with dispersability in PVPva.
Reproduced from Chapter 4, Figure 25 for convenience.

5.2.2.

Molecular Descriptors

Molecular descriptors were calculated using E-DRAGON170 (http://www.vcclab.org) and
the QSAR module of Materials Studio v.7.0 (Dassault Systèmes BIOVIA, San Diego, CA).175
Additional properties were collected experimentally, from cited literature, or from databases such
as PubChem,176 Cambridge Crystallographic Data Center (Cambridge, UK),156 and SciFinder.177
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Logistic regression was applied between experimental conclusions regarding dispersability
and select molecular descriptors and physicochemical properties to investigate simpler or more
interpretable models. Single and multiple linear regressions (MLR) were performed to assess
correlation of other physicochemical properties and molecular descriptors with R3m. For MLR,
the independent variables were checked for multicollinearity. Variables having high collinearity
were excluded from the models, since multicollinearity will result in unstable regression
coefficients, and likely lead to inaccurate future predictions.50 Statistical analyses were performed
in JMP and MATLAB.
For comparisons of three-dimensional structures, coordinates were obtained using the
CORINA algorithm178 (https://www.mn-am.com/) and the Cambridge Crystallographic Data
Center (CCDC).156 The calculation of R3m was performed using E-DRAGON or in-house
MATLAB code.

5.2.3.

The Calculation of R3m

R3m is a molecular descriptor from the R-indices sub-type of the R-GETAWAY family of
descriptors. GETAWAY is an acronym for GEometry, Topology, and Atom-Weights AssemblY.
This family of descriptors was first proposed by Consonni et al in 2001.51 The relevant matrices
and equations necessary for the calculation of this family of descriptors have been previously
described.35, 51, 179 Specific equations and matrices necessary for the calculation of R3m are given
below for convenience, but for additional information the reader is referred to the source
material.35, 51, 179
The general equation for R-indices is given below (Equation (17)).
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Rk(w) = ∑A−1
i=1 ∑i>j

(17)

√hii ∙hjj
rij

∙ wi ∙ wj ∙ δ(k; dij ) k = 1,2, … , d

Here, A is the number of atoms in the molecule, w is the weighting, i and j refer to 2 separate
atoms, hii and hjj are the leverages, and δ(k:dij) is a delta-Dirac function, where k is the topological
distance. For R3m, the topological distance (k) is equal to 3, and the weighting (w) is the atomic
mass relative to carbon. R3m is, therefore, known as the R-GETAWAY third order
autocorrelation index weighted by the atomic mass. The R3m equation is given below (Equation
(18)).
R3m = ∑A−1
i=1 ∑i>j

(18)

√hii ∙hjj
rij

∙ mi ∙ mj ∙ δ(3; dij )

Here, m is the atomic mass normalized to carbon for atoms i and j. The delta-Dirac function causes
the equation to equal zero for cases where the topological distance between i and j does not equal
3.
The terms used to calculate R3m are calculated using several matrices. The first of these
matrices is the molecular matrix (M). This matrix is a 3 column by A row matrix (where A is the
number of atoms in the molecule of interest) containing the three-dimensional coordinates of each
atom. The molecular matrix is then used to calculate the molecular influence matrix (H) as shown
in Equation (19), which resembles the leverage matrix of linear regression. 51 The leverage values
are obtained from the diagonal of the molecular influence matrix (H), which is calculated as shown
in Equation (19).
H = M ∙ (M T ∙ M)−1 ∙ M T

(19)

Here M is the molecular matrix and a superscripted T indicates a transposed matrix. The diagonal
terms in this matrix (e.g., hii and hjj as shown in Equation (17)) are known as the leverage values.
Equation (19) is calculated in the same manner as the projection or hat matrix for linear regression,
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and its interpretation is similar. In linear regression, data points furthest from the model center will
have the highest leverage.50 Similarly, for three-dimensional molecules, atoms furthest from the
geometric center of a molecule will have the highest leverage, and represents the influence of each
atom over the overall shape of a molecule.179 It is important to note that the leverage values for a
molecule will always sum to the number of dimensions considered. Only three-dimensional
structures are considered here and, therefore, the sum of the diagonal of the molecular influence
matrix will equal 3 for each molecule. If, however, a planar molecular such as benzene were
considered, the leverage values would sum to 2.
The geometry matrix (G) is calculated from the molecular matrix, and is an A×A symmetric
matrix containing the Euclidean distances between each pair of atoms in the molecule. The
geometry matrix is shown in Equation (20), below, where r is the geometric distance between the
subscripted atoms.
0
r2,1
G ≡[ …
rA,1

(20)

r1,2
0
…
rA,2

…
…
…
…

r1,A
r2,A
]
…
0

The distance between atoms (ri,j) is determined by calculating the Euclidean distance
between the atoms i and j, which is described by Equation (21).
(21)

ri,j = √(Mi,x − Mj,x )2 + (Mi,y − Mj,y )2 + (Mi,z − Mj,z )2

Mi,x, Mi,y, and Mi,z are, respectively, the x, y, and z coordinates for atom i from the molecular
matrix.
Finally the influence/ distance matrix (R) is calculated using the geometry matrix (G) and
molecular influence matrix (H) diagonal values (i.e., leverages), as shown in Equation (22).
(22)

R=
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√hii ⋅hjj
rij

The influence/distance matrix is an AxA symmetric matrix where the largest values for R arise
from the most external atoms (which have higher leverages), and from atoms in close proximity
to other atoms (low rij).51
In summary, the calculation of R3m includes information regarding the Euclidean distance
between atoms, the relative distance of individual atoms from the geometric center of a molecule
(leverage), the atomic mass relative to carbon, and atom connectivity.
Visualizations of the matrices described above are provided for each of the 18 library API
in Figure 59 through Figure 73 of the Appendix.

5.3. Results & Discussion
5.3.1.

Inferences from the calculation of R3m

5.3.1.1.

Topology

R3m contains information about the topological complexity of a molecule. Molecules
having more branching and/or more cyclic structures may result in a larger R3m value since
increased intramolecular interatomic connectivity will lead to more topological connections equal
to 3, and therefore, more contributions to the total. This is illustrated in Figure 30a, where the
topological distances equal to 3 for the nitrogen (N6) in indomethacin are shown (excluding
hydrogens for clarity). Given the structure of the molecule, the nitrogen atom has a total of 11
topological connections equal to 3 when all hydrogens are included. These connections are
indicated by arrows in Figure 30a (excluding hydrogens), where N6 has a topological connection
of 3 to C4, C10, C14, C17, C19, and C22. Owing to the ring structures in indomethacin, N6 has
more connections than it would in a linear molecule comprised of the same atoms. For example, a
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central carbon atom in an octane molecule has only 6 topological connections equal to 3, while its
terminal carbon atom has only 3 such connections. The number of topological connections for
each API in the library is given in Table 4.

Figure 30: Illustrations of the impact of some matrices relevant to the calculation of R3m.
Indomethacin is used here as an example. (a) A topological distance is illustrated with the N6
nitrogen in indomethacin. Arrows indicate 7 topological connections to nitrogen equal to 3
(excludes hydrogens for clarity). When hydrogens are included, the number of connections for N6
increases to 11. (b) The distance from the geometric center of the molecule is indicated with a redwhite-blue color scheme, (c) the leverage values for each of the atoms in indomethacin are given
(excludes some hydrogens for clarity).
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Table 4: Summary of data derived from the topology, weighted mass, and leverage components of R3m.
Topology
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API

R3m

MW
(g/mol)

Total #
Atoms

# Topological
Connections

Propranolol
Cimetidine
Melatonin
Terfenadine
Cloperastine
Nifedipine
Quinidine
Sulfanilamide
Tolbutamide
Indomethacin
Ketoconazole
Itraconazole
Chlorpropamide
Felodipine
Bicalutamide

0.342
0.403
0.407
0.561
0.562
0.568
0.593
0.595
0.687
0.737
0.814
0.872
0.927
0.964
1.001

259.38
252.39
232.31
471.74
329.9
346.37
324.46
172.23
270.39
357.81
531.48
705.71
276.77
384.28
430.41

40
33
33
76
47
43
48
19
36
41
64
87
30
44
43

94
59
68
207
120
86
131
37
80
86
157
216
65
91
100

Topological
Connections / #
Atoms
2.35
1.79
2.06
2.72
2.55
2.00
2.73
1.95
2.22
2.10
2.45
2.48
2.17
2.07
2.33

Weighted Mass
Max.
1.33
2.67
1.33
1.33
2.95
1.33
1.33
2.67
2.67
2.95
2.95
2.95
2.95
2.95
2.67

# atoms with
max. weighted
mass
2
1
2
2
1
6
2
1
1
1
2
2
1
2
1

Leverage

Sum

Avg.

Max.

Avg.

21.59
21.01
19.34
39.27
27.46
28.84
27.01
14.34
22.51
29.79
44.25
58.75
23.04
31.99
35.83

0.54
0.64
0.59
0.52
0.58
0.67
0.56
0.75
0.63
0.73
0.69
0.68
0.77
0.73
0.83

0.21
0.23
0.24
0.12
0.19
0.18
0.15
0.40
0.17
0.21
0.15
0.11
0.24
0.18
0.18

0.075
0.091
0.091
0.040
0.064
0.070
0.063
0.158
0.083
0.073
0.047
0.035
0.100
0.068
0.070

In addition to the connectivity, the overall size of the molecule can result in more
topological connections. For example, any individual carbon in a benzene molecule will only be
connected to 3 other atoms at a topological distance of 3. The relatively small size of benzene, and
fewer bonds across which topological connections can occur results in R3m=0.134, which is a
relatively small value. In contrast, indomethacin has a larger total number of atoms, as well as
more atoms with larger atomic weights (e.g., chlorine, oxygen, and nitrogen) relative to the carbons
and hydrogens that exclusively comprise benzene. In the case of indomethacin, the more numerous
atoms results in R3m=0.737, considerably larger relative to benzene owing to the increase in the
size of both the molecular and geometric matrices used to calculate it.
Table 4 summarizes the impact of topological complexity for the API library used to
predict dispersability using R3m. The importance of topology is further illustrated by cimetidine
and itraconazole. Cimetidine has only 59 topological connections equal to 3, while itraconazole
has 216 (see Table 4). This difference contributes to the discrepancy in their respective R3m values
of 0.403 vs. 0.872. Here, the difference is partially a result of the variation in the number of atoms
comprising their respective structures (33 for cimetidine vs. 87 for itraconazole). However, for the
API library, topological complexity alone cannot sufficiently explain the predictive performance
of R3m, as illustrated by quinidine. In this case, quinidine has 131 topological connections equal
to 3 and also the highest ratio of topological connections per atom (2.73), in part, due to the
presence of a bicyclic ring in its structure. Nevertheless, quinidine has a relatively low R3m value
equaling 0.593, which is a result of fewer heavy atoms in its structure, and the impact of weighted
atomic mass (see section 5.3.1.2).
While the ultimate contribution to the total value of R3m from individual pairs of atoms
with a topological distance equal to 3 may sometimes be minimal due to low weighted mass or
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large distance between atoms (see sections 5.3.1.2 and 5.3.1.3), it is important to note that these
individual contributions will always contribute some positive number to the total. As a result, as
the number of atoms in a molecule increases, the number of total topological connections will also
increase, thereby increasing R3m. This is most clearly illustrated by itraconazole, which, at 87
atoms has the most of any molecule in the library (see Table 4). Correspondingly, the 87 atoms
comprising itraconazole result in 216 topological connections equal to 3, reflected in a relatively
high R3m=0.872.
The extent to which an increase in the number of atoms contributes to R3m is not
necessarily linear, and in some cases, may be small enough to be essentially inconsequential. To
illustrate this, the effect of specific structural changes on R3m were investigated using simple
carbon chains and rings. Figure 31a and b shows the impact of increasing carbon chain length on
the value of R3m. Increasing the length of a linear chain (Figure 31a) shows a more significant
increase in R3m as the length increases from 2 carbons to 5, but the rate of this increase slowly
decreases as the chain length increases. The initial increase in R3m is primarily impacted by the
increasing number of topological connections, while the slowing rate of the increase in R3m for
longer chain lengths is primarily a result of the leverage. Figure 31b shows the impact of increasing
carbon ring size on R3m. Similarly, the value of R3m increases rapidly until the ring size exceeds
7 carbons. This is also a result of increasing topological connections and relatively short geometric
distances between atoms with topological connections equal to 3. As the distances between atoms
increase and become relatively consistent (cyclic systems >7 carbons), the R3m value remains
relatively consistent.
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Figure 31: The impact of iterative changes to the number of carbons in a (a) linear chain and (b)
cyclic systems.

Returning to the data in Table 4, there are some points to note. The molecules are listed in
increasing rank order of R3m, while the columns describing the number of topological connections
equal to 3, and these connections normalized to the number of atoms in the molecule do not appear
to have any consistent trend. That said, more topologically complex API tend to have higher R3m
values, so there may be some threshold in complexity needed for a molecule to be potentially
dispersable in PVPva. This is illustrated by the simple hydrocarbon chains and rings considered
in Figure 31. The R3m for these simple molecules plateaus well below the critical value of 0.65,
and have very few topological connections relative to any of the library API. Moreover, linear or
cyclic hydrocarbons are hydrophobic, containing no atoms with a particular affinity for PVPva,
making their dispersability in this polymer extremely unlikely, in line with their small relative
R3m. This could suggest that dispersability in PVPva requires, in part, relatively complex
structures because the atoms and arrangements of atoms responsible for higher R3m facilitate the
API-polymer interactions needed to form an ASD. Taken alone, topological complexity in
isolation is insufficient to explain how R3m is able to separate the library shown in Figure 22 into
those dispersable in PVPva from molecules that are not. This reinforces the proposed hypothesis,
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however, suggesting that the multiple matrices used in the calculation of R3m results in a value
that is more complex than, in this case, topological complexity alone, owing to a nuanced
combination of several different factors.

5.3.1.2.

Atomic Mass Weighting

The presence of relatively heavy atoms in a molecule will have a significant impact on the
value of R3m, as demonstrated in the atomic mass weighting portion of the R3m equation
(Equation (18)). Since the atomic mass weighting is relative to carbon, atoms heavier than carbon
will have a more significant contribution to the total by multiplying the relevant portions of the
R3m calculation by a value greater than 1. For the library of compounds used to build the models
(see Figure 22), these relatively heavier atoms are nitrogen, oxygen, fluorine, sulfur, and chlorine,
which have atomic mass weightings of approximately 1.17, 1.33, 1.58, 2.67, and 2.95,
respectively, and are common to API or drug-like molecules. The maximum weighted mass for
each API is also given in Table 4. In contrast to these relatively heavy atoms, the contribution of
hydrogen atoms to the value of R3m is generally quite small, and often negligible, owing to an
atomic mass weighting of hydrogen relative to carbon of approximately 0.08. Correspondingly,
this multiplier in Equation (18) significantly reduces the contribution of atoms paired with
hydrogen to the overall magnitude of R3m.
It is important to note that of the atoms comprising molecules in the Figure 22 library, those
considered relatively heavy are also more electronegative relative to the other atoms in organic
molecules. Their presence may increase the likelihood of forming noncovalent bonding
interactions with the polymer, which would reduce the potential for API recrystallization and allow
for persistence of a metastable dispersion. For example, the library compound felodipine contains
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2 Cl atoms that are connected through a phenyl ring, which results in the requisite topological
distance of 3. These Cl atoms are also located on the periphery of the molecule, leaving them
distant from the geometric center and resulting in relatively higher leverage values. This
combination of high leverage for atoms having high atomic mass weighting results in their much
more significant contribution to the value of R3m, ultimately leading to felodipine having one of
the largest values for R3m in the experimental API library (R3m = 0.964). This is illustrated in
Table 4, where felodipine has among the highest average weighted mass of the molecules studied.
While the presence of heavy atoms furthest from the geometric center of a molecule often
results in a larger R3m value, this is not always the case. Cloperastine is an example of a molecule
for which the heaviest atom (Cl) also has the highest leverage value. Nevertheless, the R3m value
for cloperastine is 0.562, which falls below the critical boundary of R3m=0.65, indicating that this
API is not dispersable in PVPva (previously confirmed experimentally48, 174). In this case, the R3m
value is decreased relative to other Cl-containing library molecules because this API has one of
the lowest average weighted masses of the molecules studied (see Table 4).
Looking more generally at the weighted mass data in Table 4, a few trends emerge. All of
the API found to be dispersable in PVPva (R3m>0.65) contain at least one S or Cl atom in its
structure. Although the presence of these atoms does not guarantee dispersion formation (i.e., 4
of the library molecules contain either S or Cl and have R3m<0.65), most of the API found not to
disperse in PVPva have N or O as their maximally heavy atom. Computationally, this contributes
to an overall lower R3m, but chemically, this suggests that S and Cl are commonly shared among
dispersable library API, suggesting importance in stabilizing interactions between drug and
polymer that allows ASD persistence.
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This is further reflected in the average weighted masses for library API, which follow a
similar ascending rank order with R3m, with notable exceptions. Molecules having the highest
weighted mass frequently have high R3m values, falling above the critical threshold of 0.65.
Cimetidine and sulfanilamide both have S atoms, while cloperastine has a Cl atom, increasing their
respective values of R3m, but not exceeding the value conforming with observed dispersability.
Although S and Cl atoms are common to all of the dispersable API in the Table 1 library, it seems
possible that other features of these 4 molecules (e.g., cimetidine’s low topological complexity
(see section 5.3.1.1), cloperastine’s low average atomic mass weighting, and sulfanilamide’s low
molecular weight (see section 5.3.1.3)) could suppress any chemical advantage the presence of
these atoms have on dispersion potential, aligning with lower R3m values indicative of molecules
that are unable to be dispersed in PVPva.
As with the previous section, it is not unexpected that the individual contributions of
weighted mass do not align perfectly with the rank order of R3m values. Exceptions, such as
cloperastine, are expected when only one part of the R3m calculation is considered. These
exceptions, however, illustrate how the combination of factors captured by the multiple matrices
used in the calculation of R3m results in a single value which is more complex than, for example,
the molecular weight (MW) alone.

5.3.1.3.

Geometric Distance & Leverage

The geometric distance between individual atoms is explicitly included in the rij term in
the R3m equation (Equation (18)) and, therefore, certain information about the overall molecular
size and shape is also captured by the magnitude of this descriptor. Geometric distance is also
important to the calculation of leverage, since leverage increases as atoms become more distant
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from the geometric center of a molecule. A compilation of leverage data and Euclidean distance
data from both the geometric center and between relevant atoms for each API is shown in Table
5.
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Table 5: Summary of data derived from the molecular matrix (M) and influence/distance matrix (R) components of R3m.
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API

R3m

Propranolol
Cimetidine
Melatonin
Terfenadine
Cloperastine
Nifedipine
Quinidine
Sulfanilamide
Tolbutamide
Indomethacin
Ketoconazole
Itraconazole
Chlorpropamide
Felodipine
Bicalutamide

0.342
0.403
0.407
0.561
0.562
0.568
0.593
0.595
0.687
0.737
0.814
0.872
0.927
0.964
1.001

Molar
Volume
(cm3/mol)
254.64
228.09
216.86
470.61
310.05
293.59
302.82
137.79
240.50
300.69
443.47
594.47
221.26
317.56
326.92

Max. distance
from geometric
center (Å)
7.33
6.76
6.56
10.77
6.52
4.97
5.89
4.17
6.99
6.68
10.34
13.94
6.03
5.99
8.07

Geometric Distance
Avg. distance
Maximum
from geometric
rij (Å)
center (Å)
4.22
3.79
4.19
4.22
3.74
3.83
5.97
3.87
3.87
3.99
3.46
3.87
3.56
3.83
2.64
4.02
4.13
4.02
3.81
3.99
5.52
3.99
7.57
4.00
3.63
4.02
3.64
4.01
4.46
4.19

Influence/Distance (R)
Sum
rij (Å)

Average
rij (Å)

Maximum
R

Sum
R

Average
R

281.5
183.4
210.4
625.9
361.4
269.3
398.1
117.4
242.7
274.9
483.6
664.2
199.6
284.6
315.9

3.00
3.11
3.09
3.02
3.01
3.13
3.04
3.17
3.03
3.20
3.08
3.08
3.07
3.13
3.16

0.056
0.058
0.079
0.047
0.058
0.070
0.055
0.114
0.056
0.064
0.045
0.037
0.079
0.070
0.059

1.81
1.17
1.55
2.08
2.14
1.19
2.02
1.51
1.90
1.43
1.89
1.92
1.87
1.34
1.69

0.019
0.020
0.023
0.010
0.018
0.014
0.015
0.041
0.024
0.017
0.012
0.009
0.029
0.015
0.017

A visualization of Euclidean distance from the geometric center is illustrated in Figure 30b,
where the geometric center of a molecule is indicated for indomethacin using a red-white-blue
color scheme for atoms that are closest (red) to farthest (blue) from the geometric center. The
corresponding leverage values for each atom are shown in Figure 30c, where the highest leverage
is observed for the Cl15 chlorine. Both the high leverage value and high relative mass weighting
for Cl result in a relatively high R3m value for indomethacin (R3m = 0.737).
The impact of leverage is additionally shown in Figure 32, which illustrates how simulated
changes in molecular conformation of chlorpropamide influence the resulting R3m value. Figure
32d shows a bar plot comparing the leverage between atoms from the different conformations, the
most striking difference of which is shown for O17, whose distance from the geometric center
changes as a result of conformational changes. In conformation 1 (Figure 32b), O17 is very close
to the geometric center of the chlorpropamide molecule, resulting in a very small leverage value
for this atom. In conformation 2 (Figure 32c), however, O17 is rotated away from the geometric
center, resulting in a much larger leverage value, which subsequently contributes to a significantly
larger R3m value (0.824 vs. 1.046).
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Figure 32: An illustration of the effect of 3D conformation on leverage used to calculate R3m. (a)
Atom labels for library compound chlorpropamide. Example conformations 1 and 2 of
chlorpropamide are shown in (b) and (c), respectively, with corresponding R3m values shown
beneath. (d) A bar plot of the leverages which result from the respective conformations. Hydrogen
atoms are excluded from the bar plot for clarity.

The combined impact of geometric distance and leverage is also supported by Equation
(22), where the geometric distance term serves as the divisor. As a result, atoms having high
leverage and which are closer to each other in 3D space will contribute more significantly to the
R3m for their molecules. This is demonstrated by chlorpropamide. Table 4 and Table 5 list data
such as the maximum leverage from an individual atom, the average leverage, and the average
contribution of each atom to an API’s influence distance matrix for each library API. The chlorine
in chlorpropamide is the highest leverage atom for the API, and this contributes to chlorpropamide
having one of the largest average contributions to the influence/distance matrix (average R =
0.029) for the library API. As indicated, chlorpropamide has the third highest R3m in the present
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library at 0.927, corresponding to a prediction of its dispersability in PVPva (previously
confirmed48,

174

). In contrast, the API having the largest average contribution to the

influence/distance matrix is sulfanilamide (average R = 0.04), which is a result of the negative
correlation between MW and the average leverage (r=-0.80). This negative correlation is the result
of larger molecules generally having atoms that are further from their geometric centers; as the
molecule gets larger, and more atoms are included in the calculation of R3m, the leverage is
distributed amongst more atoms. As previously noted, the total leverage used to calculate this
descriptor will always equal 3, and therefore, as the number of intramolecular atoms increases, the
largest possible leverage for any individual atom will decrease. Since sulfanilamide is the smallest
molecule in the library (MW = 172.23 g/mol), its individual atoms tend to have larger leverage
values, resulting in its higher average contribution to the influence/distance matrix. This further
illustrates how the multiple matrices used in the calculation of R3m captures more complex
information about the physical and chemical properties of an API than, for example, API geometry
alone.
Both the leverage and geometric distance capture information relevant to the 3D
conformation of the API. The geometry of a molecule is important because of the potential
implications with respect to ASD formation. If an accurate 3D representation of the API is captured
by R3m (an assumption supported by an investigation described in Chapter 6), the descriptor is
likely capturing information relevant to the kinetics of the ASD, as it forms. In melt-quenched
sample preparation, for example, the supersaturation of the API in PVPva increases upon cooling.
The API will then be thermodynamically driven to phase separate, and subsequently crystallize.
However, if an API molecule has a large relative volume, and occupies more interstitial volume
between polymer chains, kinetic inhibition of phase separation is more likely in these systems as
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larger molecules will diffuse more slowly through the polymer chain network. As such, these
larger molecules are more likely to be trapped in the dispersed state than an API molecule with a
much smaller volume.
To compare the relative geometries of library molecules the molecular van der Waals
volumes were calculated using the QSAR module in Materials Studio, and are reported in Table
5. The average Euclidean distance from the geometric center (Table 5) is highly correlated with
the molar volume (r=0.92), where longer distances correspond with larger volumes. For example,
itraconazole has the highest molecular volume of any API in the library (594.47 cm 3/mol), and
also has the largest average Euclidean distance from the geometric center (7.57 Å).
In evaluating trends in the data from Table 5, consider that the API are again presented in
increasing rank order of R3m, where R3m>0.65 corresponds with molecules dispersable in PVPva.
As with other components of the R3m calculation, molar volume alone was not expected to follow
the same rank order of R3m, however, there does not appear to be any trends with respect to the
molar volumes of the API studied. Chlorpropamide (R3m=0.927) has a relatively low molar
volume (221.3 cm3/mol), but the third highest R3m, and forms dispersions with PVPva. Compared
to the contributions of topological connectivity (section 5.3.1) or the weighted mass (section
5.3.1.2), trends in Table 5 with respect to molar volume, geometric distance, and influence/distance
and the calculation of R3m are less obvious. For example, small, moderate, and large volume API
appear on either side of the R3m=0.65 dispersability boundary, without any apparent connection
to the ascending rank order of R3m for library molecules.
The importance of geometry to the interpretation of R3m, therefore, likely incorporates
details from the other matrices in contributing to calculating this descriptor. One such way is by
combining geometry with information about the relative location of heavy atoms within the 3D

144

representation of the molecule. This information may be useful for interpreting the meaning of
R3m as it relates to dispersability in PVPva, considering that atoms furthest from the geometric
center of an API will be most likely to interact with other polymer molecules in a potential
dispersion, since these atoms will be on the external surface of the 3D conformation. Moreover,
since the heavy atoms considered in the extant library are more electronegative than the other
intramolecular atoms, high R3m values could suggest a greater potential for molecules to undergo
noncovalent bonding with the PVPva. For example, the large dipole moment present in side groups
of polyvinylpyrrolidone can strongly interact with other dipoles present in the system.173 The
presence of highly electronegative atoms could induce a dipole, and lead to such dipole-dipole
interactions. Consider, again, the example of chlorpropamide, where the Cl atom having the
largest leverage is also the intramolecular atom having the largest atomic weight, where the Cl is
on the periphery of the molecule, fully exposed for potential interactions with the PVPva. All of
these factors combine synergistically to result in a larger R3m=0.927, while contributing to
physical conditions that may favor dispersion formation. In contrast, terfenadine, has one of the
largest molar volume of the molecules found not to disperse in PVPva (R3m=0.561), also having
one of the higher average distances from its geometric center for all of the library molecules. As
shown in Figure 22, and reinforced in Table 4, the two heaviest atoms in terfenadine are the O
contained in OH groups well separated on the molecule. Moreover, terfenadine also contains a
single N atom near the center of the molecule. Despite the presence of these relatively heavy
atoms, none is located on the perimeter (e.g., the N has one of the lowest leverage values, see
Figure 72h in the Appendix), decreasing the potential for their interaction with the PVPva.
Additionally, the absence of the heavier and more electronegative atoms such as S and Cl typical
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of all dispersable library API also contributes to the smaller R3m value, and helps to explain why
terfenadine was not observed to successfully form a dispersion with PVPva.

5.3.1.4.

Connecting R3m with physical environment and chemical interactions

The usefulness of the R3m descriptor to predict dispersability in PVPva is believed to be a
result of the physical and chemical information that is captured from the matrices derived from the
3D representation of the molecule. In the extant API library, intramolecular S, N, O, Cl, and F
atoms were all relatively heavier than any other intramolecular atoms (e.g., C and H). The location
and relative position of these heavier atoms is highly significant to the resulting R3m value. As
described in section 5.3.1.2, when these atoms are located on the periphery of the molecule, the
R3m value increases relative to when these same atoms are located closer to the geometric center
of a molecule. In certain cases, these heavier atoms are more electronegative than the others (e.g.
Cl, F). This potentially explains some of the importance of peripheral intramolecular Cl or F atoms
for dispersability in PVPva. When these atoms are on the API perimeter, and not sterically
hindered from interaction with the polymer, there is expected to be an increased probability for the
formation of electrostatic interactions with the PVPva. For example, induced-dipole interactions
have been observed between ketoconazole and the carbonyl group in the vinyl pyrrolidone
monomer of PVPva,180 which is also consistent with our finding that ketoconazole is dispersable
in this polymer, having an R3m value of 0.814. The location and position of atoms such as O and
N could also capture information about the potential to form hydrogen bonds with the polymer,
but the peripheral Cl leverages heavily into the calculation of R3m, which is well above the
threshold indicative of dispersability in PVPva. In a separate example, indomethacin (R3m =
0.736), whose carboxylic acid hydroxyl group has been shown to facilitate formation of stable
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dispersions in PVP through the formation of hydrogen bonds with the amide carbonyl, also
computes to an R3m value >0.65 owing to the presence of a peripheral Cl, promoting further
stabilizing interactions with the PVPva.
It is also important, however, to note that the connection between the value of R3m and
specific non-covalent drug-polymer interactions has limitations. The heavy intramolecular atoms
in the API library tend to be more electronegative, and, therefore, the information about their
potential to form stabilizing electrostatic interactions with PVPva during dispersion formation is
captured indirectly. This is an important limitation of the model, since a molecule containing heavy
intramolecular atoms will result in a larger R3m value regardless of whether or not those atoms
are electronegative. As an example, consider iopanoic acid, which contains three I atoms in its
structure, and computes to an R3m = 3.616, which is much higher than any value calculated for
the extant API library. With an R3m > 0.65, iopanoic acid would numerically predict to be
dispersable in PVPva, however, electrostatic interactions between the polymer and the I atoms are
highly unlikely. Ultimately, the introduction of API containing intramolecular atoms that were not
in the calibration dataset used to build the original R3m model will be an extrapolation, and likely
to result in poor predictions.
Additionally, it is important to note that the value of R3m also does not give an indication
of what type of API-polymer interactions can or do occur. Although a large value of R3m may
occur for a molecule which undergoes induced-dipole interactions, another molecule having a
similar R3m value may instead undergo hydrogen bonding, or may not be capable of establishing
any significant non-covalent interactions with PVPva at all. To assess the presence or absence of
specific interactions between the API and PVPva, further experiments must be performed (e.g. FTIR, solid state NMR, etc.). Alternatively, potential interactions could be explored using more
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advanced computational methods such as DFT. These studies could be pursued in the future to
draw a more direct connection between the presence of non-covalent interactions and the resulting
value of R3m.
Beyond specific intramolecular atom types, the value of R3m also captures information
about the size and shape of API molecules in the extant library (see sections 5.3.1.1 and 5.3.1.3),
which, in relation to dispersability in PVPva, is expected to influence the kinetics of phase
separation, and subsequently, nucleation and crystallization. A large, irregularly shaped molecule,
which will tend to have a higher value of R3m, is expected to have a lower diffusivity during
preparation of co-solidified mixtures than a small molecule with a more isotropic shape. In the
melt-quench preparation method, for example, as the molten API-polymer mixture is cooled, the
API may be thermodynamically driven to recrystallize owing to its rapidly decreasing solubility
in the polymer. As the solubility decreases, the API will be thermodynamically driven to first phase
separate from the polymer, and subsequently nucleate, and crystalize. Simultaneously, the mobility
of the molecules will also decrease with temperature. A larger, irregularly shaped molecule will
likely have a lower diffusivity as it attempts to move through the solidified network of polymer
chains, while a smaller isotropic API molecule should be able to move with less resistance.
Correspondingly, higher values of R3m, which are expected for large, branched molecules, may
reflect the API’s greater likelihood to persist in the amorphous state beyond initial characterization,
owing to much slower recrystallization kinetics. In contrast, the smaller, more isotropic molecules
in the API library, which tend to have lower values of R3m, may recrystallize very rapidly during
(or shortly after) preparation, resulting in characterization as a system that failed to disperse in
PVPva.
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The extent to which R3m captures the size and shape of API also has limitations, which
are best illustrated by examining extreme cases. For very small molecules, such as methane, R3m
cannot be calculated because the molecules do not contain any topological connections equal to 3,
resulting in a value equal to zero. Perhaps more importantly, molecule size and shape are only
captured to a certain extent by the numerical value of R3m, owing to the inverse relationship
between leverage and size (see section 5.3.1.3). This is also illustrated by Figure 31. As the
molecule grows in size, the highest individual leverage values decrease because the sum total of
all of the leverage values must equal 3. Therefore, for very large molecules, the degree to which
size and shape impact R3m will decrease until it becomes essentially inconsequential.
While the molecules in the API library are relatively diverse in their chemical structure and
3D geometry (at least insofar as examples of small organic drug molecules predominantly
belonging to BCS Class II), the manners in which they are similar should not be ignored, as these
similarities highlight the limitations of the model. For example, the molecular weight of the API
in the library ranges from approximately 172 to 706 g/mol. The dispersability of molecules with
molecular weights significantly outside this range may be poorly predicted in PVPva, owing to the
limitations in the calculation of R3m with respect to extremes in this attribute, as described in the
preceding sections. Likewise, the model considered co-solidified mixtures at two concentrations
(15 and 75% w/w API). However, predictions made by R3m may not hold true at extremes of
composition. As an example, consider the case of a mixture of 1% API to 99% PVPva. Such a low
API concentration is expected to be below the solubility limit in the polymer, making phase
separation and crystallization highly unlikely.

In turn, this would render predictions of

dispersability using R3m moot, because all of the systems would likely form stable, homogenous
mixtures. Likewise, R3m is also unlikely to be useful in the opposite case (99% API), since the
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solubility limit is likely to be exceeded in all cases, making rapid crystallization far more probable
and resulting in systems that all fail to form a dispersion. In summary, while R3m appears to
capture useful information as described above, it is important to consider the dataset upon which
the model was built. Applying R3m for prediction of dispersability for a significantly different
API constitutes model extrapolation and is likely to result in poor predictions.

5.3.1.5.

Illustrating the combined impact of matrices on R3m

To further illustrate the impact of the different matrices used for the calculation of R3m,
Figure 33 shows a visualization of the relevant matrices for felodipine. Figure 33a shows the
labeled molecular structure, Figure 33b shows the molecular matrix with a blue-white-red color
map, Figure 33c shows the topology matrix, where yellow blocks indicate atoms which are
connected by a topological distance of 3. Visualization of the subsequent matrices have been
simplified to show only relevant topological connections by multiplying these matrices by the
topological matrix (resulting in non-relevant cells being reduced to a value of 0). Figure 33d shows
the geometry matrix, where the Euclidean distance between atoms is shown for atoms having the
appropriate topological connectivity. Figure 33e gives a visualization of the influence/distance
matrix, and Figure 33f gives the weighted mass for each atom of felodipine. Figure 33g shows the
influence/distance matrix multiplied by the associated weighted masses. The sum of this matrix
divided by 2 (since the matrix is symmetric) gives the value for R3m. This figure, in particular, is
helpful for visualizing the overall contribution of each atom to the final value of R3m. The pair of
peripheral Cl atoms in felodipine, referred to earlier, can be seen as the bright yellow spots in
Figure 33g (row 18, column 19 and row 19, column 18). This atom pair contributes approximately
25% to the R3m value of felodipine. The substantial contribution from these heavy atoms in close
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proximity on the molecule indicates that R3m can capture useful information regarding the dipole
moment, which is significant since it may indicate an increased likelihood of interactions with the
polymer. This is also consistent with the observation that felodipine, like all library molecules
with R3m>0.65, was dispersible in PVPva, suggesting that these molecules more readily interact
with the polymer carrier. Finally, Figure 33h gives the leverages for each of the atoms in
felodipine. A similar figure for each API is given in the Appendix (Figure 59 through Figure 73).
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Figure 33: Felodipine. (a) 2D structure with atom numbers labeled. Visual representation (matrices
and bar plots) of data relevant to the calculation of R3m: (b) molecular matrix, (c) topology matrix,
(d) geometry matrix, (e) influence/distance matrix, (f) bar plot of weighted mass, (g) contribution
to R3m, (h) bar plot of leverages.

152

5.3.2.

Confirming No Simpler, More Interpretable Model

Exists
While the application of R3m for the prediction of ASD formation has been supported via
model expansion to different manufacturing methods and concentrations (Figure 29),174
reinforcing that the specific matrices involved in its calculation combine to provide information
essential to predicting dispersability in PVPva required confirmation that no simpler, more
interpretable model could perform as well as, or better than the one developed using the R3m
molecular descriptor. Ultimately, the application of a model that is difficult to interpret would be
unnecessary if such a model did not outperform a simpler model. To investigate this, properties
more typically studied for their influence on ASD formation and persistence were investigated for
improved prediction of dispersability in PVPva across 2 different ASD preparation methods and 2
different drug loading concentrations. Of specific interest were descriptors and properties
previously reported in studies relevant to ASD formulation development and glass formation (see
Table 6).16, 42-45, 96, 97, 115, 181 A few of these descriptors showed statistical significance (p<0.05)
when modeled against the experimental data that confirmed dispersability of library compounds
in PVPva, and are indicated in Table 6 in bold. Models constructed using either average molecular
weight (AMW) and MW both showed statistically significant performance in predicting ASD
formation for experimental data collected from the melt-quench method and for the 75% API
solvent evaporation data. However, both models performed poorly for the 15% solvent evaporation
data set. Nonetheless, the performance of the AMW and MW models in predicting some
dispersability behavior of the library API prompted a more thorough investigation into potential
relationships of these properties with R3m (see section 5.3.3). Of the properties listed in Table 6,
none resulted in as statistically significant a model for prediction of ASD formation using the
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present library of API as R3m over the multiple concentrations and preparation methods studied.
The R3m dispersability model remained statistically significant across all concentrations and
manufacturing methods examined, while no other property was able to model dispersion formation
in PVPva with consistent significance under all circumstances.

Table 6: Logistic regression model statistics for relevant molecular descriptors and
physicochemical properties.
Dependent Variable
Average Molecular weight
Crystallization Tendency‡
# H-bond acceptors
# H-bond donors
Heavy atom count
log P†
log S†
Molecular weight
# of Nitrogen
R3m
Rotatable bond fraction
# Rotatable bonds
Tg (K)*
Tm (K)*
Topological Surface Area

Melt Quench
(n=15 API)
2
χ
p-value
7.46
0.59
6.10
1.80
2.35
0.78
1.20
3.89
0.53
20.73
0.04
0.29
0.24
0.02
1.70

0.006
0.44
0.01
0.18
0.13
0.38
0.27
0.05
0.47
< 0.0001
0.85
0.59
0.63
0.90
0.19

15% API Solv. Evap.
(n=18 API)
2
χ
p-value

75% API Solv.
Evap. (n=16 API)
χ2
p-value

1.36
0.49
0.48
0.73
0.19
1.81
3.36
0.54
1.97
4.65
0.09
0.001
0.05
0.07
0.15

0.24
4.38
0.04
0.49
2.24
0.13
0.49
1.22
0.27
0.39
1.66
0.20
0.66
5.38
0.02
0.18
2.12
0.15
0.07
3.36
0.07
0.46
5.44
0.020
0.16
1.03
0.31
0.03
12.36
0.0004
0.77
0.02
0.90
0.98
0.99
0.32
0.82
0.40
0.52
0.79
0.68
0.41
0.70
0.0004
0.98
p-values < 0.05 are indicated in bold.
†
Calculated using ALOPS170
‡
96
Experimentally determined using the method described by Baird et al, or compiled from previously collected
data in Baird et al96 and Alhalaweh et al181
*
Experimentally determined by DSC (20°C/min ramp rate)

In addition to the well understood properties and descriptors described in Table 6, other
GETAWAY descriptors were investigated to confirm that R3m was truly the most predictive
descriptor for ASD formation in its class. It is possible that another GETAWAY descriptor
calculated using some other weighting and/or topological distance could outperform R3m when
the more recently collected experimental dataset (Figure 29) is considered. The correlation
between R3m and other R-GETAWAY descriptors is shown for the 18-member library API in
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Figure 34. R-GETAWAY descriptors with similar topological distances were highly correlated
with R3m (r > 0.75 for R2m and R4m), as shown in Figure 34a.

Figure 34: Bar plots showing the correlation coefficient (r) between R3m and other R-GETAWAY
descriptors. (a) Correlation between R3m and descriptors with different topological distances
within the library (green bars). (b) The correlation between R3m and other descriptors with
different weightings (u = unweighted, v = van der Waals volume, e = Sanderson electronegativity,
p = polarizability, + = maximal) within the API library (orange bars).

RTm, known as the R total index weighted by mass (Equation (23)), considers every possible
topological distance, and was found to be the most highly correlated with R3m for the library API
(see Figure 34a, r = 0.91).
RTm = 2 ∙ ∑A−1
i=1 ∑j>i

(23)

√hii ∙hjj
rij

∙ mi ∙ mj

This equation is similar to that of R3m (see Equation (18)), but the topological distance delta-Dirac
function is excluded and, therefore, RTm considers every possible topological connection rather
than being limited to only topological distances of 3. It is currently unclear why, specifically, a
topological distance of 3 would be most important to predicting ASD formation in PVPva, from
our library of API. The fact that these descriptors are highly correlated indicates that they contain
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similar information, but the RTm descriptor may be more interpretable, since it assumes no
specific topological distance is of particular importance for ASD formation. Interpretability
notwithstanding, R3m remains the best predictor for dispersability using the existing library,
having a consistently lower p-value than the remaining R-GETAWAY descriptors (see Table 7).

Table 7: Logistic regression models for R-GETAWAY descriptors with differing atomic mass
weighting,

Melt Quench
(15% & 75%
w/w API)
n = 15

Solvent Evaporation
(75% w/w API)
n = 16

Solvent Evaporation
(15% w/w API)
n = 18

Method

Predictor(s)
R3m
R1m
R2m
R4m
R5m
R6m
R7m
R8m
RTm
R3m
R1m
R2m
R4m
R5m
R6m
R7m
R8m
RTm
R3m
R1m
R2m
R4m
R5m
R6m
R7m
R8m
RTm

Regression Equation
logit P(Y) = -3.96 + 6.48(R3m)
logit P(Y) = -2.896 + 2.715(R1m)
logit P(Y) = -2.850 + 3.511 (R2m)
logit P(Y) = -2.37 + 5.122(R4m)
logit P(Y) = -2.715 + 7.732(R5m)
logit P(Y) = -2.341 + 7.872(R6m)
logit P(Y) = -1.378 + 6.128(R7m)
logit P(Y) = -1.153 + 7.047(R8m)
logit P(Y) = -3.07 + 0.333(RTm)
logit P(Y) = -12.47 + 18.16(R3m)
logit P(Y) = -4.238 + 3.177(R1m)
logit P(Y) = -6.273 + 6.435(R2m)
logit P(Y) = -7.951 + 14.473(R4m)
logit P(Y) = -5.218 + 11.644(R5m)
logit P(Y) = -2.874 + 6.626(R6m)
logit P(Y) = -1.75 + 4.378(R7m)
logit P(Y) = -3.025 + 12.331(R8m)
logit P(Y) = -9.862 + 0.920(RTm)
N/A (separation)
logit P(Y) = -8.707 + 7.411(R1m)
logit P(Y) = -10.717 + 12.053 (R2m)
logit P(Y) = -10.142 + 18.980 (R4m)
logit P(Y) = -4.371 + 10.281 (R5m)
logit P(Y) = -2.544 + 6.635 (R6m)
logit P(Y) = -1.358 + 4.258 (R7m)
logit P(Y) = -2.911 + 13.774 (R8m)
logit P(Y) = -12.190 + 1.212 (RTm)

LR (χ²)
4.65
2.058
2.727
3.371
5.177
5.397
3.299
1.933
3.683
12.36
2.601
6.188
10.031
8.512
4.913
2.219
4.443
10.738
20.728
8.247
11.945
13.093
7.404
4.728
2.069
5.623
13.926$

Misclassification Rate
27.8% (n = 18)
27.8%
27.8%
16.7%
22.2%
22.2%
27.8%
22.2%
16.7%
6.3% (n=16)
31.3%
12.5%
12.5%
12.5%
12.5%
25.0%
18.8%
6.3%
0% (n = 15)
13%
13%
7%
13%
13%
27%
20%
7%

p-value
0.031
0.152
0.099
0.066
0.023
0.020
0.069
0.164
0.055
0.0004
0.107
0.013
0.002
0.004
0.027
0.136
0.035
0.001
<0.0001
0.004
0.0005
0.0003
0.0065
0.030
0.150
0.018
0.0002

Another subset of R-GETAWAY descriptors considers weightings other than atomic mass.
These include volume, electronegativity, polarizability, maximal (i.e., only the maximum value is
considered) weightings, as well as the absence of a weighing (unweighted). The correlation of
these descriptors with R3m for the library API is shown in Figure 34b. These descriptors were
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more poorly correlated with R3m. The performance of models constructed using these differently
weighted R-GETAWAY descriptors is shown in Table 8. Models with statistically significant pvalues (p<0.05) are indicated in bold. No R-GETAWAY descriptor with a different weighting
performed as well as R3m, leading to the conclusion that the atomic mass weighting is important
to the predictive performance of R3m. However, it is important to note that the usefulness of R3m
is not derived solely from the mass weighting. As seen in Table 6, when only the number of nonhydrogen heavy atoms, MW, or AMW was considered, ASD formation of the library of API in
PVPva was not as successfully predicted as compared to R3m alone.
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Table 8: Logistic regression models for R-GETAWAY descriptors which consider atom topology
= 3, but different weightings (u = unweighted, v = van der Waals volume, e = Sanderson
electronegativity, p = polarizability, + = maximal).

Melt Quench
(15% & 75% w/w API)
n = 15

Solvent Evaporation
(75% w/w API)
n = 16

Solvent Evaporation
(15% w/w API)
n = 18

Method

5.3.3.

Predictor(s)

Regression Equation

LR (χ²)

R3m
R3u
R3u+
R3m+
R3v
R3v+
R3e
R3e+
R3p
R3p+
R3m
R3u
R3u+
R3m+
R3v
R3v+
R3e
R3e+
R3p
R3p+
R3m
R3u
R3u+
R3m+
R3v
R3v+
R3e
R3e+
R3p
R3p+

logit P(Y) = -3.96 + 6.48(R3m)
logit P(Y) = 0.458 - 0.137(R3u)
logit P(Y) = 1.898 - 27.19(R3u+)
logit P(Y) = -1.158 + 26.51(R3m+)
logit P(Y) = -3.139 + 5.34(R3v)
logit P(Y) = -0.240 + 19.24(R3v+)
logit P(Y) = -0.381 + 0.346(R3e)
logit P(Y) = 1.117 - 13.410(R3e+)
logit P(Y) = -2.856 + 4.275(R3p)
logit P(Y) = -1.024 + 45.526(R3p+)
logit P(Y) = -12.47 + 18.16(R3m)
logit P(Y) = 1.020 - 0.299(R3u)
logit P(Y) = 0.180 - 11.109(R3u+)
logit P(Y) = -2.458 + 34.688(R3m+)
logit P(Y) = -7.540 + 11.063(R3v)
logit P(Y) = -4.782 + 172.724(R3v+)
logit P(Y) = -2.714 +1.263(R3e)
logit P(Y) = -0.636 + 1.847(R3e+)
logit P(Y) = -7.031 + 8.947(R3p)
logit P(Y) = -4.723 + 147.920(R3p+)
N/A (separation)
logit P(Y) = -1.095 + 0.566(R3u)
logit P(Y) = 1.540 - 26.579(R3u+)
logit P(Y) = -5.874 + 105.384(R3m+)
logit P(Y) = -5.419 + 8.423(R3v)
logit P(Y) = -3.033 + 118.41(R3v+)
logit P(Y) = -3.439 + 1.898(R3e)
logit P(Y) = -0.073 - 0.880(R3e+)
logit P(Y) = -5.445 + 7.360(R3p)
logit P(Y) = -5.28 + 181.670(R3p+)

4.65
0.0066
0.759
2.39
1.255
0.036
0.034
0.432
1.115
0.483
12.36
0.028
0.114
3.939
3.516
2.462
0.375
0.007
3.249
3.752
20.728
0.107
0.623
10.04
2.583
1.242
0.916
0.002
2.695
4.417

Misclassification
Rate
27.8%
44.4%
38.9%
33.3%
27.8%
38.9%
33.3%
44.4%
27.8%
38.9%
6.3%
37.5%
31.3%
25.0%
25.0%
18.8%
25.0%
31.3%
31.3%
18.8%
0%
33.3%
33.3%
13.3%
20.0%
26.7%
33.3%
40.0%
20.0%
26.7%

p-value
0.031
0.935
0.384
0.122
0.263
0.849
0.854
0.511
0.291
0.487
0.0004
0.866
0.736
0.047
0.061
0.117
0.540
0.929
0.072
0.053
<0.0001
0.744
0.4299
0.0015
0.108
0.265
0.339
0.9665
0.101
0.0356

MLR modeling to further explore the meaning of

R3m
Until this point, correlations between R3m and other properties have been limited to the 18
API for which experiments have been performed, consisting of ASD formation attempts with
subsequent physical characterization. With relatively few API, any identified correlations between
R3m and other descriptors or properties could be somewhat limited by the relatively small dataset.
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However, many descriptors can be rapidly calculated using only 1D information (e.g., SMILES
files). To investigate potential relationships between R3m and other properties, and thereby
support the previously discussed inferences about the meaning of R3m, a larger dataset of
descriptors for 176 primarily BCS class II compounds was compiled. A list of included compounds
can be found in the Appendix (Table 21). Of specific interest were more easily interpretable
molecular descriptors, including descriptors which have been used in the literature (e.g., to predict
glass forming ability, physical stability of glasses, etc.), such as the physicochemical properties
and descriptors listed in Table 6, as well as descriptors which capture information about size,
shape, and volume of the API (e.g., spatial descriptors in Materials Studio,175 Connolly surface
area and volume, etc.), chemical information (e.g., number of hydrogen bond donors and
acceptors, number of heavy atoms, calculated log P and log S, topological polar surface area), and
information about molecular mobility (e.g., rotatable bond number, molecular flexibility, radius of
gyration, etc.).
Among the descriptors of interest was AMW, which was previously found to have a
moderate positive correlation with R3m (r = 0.75).174 This relationship appears to be mostly
maintained with the larger dataset (see Figure 35, r = 0.66), and increases confidence in the
chemical diversity of the original API library. If the original library had not been chemically
diverse, these correlations may have changed much more significantly, since similar compounds
would not have sufficiently captured the true variability of the descriptors of interest. The
relationship between R3m and AMW is a direct result of the weighted mass portion of the R3m
equation (Equation (18)). The weighted masses used in R3m are normalized to carbon, and since
carbon is a major component of the organic small molecules which compose the library, it is likely
that AMW will be correlated with this portion of the equation. However, as shown in Table 6,
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AMW fails to perform as well as R3m for the prediction of ASD formation among the original 18compound library. This suggests AMW helps explain the importance played by heavier atoms in
contributing to higher values of R3m, but cannot be used as a surrogate to model dispersion
potential in PVPva.

Figure 35: The relationship between R3m and average molecular weight (AMW) for a dataset of
176 API.

Multiple linear regression (MLR) was also applied to examine more complex relationships
between R3m and other simpler descriptors in an attempt to further advance understanding of the
physicochemical meaning of R3m. The most promising model is shown in Figure 36, where MW
and molecular density help to illustrate what sort of information is being captured by the R3m
descriptor. The collinearity of MW and molecular density was confirmed to be low (r = -0.07), and
permits their application in an MLR model. Molecular density describes the atomic weight per
volume of a molecule, reflecting the types of atoms and how they are packed within a molecule,175
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such that API having a relatively small volume comprised of more heavy atoms will have a higher
numeric value. Molecular density captures information very similar to AMW (r=0.96), but
considers volume rather than total number of atoms. The moderate correlation observed between
R3m, MW, and molecular density supports the conclusions that the R3m descriptor captures
information about the size and shape of a molecule, and that it captures information about the
relative position of heavy atoms.

Figure 36: A multiple linear regression model of molecular weight and molecular density vs. R3m.
(a) a 3D surface plot showing the linear fit as a surface (R2 = 0.59), (b) the actual vs. predicted
plot.

In addition, the relationship between MW and descriptors which capture information about
volume, area, and shape of molecules is illustrated in Figure 37. MW has a high correlation (r
ranging from 0.68 to 0.97) with these descriptors, and the usefulness of MW in the MLR model
with R3m further supports the idea that R3m is capturing information about the size and shape of
the API molecules.
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Figure 37: Correlation coefficient (r) between molecular weight and other descriptors which
describe API shape, volume and area.

As a means of separating structurally diverse molecules into their respective dispersion
behavior in PVPva, R3m appears to succeed relative to any other simple, more intuitive property
precisely because it encodes structural information that is not obvious. Given the complexity
inherent to ASD formation, it is not surprising that identifying the nuanced combination of
properties needed to form a dispersion in a polymer comes down to a complicated molecular
descriptor. Moreover, ASD formation combines not only the chemistry of API and polymer, but
also depends on a number of thermodynamic and kinetic factors, placing a nearly impossible
burden on a simple physical or chemical property to capture all elements of this complexity. For
example, although MW may reflect some of the kinetic factors associated with ASD formation,
since larger molecules are generally better glass formers, MW alone is unable to group library
molecules according to dispersion formation in PVPva, as illustrated in Table 6. R3m, on the other
hand, is influenced by MW, and captures some of the same information, but the impact of
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molecular size on R3m changes as the molecular size increases owing to the competing impact of
weighted mass and leverage, capturing other important information such as the relative
intramolecular location of heavy atoms, whose positions may contribute to better or worse
facilitation of the API-polymer interactions needed for ASD formation. Ultimately, the complexity
of R3m is a result of its calculation from several matrices, each of which contains physically and
chemically relevant information that appears to help separate the library with respect to dispersion
formation with much greater accuracy than any other more intuitive or easy to interpret descriptor
or property.
The results reported here have revealed additional information about the physicochemical
meaning of R3m and its usefulness for the prediction of ASD formation. The formation of ASDs
is believed to be a complex phenomenon that is impacted by both thermodynamic and kinetic
factors. However, the extent to which R3m captures kinetic and thermodynamic information
(independently or in combination) remains unclear. Future work will focus on investigating to
what extent R3m captures specific thermodynamic and/or kinetic information.

5.4. Conclusions
This chapter has discussed the calculation of R3m, has elucidated the physicochemical
meaning of the molecular descriptor, and has revealed potential reasons for its usefulness as a tool
for the prediction of ASD formation with the polymer PVPva. R3m contains information about
the size and shape of an API molecule, the number and relative positions of intramolecular atoms
in 3D space (with increasing significance for heavier atoms), and increasing topological
connectivity which indicates increased branching. In general, large molecules, having increased
topological connectivity (reflective of increased branching), molecules having more heavy atoms
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(higher molecular density), and with heavy atoms furthest from the geometric center (on the
periphery of the 3D conformation of the molecule) have higher R3m values, suggesting these
attributes conform to R3m>0.65, which corresponds to API which are dispersable in PVPva.
Multiple linear regression of R3m against simpler, more intuitive descriptors and properties
showed a relationship with MW and molecular density, which further supports these conclusions.
The size and shape of API molecules is believed to be important to the kinetics of ASD formation.
The relative location of heavy atoms is expected to increase the likelihood of non-covalent
interactions with the polymer, since the atoms heavier than carbon in the API library considered
are more electronegative. Heavy atoms which are far from the geometric center of the molecule,
and close to each other in Euclidean space, are more likely to result in a larger R3m value, and
also increase the likelihood of an increased dipole moment in that molecule. This is expected to
increase the likelihood of non-covalent interactions (i.e., dipole-dipole interactions), and thereby
impact thermodynamic parameters such as the enthalpy of mixing. The formation of ASDs is a
complex phenomenon that involves thermodynamics and kinetics. As a result, individual
parameters are generally insufficient to capture sufficient information for the prediction of ASD
formation. In contrast, R3m is more useful despite also being a single parameter because it contains
more information as a result of its derivation from several matrices which contain physically and
chemically relevant data.
An important premise for the interpretability of R3m with respect to geometry is that it is
able to capture three-dimensional (3D) information about the API. However, this assumes that the
predicted conformation used for the calculation of R3m which has been used up to this point
reasonably matches the ‘true’ conformation of the API during co-solidification. If this assumption
is invalid, the conclusion that R3m contains useful geometric information is weakened. The next
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chapter will investigate the validity of this premise, and continue to advance the interpretability of
R3m.
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Chapter 6. The Impact of API Three-Dimensional
Conformation on R3m
6.1. Introduction
As described in Chapter 4, R3m was found to correctly predict the formation of ASDs for
a 15 member library of API (Figure 38) prepared using the melt-quench method at 2 concentrations
(Figure 39).48,
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A decision boundary of R3m equal to 0.65 was identified as being 100%

predictive for ASD formation in PVPva by the melt-quench method, where molecules having
R3m>0.65 all formed persistent ASDs in the polymer, as confirmed using a suite of analytical
characterization techniques. Additionally, Chapter 5 showed that R3m contains information about
the size and shape of a molecule, the number and relative positions of API atoms in 3D space (with
increasing significance for molecules containing heavier peripheral atoms), and topological
connectivity. R3m is useful because it is derived from multiple matrices which contain physical
and chemical data which is relevant to the complexity of ASD formation. Ultimately, the utility of
the R3m descriptor is based, in part, on its ability to capture relevant three-dimensional (3D)
information about the API. However, this assumes that the predicted conformation used for the
calculation of R3m reasonably matches the ‘true’ conformation of the API during co-solidification.
In order to support or refute the argument that the R3m descriptor is useful because of the
geometric information it contains, it is necessary to investigate the impact of 3D conformation of
the resulting value of R3m, and to investigate if the predicted 3D conformation is representative
of the amorphous form.
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Figure 38: Molecular structures of API in the M/Q compound library with R3m values given
parenthetically.
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Figure 39: Modeling of dichotomous classifications of API dispersability in PVPva for cosolidified mixtures prepared by melt-quenching against the molecular descriptor R3m. Separation
is observed in the melt quench models, where all API having R3m > 0.65 were dispersable in
PVPva.48, 174 Reproduced here from Figure 25a, for convenience.

Until this point, the calculation of R3m resulted in a single number determined using the
lone conformation obtained from the crystal structure for each molecule, or from a predicted
conformation. Predictions of dispersability in PVPva using R3m, however, would ideally capture
information about the distribution of conformations that is possible for a molecule in its amorphous
state. To further understand the validity of the R3m dispersability model it is necessary to
investigate whether the values used to build the original model are representative of the
conformational distributions expected for amorphous API as dispersions form. This chapter
considers the hypothesis that the predicted 3D conformation used to calculate R3m is sufficiently
representative of the geometry of an API in its dispersed state (approximated herein by the
amorphous conformation of the API alone). Specifically, the values of R3m determined from
predicted conformations are expected to fall within the distributions of R3m values calculated from
conformations expected in the amorphous state. As such, the decision boundary concerning
dispersability will remain unchanged, and therefore, no changes in the original classifications of

168

dispersability for library molecules is expected. To address this hypothesis, the overall impact of
3D conformation on the value of R3m will be investigated. Next, molecular dynamic simulations
will be used to obtain a reasonable distribution of conformations expected for the amorphous forms
for each library API molecule. Distributions of R3m will be evaluated to see if they contain the
original value (calculated from the conformation in the crystal structure). Finally, the model for
the prediction of ASD formation will be updated to include these distributions in R3m which result
from the variation in 3D conformations for each API. Inclusion of this conformational information
is expected to improve future predictions, particularly for API which fall near the established
decision boundary.

6.2. Experimental Section

6.2.1.

Preparation of Co-solidified Mixtures

The preparation of co-solidified mixtures has been previously described in Chapter 4 (see
section 4.2.2). Briefly, the melt-quench method involves dry blending the polymer and API at a
specific weight ratio and transferring to a crucible, where the mixture is then heated to 10°C above
the melting point of the API for approximately 30 minutes with intermittent stirring. The molten
mass is then quenched by immersion of the crucible in ice water under dry N2 purge to minimize
exposure to water condensation and plasticization. The resulting solids were stored overnight in a
desiccator containing P2O5 and characterized the next day using powder X-ray diffraction (PXRD),
differential scanning calorimetry (DSC), and hot-stage polarized light microscopy. Additional
details concerning the categorization of dispersability can be found in Chapter 4. Dispersion
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behavior was regressed against a database of molecular descriptors, from which R3m was the only
one that correctly separated the library according to dispersability in PVPva (Figure 2). Although
co-solidified mixtures were also prepared using a solvent evaporation method in the cited
reference, this chapter will focus on the melt-quench data to eliminate the potentially confounding
presence of organic solvent in those mixtures.

6.2.2.

Crystal Structure Data

To explore the variation in R3m between experimental and predicted conformations
beyond the original library shown in Figure 38, 80 individual molecules were identified, consisting
of primarily BCS class II API. Crystal structure files were obtained from the Cambridge
Crystallographic Data Centre (CCDC)156 in order to compare predicted 3D structures to
experimental (crystal) data. A total of 130 CCDC files were used, comprised of 50 polymorphic
forms of 33 of the 80 API. The CCDC reference codes for these files can be found in Table 20 in
the Appendix. For cases where multiple crystal structure files existed for a single polymorph, the
file with the lowest reported R-factor was selected.

6.2.3.

Molecular Dynamics

Molecular Dynamics (MD) simulations were performed using Materials Studio175 to
sample multiple 3D structural conformations in the amorphous form. The COMPASS II force field
was applied for all of the simulations described since it has been parameterized for drug-like
molecules, includes functional groups of interest, and has been optimized using experimental
data.182 The MD process is illustrated in Figure 40. First, the API structure was drawn and its
geometry optimized using the Forcite module. The Conformers module was then applied using the
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systematic grid scan method to identify the conformation of lowest total energy (Figure 40a). This
was performed to ensure the initial structure for MD simulations was not sterically trapped in an
unlikely conformation. Next, the amorphous structure was built using the Amorphous Cell module,
where 40 molecules derived from the previously identified lowest energy conformation of the API
were placed into a virtual box with cubic dimensions and a density of 1 g/cm3. The construction
of the amorphous cell was replicated for a total of 10 cells, and the 3 cells having the lowest total
energy following geometry optimization were selected for subsequent MD simulations (Figure
40b). Finally, MD simulations were conducted using the Forcite module for a total of 500 ps using
the NPT ensemble to permit the cell volume to fluctuate (Figure 40c). The virtual temperature was
held at 298 K using the Nosé-Hoover thermostat, and the virtual pressure was held at 1 atm using
the Berendsen barostat. The amorphous density for each API was determined by taking the average
of the density over the final 300 ps of the simulation. 3D molecule conformations were extracted
from 7 frames equally spaced throughout the final 300 ps of the simulation (illustrated by red boxes
in Figure 40c). Individual molecular conformations were then extracted and R3m was calculated
for each conformation (Figure 40e), resulting in a total of 840 conformations for each API. A larger
cell was constructed using 200 API molecules to confirm that the size of the amorphous cell did
not have a significant impact on the calculated R3m distribution, nor the predicted amorphous
density. No significant change in the resulting distribution of R3m values was observed (see Figure
74 in the Appendix), so an amorphous cell containing 40 molecules was used for all future studies
to save on computational time.
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Figure 40: Example molecular dynamics simulation. (a) The conformer tool is used to identify the
lowest energy conformation (black dashed line). (b) This conformation is used to construct 10
amorphous cells. The 3 with the lowest energy (indicated in orange) are selected for MD
simulations. (c) The MD simulation using the NPT ensemble. Multiple frames are selected after
equilibration (indicated by the red boxes). (d) The selected frames are saved and coordinates are
extracted using MATLAB to calculate R3m values for each individual molecule. (e) Some
example conformations from a single MD frame.
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6.2.4.

Extraction of Conformations from MD Simulations

and Calculation of R3m
The extraction of the 3D molecule conformations from the Materials Studio MD simulation
was performed using MATLAB. Seven frames per simulation were saved as .xsd files. Relevant
data from these files, such as the atom types, atom coordinates, connectivity, etc. were extracted
using in-house MATLAB code. The coordinates of each molecule were then centered and the R3m
descriptor was calculated for each conformation using another in-house MATLAB function. The
MATLAB functions for this process can be obtained via the links provided in Table 21 in the
Appendix.

6.3. Results & Discussion
R3m belongs to the geometry, topology, and atom weights assembly (GETAWAY) class
of descriptors. The calculation of the R-GETAWAY class of molecular descriptors is described in
more detail elsewhere.35, 51 The R3m equation is given in Equation (18),35 and reproduced below
(equation (24)) for convenience.
(24)

R3m = ∑A−1
i=1 ∑i>j

√hii ∙hjj
rij

∙ mi ∙ mj ∙ δ(3; dij )

Here, A is the number of atoms in the molecule, m is the atomic mass normalized to carbon, i and
j refer to 2 separate atoms, rij is the Euclidean distance between atoms, hii and hjj are the leverages,
and δ(k:dij) is a delta-Dirac function, where k is the topological distance. For R3m, the topological
distance (k) is equal to 3, and the weighting is the atomic mass relative to carbon. The terms, which
are used to calculate R3m, are calculated using several matrices. The first is the 3×A molecular
173

matrix, which contains the atomic coordinates. The geometry matrix is an A×A symmetric matrix
containing the Euclidean distance between each atom in the molecule. The molecular influence
matrix is an A×A matrix calculated in the same manner as the leverage matrix for linear
regression,51 and the diagonal of this matrix contains the leverage values used in Equation (24)
(i.e., hii, hjj).
The matrices comprising Equation (24) are all impacted to some extent by the 3D
conformation of a molecule. Changing the conformation of a molecule will result in a change to
the values of an API’s molecular matrix, and subsequently, its geometry matrix. While the
Euclidean distance of atoms having a topological distance of 1 (i.e., atoms connected by a covalent
bond) will remain essentially unchanged due to the consistency of these bond lengths, the
Euclidean distances of atoms, which are separated at larger topological distances, will vary due to
conformational differences resulting from altered torsion and bond angles. Likewise, leverage
values, which are a measure of the distance of atoms from the geometric center of a molecule, will
also change owing to potentially significant changes in the location of the geometric center caused
by changes in torsion angles. It is evident, then, that changes in 3D conformation will likely result
in changes to R3m. However, the extent and significance of these changes remains unclear. It was,
therefore, necessary to first investigate whether conformational changes could result in any
significant changes to R3m, and by extension, have a potential impact on future predictions of
ASD formation in PVPva made by the R3m model.
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6.3.1.

Investigating the Potential Impact of 3D

Conformation
The 3D coordinate system of the API impacts the magnitude of the R3m value owing to
changes in both geometric distances and leverage values. It is, therefore, important to consider the
source of the coordinates. Ideally, the coordinates used to calculate R3m should be representative
of the API conformation in an ASD so that the model can capture realistic information regarding
molecular size and shape, and the potential to interact with the polymer. Using inaccurate 3D
coordinates would make arguments about relationships between R3m and physical properties more
tenuous. As a result, 3D coordinate predictions were investigated and compared with experimental
data and with molecular dynamics simulations.

6.3.1.1.

CORINA vs. crystal structure data

The 3D conformations of the 15 library API shown in Figure 38 were predicted using the
COoRdINAtes (CORINA) algorithm.178 CORINA sets bond angles and lengths based on the types
of atoms, hybridization states, and types of bonds. Additionally, atom positions are adjusted to
avoid non-bonded atom overlap, and a pseudo-force-field is applied to minimize the sum of
stretching, bending, out-of-plane, and torsional energies.178 While it is possible to calculate R3m
using experimentally obtained coordinates (e.g., crystal structure data), the model was built using
1D data (simplified molecular input line entry specification (SMILES) files) in order to make the
model more generally applicable. For example, in the event that a new chemical entity does not
have a solved crystal structure, the model could still be applied. However, it is important to
consider the performance of the CORINA model in comparison to the physical state of interest,
since a reasonable 3D conformation is believed to be integral to the model.
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Given the abundance of structural information available in the CCDC, an initial
comparison of predictions relevant to the solid state began with crystalline conformations for the
molecules being investigated. The CORINA algorithm has been previously shown to make good
predictions of molecular conformation in crystals,178 and a more recent study with a larger dataset
of 2,443 small organic molecules showed an average root mean square deviation of 0.95 Å between
actual and predicted conformations.183 However, it remained unclear how the value of R3m
between experimental and predicted structures would vary. To address this question a dataset of
primarily BCS class II crystalline structures were assembled (see Table 20 in the Appendix for a
list of API and their respective CCDC reference codes). The R3m descriptor was calculated using
both the reported crystallographic structures and for CORINA-predicted structures. In cases for
which crystal structures for polymorphic forms of API were available (33 API, for a total of 50
polymorphs), the R3m value was determined using these coordinates as well. Inclusion of
polymorphs allowed for the assessment of 3D conformational variability within individual API.
Histograms of the average absolute difference between calculated R3m values are shown in Figure
41a and b, where Figure 41a is a compilation of 80 different API structures, and Figure 41b
includes a total of 130 API (50 of which are polymorphs of 33 of the original 80 structures). A low
average absolute difference between R3m values is observed, with a majority of the API having a
difference in R3m of ≤0.05 between CORINA and CCDC 3D coordinates. Specifically, a
difference in R3m≤0.05 was observed for 68% of the 130 structures (API and polymorphs) while
86% had a difference in R3m≤0.1. Figure 41c shows a linear regression fit for the 80 individual
API, and Figure 41d shows a similar regression including the polymorphs (130 API total). The
slopes of the lines are 0.91 and 1.04, respectively.
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Figure 41: Histograms of the average absolute difference between R3m values calculated using
CORINA and R3m calculated using crystal structures obtained from the CCDC. (a) 80 API, and
(b) 130 API, which included 50 polymorphic forms of the original 80 compounds. Linear
relationship between (c) R3m values for 80 API calculated using 3D structures from CCDC vs.
the CORINA algorithm, and (d) R3m values for 80 API (blue diamonds) and 50 polymorphic
forms for a total of 130 API (orange circles). The orange regression line reflects the fit for all 130
API. Points indicated by the red box show R3m values calculated for the different polymorphs of
aripiprazole.

While the difference in R3m between CORINA predictions and experimentally determined
3D conformations was generally negligible, there were some notable exceptions. One such
example is aripiprazole, for which the largest difference between CCDC and CORINA R3m values
was observed (ΔR3m = 0.28). The aripiprazole polymorphs are indicated by the red box in Figure
41d. Figure 42 shows a comparison of the 3D coordinates from CCDC crystal structures for the
aripiprazole polymorphs having the largest difference in R3m value. The observed difference in
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R3m is the result of a significant change in the torsion angle of the linear butyl carbon chain in
aripiprazole. Polymorph I has a dihedral angle of 174.7°, while polymorph VII has a dihedral angle
of 58.34°. This change in dihedral angle causes a shift in the geometric center of the molecule, and
results in changes to the leverage values. This change will also result in changes in specific atomic
positions, and therefore, changes in the Euclidean distances between atoms.

Figure 42: (a) Molecular structure of aripiprazole. (b) A comparison of the CCDC structures
obtained for 2 aripiprazole polymorphs, where the dichlorophenyl groups are overlaid on the left.
The change in 3D coordinates results in a relatively significant difference in R3m values
(aripiprazole I (CCDC ID: MELFIT01,184 orange) R3m = 0.951, aripiprazole VII (CCDC ID:
MELFIT07,185 teal) R3m =1.204).

While in certain cases, larger differences in R3m were observed, the average absolute
difference in R3m for all 180 conformations was 0.06. Nevertheless, it is evident that the potential
variation in R3m is important to consider. It is possible that a calculated R3m value may deviate
significantly from the ‘true’ R3m value, where the ‘true’ value would be representative of the
distribution of real 3D conformations of the API in the environment of interest. When used in the
extant R3m model for predicting ASD formation in PVPva, variations in R3m owing to
conformation may potentially affect the accuracy of the model, since dispersion behavior is
predicted based on a boundary value of R3m = 0.65. In certain cases, particularly for API having
an R3m close to 0.65, conformational changes could potentially cause the calculated R3m value
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to fall on either side of this boundary, resulting in different dispersability predictions. As a result,
the calculation of R3m should be based on a realistic conformation so that accurate predictions can
be made.
Calculated values for R3m may also vary depending on the environment of the API. For
example, if the 3D conformation of an API in a solvent system is significantly different, there may
be a difference in the ‘true’ R3m value. Accounting for these types of variabilities may help to
improve predictions of dispersability in the future. This potential route for model improvement has
driven the investigation described below. In previous work, differences in dispersability were
observed between melt and solvent preparation methods.174 Understanding API conformational
changes that result from changes in the environment surrounding the API may also lead to better
predictions of ASD formation, and is a topic of future research.

6.3.2.

Simulation of Amorphous 3-D Conformations using

Molecular Dynamics
While the CORINA algorithm appears to adequately predict the crystalline structure of
most API (ΔR3m<0.1 for 86%), it remained unclear if the crystalline conformation was sufficiently
representative of the API in its amorphous state. Ideally, since the value of R3m is being used to
predict the formation of ASDs in PVPva, the calculated R3m should be representative of the
conformations of the API that are most likely in the amorphous state. The conformations of each
API in the amorphous form will likely adopt a distribution of possibilities relative to the crystalline
form owing to the increased entropy, volume, and free energy. Correspondingly, a wide
distribution of R3m values is possible for each API depending on how much each matrix is
influenced by molecular conformations. By determining the breadth of R3m distributions for each
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API in our library, it is possible to establish a sense of the possible variation relative to the original
R3m values used to build the dispersion prediction model, and comment on the likelihood of
misclassified dispersion behavior. The width of these distributions may significantly impact the
model decision boundary, and subsequently, future predictions.
Since experimental data for the 3D conformations likely in the amorphous form are not
available, molecular dynamics (MD) simulations were applied to predict structures more
representative of the amorphous form, as described in section 6.2.3. A 500 ps simulation was run
in triplicate for each API. Individual simulation frames were extracted after the system appeared
to reach equilibrium (after 200 ps). The individual 3D coordinates from the molecules in these
frames were extracted using MATLAB to obtain a sampling of possible 3D conformations, and
the values for R3m were calculated for each. Links to relevant MATLAB code can be found in
Table 21 in the Appendix. In total, R3m values for 840 conformations were calculated for each
API, and resulted in a distribution of possible R3m values for molecules in the amorphous state.
It is important to note that while MD simulations may yield a result, its usefulness will
depend on the assumptions and parameters applied to obtain it. It is necessary to consider the
limitations of the computation and to compare results with other physical models, where available,
to ensure that each output is meaningful.186 For this reason, the amorphous density as determined
by MD simulations was compared with the experimental amorphous density values, where
available. The corresponding MD amorphous densities, experimental values, and crystallographic
densities for each API are given in Table 9.
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Table 9: Predicted and actual (where available) amorphous densities for library API.
Experimentally determined densities were obtained from the literature.
API

R3m

Propranolol
Cimetidine
Melatonin
Terfenadine
Cloperastine
Nifedipine
Quinidine
Sulfanilamide
Tolbutamide
Indomethacin
Ketoconazole
Itraconazole
Chlorpropamide
Felodipine
Bicalutamide

0.342
0.403
0.407
0.561
0.562
0.568
0.593
0.595
0.687
0.737
0.814
0.872
0.927
0.964
1.001

Actual
Amorphous
Density (g/cm3)
N/A
N/A
N/A
N/A
N/A
a
1.20
N/A
N/A
N/A
b
1.34
c
1.30
d
1.30
N/A
a
1.28
N/A

Predicted
Amorphous
Density (g/cm3)
1.08
1.20
1.16
1.04
1.11
1.23
1.14
1.44
1.21
1.29
1.30
1.26
1.36
1.26
1.43

Actual
CCDC
Crystalline
Refcode156
3
Density (g/cm )
1.164
IMITON187
1.312
CIMETD188
1.276
MELATN01189
N/A
N/A
N/A
N/A
1.382
BICCIZ03190
1.234
BOMDUC191
1.514
SULAMD03192
1.252
ZZZPUS18193
1.401
INDMET03194
1.4
KCONAZ195
1.36
TEHZIP196
1.45
BEDMIG10197
1.451
DONTIJ198
1.554
JAYCES199
a – Marsac, et. al.85
b – Tong, et. al.200
c – Van den Mooter et. al.6
d – Six et. al.201

As shown, experimentally determined amorphous densities were available in the literature
for nifedipine, indomethacin, ketoconazole, itraconazole, and felodipine. For these 5 API, the
difference between the experimental and MD predicted amorphous densities was less than 4%,
and, as expected for amorphous solids, always lower than the corresponding crystallographic
density obtained from CCDC files. Similarity between predicted and experimental amorphous
density increased confidence that the results of the MD simulations were meaningful.
Figure 43 shows a box-and-whisker plot for the R3m values that were calculated by
sampling structures from the MD simulations. The boxes indicate the upper and lower quartile of
the R3m distribution for each API, and whiskers indicate the edges of a normal distribution. Red
crosses indicate outliers from the normal distribution, the red horizontal line within the boxes
indicates the median, and the center of the black diamonds indicates the mean. The original R3m
values, which were determined using the CORINA predicted 3D structure, are shown by the blue
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dashed horizontal lines. The dotted black horizontal line indicates the original R3m boundary of
0.65, where molecules having R3m greater than this value were confirmed to be dispersable in
PVPva.

Figure 43: A box-and-whisker plot of the R3m values calculated from MD simulations (840 R3m
values for each API). The red line toward the center of the box is the median, the box shows the
interquartile range, and the whiskers indicate the interquartile range multiplied by 1.5. Values
outside of this range have the red ‘+’ symbol, indicating values that fall outside of a normal
distribution. The black diamonds indicate the mean, and the blue dashed lines indicate the R3m
values calculated from SMILES files and the CORINA algorithm. The horizontal black dotted line
indicates the original R3m decision boundary, and the horizontal black dot-dashed line indicates
the boundary updated using MD simulation results (R3m=0.632, see Figure 45). The green boxes
indicate API which were experimentally observed to successfully form ASDs using the melt
quench method, while those API in red indicate compounds which failed to form ASDs.

The median R3m values determined using MD simulations were generally similar to CORINA
predicted values originally used to build the dispersability model. The average absolute difference
between CORINA and both the mean and median MD determined R3m values was 0.03. The
largest difference between median MD determined R3m and the corresponding R3m values
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calculated using CORINA was observed for cimetidine, which had an absolute difference of 0.11.
The variability observed for cimetidine is specifically a result of the variation in Euclidean distance
between the intramolecular sulfur and the two intramolecular nitrogen atoms, which are separated
from it at a topological distance of 3 (see Figure 38). The flexibility of the chain that extends from
the imidazole group, and the resulting impact on the Euclidean distance between these heavier
atoms, has more impact on the value of R3m. As the sulfur and nitrogen atoms approach each other
in 3D space, the R3m value is expected to increase.
In general, the R3m value from CORINA predicted conformations fall within the
distributions or R3m values determined by MD simulations. Only propranolol fell outside this
distribution (see Figure 43). This was the result of a linear 3D conformation predicted by the
CORINA algorithm, as shown in Figure 44b. The blue propranolol molecule shown in Figure 44b
and Figure 44c corresponds to the CORINA conformation. The red molecule in Figure 44b was
pulled from the MD simulation and had an R3m value matching the MD median value. The green
molecule in Figure 44c was also extracted from the MD simulation based on its similarity to the
CORINA calculated R3m value (difference in R3m = 0.0014). A linear conformation is less
commonly observed in the MD simulation due to the impact of the surrounding environment. A
rotation about the O8, C7, C6, C5 dihedral is more common, and results in an increase in R3m
relative to that calculated for a linear conformation predicted by CORINA due to the shift in the
geometric center of the molecule, and subsequent change in leverage values.
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Figure 44: Propranolol conformations and their effect on R3m. (a) Propranolol with atoms labeled.
Propranolol molecules in blue correspond to the CORINA calculated conformation ((b) and (c)).
(b) The propranolol molecule in red was extracted from MD simulations and has an R3m value
equal to the median. (c) The green propranolol molecule shows a conformation from the MD
simulation having an R3m value most similar to the CORINA conformation (difference in R3m =
0.0014).

The result is an increased confidence that R3m values determined using the predicted 3D
conformation from the CORINA algorithm are sufficiently representative of the amorphous form.
The R3m values applied to build the original dispersability model all fall reasonably close to the
median values calculated using conformations obtained from the MD simulations, where the
largest absolute difference between median MD R3m and CORINA R3m values was 0.11. This
indicates that the R3m values used to build the original model captured relevant and more realistic
structural information for the API molecules relative to how they might appear during ASD
formation with PVPva. This increased confidence that the conformation is representative of the
amorphous form strengthens the idea that R3m captures meaningful physicochemical properties.
In contrast, if the model had been originally built using descriptor values that were not sufficiently
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representative of the amorphous form, the failure to capture the ‘true’ 3-D conformation would
significantly weaken arguments that size and shape information captured were relevant to the
formation of ASDs. Ultimately, the MD determined R3m values do not significantly affect the
model, and the resulting predictions are unchanged. However, it is important to note that variations
in conformation can have a significant impact on the R3m value, and, therefore, could potentially
impact predictions for molecules subject to large conformational differences. Inclusion of this
conformational variability is likely to improve future predictions (see section 6.3.3). Applying the
median R3m value for future predictions may also help to improve future predictions by capturing
the R3m value of the energetically preferred conformation. A bar plot comparing R3m values
calculated from CORINA generated structures, structures obtained from the CCDC, and MD
simulation structures are shown in the Table 20 of the Appendix.

6.3.3.

Updated R3m Model

As discussed in the previous sections, the original dispersability model was built using
individual R3m values for each API based on a single predicted 3D conformation generated by the
CORINA algorithm. However, the conformation of an API in the amorphous form will likely have
a wider distribution of possible conformations relative to the crystalline form due to the increased
entropy, volume, and free energy, and therefore, a distribution of possible R3m values. Wide
distributions of R3m may significantly impact the model decision boundary, and subsequently,
future predictions. Therefore, since a large number of potential conformations have been extracted
from MD simulations, and their respective R3m values were calculated, these data were modeled
against experimental observations using logistic regression. The resulting logistic regression
model is shown in Figure 45.
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Figure 45: Logistic regression model using the expanded MD dataset. This model contains 12,600
data points for R3m (jittered to more clearly show the amount of data). Red circles correspond to
API which failed to form an ASD in PVPva by melt-quenching, while green circles correspond to
API which were observed to successfully form an ASD in PVPva by melt-quenching. The blue
line shows the logistic curve. This expanded model resulted in an updated boundary value of 0.632.
The equation for the regression line and the standard errors of the coefficients are given.

The value of R3m at the model boundary was of particular interest, since this boundary will be
applied for future predictions of ASD formation in PVPva. The updated model resulted in a shift
in the R3m decision boundary from approximately 0.65 to 0.632. This change is illustrated by the
horizontal dotted and dot-dash lines in Figure 43, respectively, and the updated model is shown in
Figure 45. When this updated boundary is compared to the individual R3m values determined from
CORINA 3D conformation prediction of SMILES files, the predictions regarding dispersability in
PVPva remain unchanged relative to the original model. This is because the updated boundary still
falls within the gap on the R3m axis where complete separation of the data occurred. All API
having R3m values below 0.6 failed to form ASDs, while those having R3m above 0.68
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successfully formed ASDs in PVPva. This complete separation results in large standard errors for
the coefficients in logistic regression,121 and ultimately, it was unnecessary and inappropriate to
apply logistic regression to the completely separated data.202 Instead, this boundary (R3m=0.65)
was defined as the mid-point between the values at the edge of each phenomenological category.
It is important to note that the conformational flexibility of the molecules at the decision
boundary resulted in some of the calculated R3m distributions having values at their extremities
that crossed the updated threshold value. For example, cimetidine, nifedipine, and quinidine have
a few simulated conformations whose R3m was greater than 0.632. Additionally, tolbutamide and
indomethacin have some simulated conformations whose R3m fell below 0.632. Molecules that
have R3m values that cross the updated boundary may help to explain some of the
misclassifications observed in the solvent evaporation data described in Chapter 4. For example,
at 15% w/w drug loading, nifedipine was found to successfully disperse in PVPva despite an
R3m<0.65, while tolbutamide, at 75% drug loading regularly failed to disperse in PVPva when
co-solidified mixtures were prepared by solvent evaporation, despite an R3m>0.65. These
misclassifications by the model, combined with the distribution of R3m values that cross the
decision boundary, warrant further future investigation regarding the API conformation in the
presence of solvent. If these API have sufficiently different preferred 3D conformations in the
presence of methanol, this could help to explain deviations from the R3m model, and ultimately
improve the model performance.
In the original R3m model there was uncertainty for future predictions at the decision
boundary because of the gap between R3m values near the boundary (0.595 for sulfanilamide and
0.687 for tolbutamide). This gap led to the selection of a boundary value of 0.65 (their mean), but
predictions for new API having values between 0.595 and 0.687 would not be supported by data
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in the model. Inclusion of the R3m data from conformational information has resulted in a betterdefined decision boundary and permits the application of logistic regression. Although the updated
boundary (R3m=0.632) is based on a larger dataset of 3D conformations, the categorization of
dispersion behavior for each API using the original model remains unchanged. The similarity
between the models further supports the conclusion that the R3m descriptor is able to capture
relevant 3D information about the API. Incorporation of these additional data into the model has
resulted in improved confidence in the model boundary by ensuring that the model incorporates
conformational flexibility. As a result, future predictions will likely improve, particularly for API
with R3m values near the model boundary.

6.4. Conclusions
The 3D conformation of an API molecule has an impact on its R3m value, especially if
shape changes influence matrices used to calculate this molecular descriptor. Comparisons
between 3D conformations obtained using the CORINA algorithm, crystal structure data, and MD
simulations showed that the resulting variations in R3m was generally low for each API. A large
majority (86%) of an expanded dataset of API had a difference in R3m≤0.1, with a maximum
difference in R3m equal to 0.28. The average absolute difference between CORINA and both the
mean and median MD R3m values was 0.03, and the largest difference between median MD R3m
and CORINA R3m values was 0.11. Ultimately, these results support the hypothesis that predicted
3D conformation originally used to calculate R3m is sufficiently representative of the geometry of
an API in its amorphous conformation as it forms an ASD in PVPva. However, the potential for
large conformational changes to impact the R3m value should not be ignored, since these large
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variations, although less common, can have significant impact on predictions of ASD formation,
particularly if the calculated R3m value lies near the model boundary.
Ultimately, this study further supports the idea that R3m captures relevant 3D conformation
information about the API. The incorporation of additional conformational variability into the
model has improved confidence in the model boundary. Inclusion of conformational flexibility
will capture a more realistic distribution of R3m values, and subsequently, will improve future
predictions.
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Chapter 7. Investigating the Relationship Between
R3m & Solubility of API in PVPva
7.1. Introduction
The previous chapters have shown that R3m continues to be useful for the prediction of
ASD formation for the polymer PVPva, and provides additional details regarding the
physicochemical interpretation of R3m. However, while R3m has been shown to be useful for an
extant API library, the extent to which R3m captures thermodynamic and/or kinetic factors
remains unclear. The purpose of the research described in this chapter is to investigate whether the
molecular descriptor R3m is specifically related to thermodynamic factors that are known to be
important to ASD formation. Specifically, the solubility of an API in a polymer carrier is expected
to be an important factor for dispersability. If an API is soluble in the polymer at a concentration
and temperature of interest, the resulting mixture will be thermodynamically stable, and will not
phase separate or crystallize. In this case, the successful formation of an ASD is not
thermodynamically inhibited. However, as the concentration of an API increases beyond the
saturation solubility, the system will be thermodynamically driven to crystallize, and the likelihood
of successfully forming an ASD will decrease. Therefore, the solubility is important for ASD
formation because it gives a measure of the thermodynamic driving force for phase separation and
recrystallization. Figure 46 (reproduced from Figure 1 in section 1.2.2.3 for convenience) shows
a phase diagram for API-polymer mixing. Of particular interest in the present chapter is the
boundary representing crystalline API-polymer solubility, which describes thermodynamically
stable mixtures. Progressing in the positive y-direction from this solubility curve results in
increasing levels of supersaturation, and therefore, increasing the thermodynamic drive to phase
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separate and crystallize. The solubility of crystalline API in polymer is expected to be a useful
measure of the relative thermodynamic driving force for phase separation and recrystallization,
and therefore, give an indication of the likelihood of successful ASD formation. This important
boundary in the phase diagram can be experimentally estimated, and this chapter will focus on the
determination of the crystalline API-polymer solubility.

Figure 46: Theoretical figure illustrating both drug-polymer solubility and miscibility. (Adapted
from the Journal of Pharmaceutical Sciences, Vol 99(7), F. Qian, J. Huang, M. A. Hussain., Drug–
Polymer Solubility and Miscibility: Stability Consideration and Practical Challenges in
Amorphous Solid Dispersion Development, Pages No. 2941-2947, Copyright 2010, with
permission from Elsevier).4 Zones I and II indicate thermodynamically stable mixtures, Zones III
and IV indicate meta-stable zones, and Zones V and VI are unstable zones where recrystallization
is certain within a timeframe dictated by the molecular mobility of mixtures. Of particular interest
to this chapter is the red solid line representing crystalline API-polymer solubility. Reproduced
from Figure 1 for convenience.

It is important to note that determination of API solubility in a polymer is non-trivial.
Methods for measuring both miscibility and solubility of API in polymers have been reported in
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the literature. For the purposes of this chapter, both were reviewed and reported here for
completeness (Table 10). Currently, there is no generally accepted method for such measurements.
Since it is not possible to measure solid-solid solubility, the solubility of API in polymer is usually
determined by extrapolation from data obtained when the polymer is in a liquid-like state, or by
performing measurements using polymer liquid analogues. Each of these methods is, therefore,
subject to its own assumptions, whose validity, especially for the temperature range of interest
must be considered before selecting a method. A number of these methods and their associated
experimental assumptions are described in Table 10. Since the focus of the chapter is on solubility,
those methods appropriate for measuring solubility were considered, and the dissolution end-point
method203 was selected.
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Table 10: Comparison of methods for the determination of API solubility in polymer.
The API and polymer are sieved to ensure a small particle size, then
geometrically mixed at the appropriate weight %. The mixture is
analyzed by differential scanning calorimetry (DSC) at a slow ramp
rate to identify the melting point depression. This value can be related
to the interaction parameter (χ) via the application of the FloryHuggins theory and, thereby, related to miscibility.

• Small, controlled particle size (e.g. Marsac et al30 used 45-75
μm).
• Molecular mixing occurs during the timescale of the DSC
experiment.
• 100% Crystalline API.92
• Application of Flory-Huggins lattice theory is acceptable.
o A single lattice is suitable to characterize both solvent and
solute.84
o The solution configuration is random.84
• Extrapolation of Flory-Huggins theory is reliable.
• API is thermally stable over the temperature range of the DSC
experiment.
• Comminution of particles increases potential for interparticulate close contact.
• Molecular mixing occurs during the timescale of the DSC
experiment.
• API not fully amorphous, since this would result in no
detectable dissolution.
• API is thermally stable.
• Selected extrapolation method can be reliably applied to the
temperature of interest.
• API does not degrade during annealing (4-10 h)
• Annealing time is sufficient to allow the sample to reach
equilibrium.

API and polymer are weighed in the appropriate weight fractions and
cryomilled to reduce particle size and, thereby, increase close contact
between particles. The resulting solid is analyzed by DSC at a slow
ramp rate to identify the dissolution endpoint (a.k.a. melting point
depression). The process is repeated at multiple concentrations to
create a plot of the log solubility vs. 1/T. The data can be extrapolated
to lower temperatures using the Van’t Hoff equation (solubility) or by
applying Flory-Huggins theory (miscibility).
API and polymer are cryomilled to reduce particle size and achieve
close contact. The resulting solid is then analyzed by DSC, where the
sample is annealed at a specific temperature for 4-10 h. During
annealing, the sample is expected to reach equilibrium. The sample is
then heated through Tm to determine if any crystals remain. Remaining
crystals would indicate that the annealing temperature was too low to
achieve complete dissolution. The process is repeated to isolate the
appropriate temperature that corresponds with the solubility at the
selected concentration. The process is repeated for multiple
concentrations. The resulting data can be fit to the Flory-Huggins
model to obtain χ to estimate miscibility.

Method
Ref.

Hoei et al.88
Marsac et al.30

Assumptions

Tao et al.203

Description

Sun et al.204

Annealing
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Dissolution End Point

Melting point depression

Method

Table 10 (continued)
API and polymer are co-milled to generate a supersaturated system. A
subsample of the resulting mixture is annealed in the DSC above Tg
to allow de-mixing to the equilibrium solubility. The resulting mixture
is then cooled and scanned to identify the T g corresponding to the
solubility at the annealed temperature. The Gordon-Taylor equation is
then used to determine the equilibrium solubility from the
experimentally determined Tg. Finally, the data can be extrapolate to
other temperatures using Flory-Huggins theory to estimate
miscibility.
Excess crystalline API is added to a temperature-controlled vessel
containing the liquid polymer analogue. The mixture is stirred for
sufficient time to ensure equilibrium has been reached (e.g., >24 h).
The resulting liquid is then decanted, centrifuged, and filtered to
remove solid particles. The solubility of the API in the liquid polymer
analogue is then determined by UV or HPLC. The activity coefficient
can then be determined using the experimentally obtained solubility
and the free energy difference between the amorphous and crystalline
forms of the API. The activity coefficient can then be compared to
the Flory-Huggins interaction parameter using the appropriate
equation (see Marsac et al85), and used to estimate miscibility.

• API recrystallization is faster than dissolution.
• Supersaturated systems can be obtained by co-milling
• Phase separation is complete during annealing.
• No deviations from the Gordon-Taylor relationship
• API does not degrade during annealing (≥2 h).
• No significant changes to the sample occur post-annealing
(i.e., during cooling and heating to determine the Tg).

Polymer solutions of known concentrations are prepared by dissolving
the polymer in an inert solvent. An excess of crystalline API is then
added to the solution and mixed for 1 week to ensure equilibrium is
reached. The samples were then filtered and analyzed by HPLC. The
polymer concentration is varied and the method is repeated to generate
a linear fit of API solubility vs. polymer concentration, where the yintercept is the solubility of the drug in the solvent with no polymer.
The slope of the resulting line is used to estimate the API-polymer
solubility in the solid state.

• The polymer of interest has a low molecular weight liquid
analogue available.
• The mixture is permitted to reach equilibrium before analysis.
• Measured thermodynamics of the API indicates compatibility
with the polymerized version of the polymer.
• API mixes with the polymer analogue with ideal entropy of
mixing.
• Interactions between the polymer liquid analogue and API are
identical to polymer-API interactions.
• The determined activity coefficient of the API at the solubility
limit of the analogue is the same at the solubility limit of the
API in polymer.
• The solvent is inert. Specifically, the interactions between API
and polymer in the dissolved state are similar to the
interactions in their solid state. Also, the solvent should not
impact the structure of the API and polymer.
o If the solvent is not inert, the resulting curve is expected
to be non-linear.
• The API is stable in solution.
• The polymer is sufficiently soluble in the selected solvent.

Method
Ref.

Mahieu et al.93

Assumptions

Marsac et al.85

Description

Knopp et al.107

Polymer in solution
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Liquid Polymer analogue

Recrystallization

Method

Description

Assumptions

Mixtures of polymer and API of a known concentration are annealed
at different temperatures to allow dissolution of API into the polymer.
The API concentration should be high enough to ensure API crystals
remain post annealing. The resulting mixture is then analyzed by DSC
to obtain the melting enthalpy of the remaining crystalline phase. The
process is repeated at multiple concentrations to generate a plot of
enthalpy of melting vs. dissolved mass fraction. The data are linearly
extrapolated to zero enthalpy to determine the solubility at that
temperature. The process is repeated for multiple annealing
temperatures to determine the solubilities at the respective
temperatures.

• Assumes the presence of one polymorph, since the presence of
multiple polymorphs would impact the resulting enthalpy.
• API does not degrade during annealing (10 h)
• Annealing time is sufficient to allow the sample to reach
equilibrium
o Rate of mixing may significantly decrease with increase
in polymer concentration

Method
Ref.

Amharar et al.205

Method

Zero Enthalpy
Extrapolation

Table 10 (continued)
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For this work, the dissolution endpoint (Tend) method described by Tao et al203 was selected
for the determination of API solubility in PVPva, primarily because quantitative data could be
obtained relatively fast, while also avoiding long annealing times at high temperatures which could
result in chemical degradation of API and/or polymer. For example, the annealing method requires
holding drug-polymer mixtures at elevated temperatures for 10 h or longer. Thermogravimetric
analyses of library API have shown weight loss in some cases during 30 min isothermal holds
above their respective Tm (e.g., chlorpropamide). Although these weight losses were minor (<2%),
extended annealing times are expected to result in more significant degradation. Additionally, API
degradation can also result in melting point depression due to the subsequent presence of
impurities and/or the reduction in the weight fraction of the compound of interest. This would
further complicate results, particularly for the thermal methods described in Table 10.
Ultimately, methods requiring stability of the API at elevated temperatures for extended
durations were excluded because it was unlikely that they could be applied for all of the drugs in
the existing library and, therefore, would complicate direct comparisons between API. In addition,
the application of cryomilling for the dissolution endpoint method will result in reduced particle
size, increased particle-particle contact, and subsequent reduction in the extent of diffusion
necessary to accomplish API-polymer mixing. This is expected to reduce the effect of mixing
kinetics on experimental data. Initial screening studies for this method showed good repeatability
(i.e., low variability between replicates of differential scanning calorimetry (DSC) measurements)
and reproducibility (i.e., low variability between cryomilled batches).
For the Tend method, mixtures of API and polymer were evaluated using DSC to identify
temperatures ranging between Tg and Tm corresponding to the solubility of API in PVPva. By
varying the concentrations of the binary mixtures, the relationship between temperature and
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solubility was estimated. The reduction in the Tm for an API in these mixtures is a result of the
reduced chemical potential due to the presence of the polymer, which causes a significant decrease
in the entropy of the mixture relative to the pure API.30 If cohesive interactions between the API
and polymer are more numerous and/or stronger than their individual adhesive interactions, the
change in enthalpy will also contribute to a decrease in the chemical potential.30 Therefore, the
Tend can be used to experimentally determine the solubility of the API in polymer.

7.2. Materials & Methods
Five API were selected from the extant library, which spanned the range of R3m values.
These included cimetidine (R3m = 0.403), nifedipine (R3m = 0.568), indomethacin (R3m =
0.737), ketoconazole (R3m = 0.814), and chlorpropamide (R3m = 0.927). Ketoconazole (6527742-1) was purchased from Spectrum Chemicals (Gardena, CA). Chlorpropamide (94-20-2) was
purchased from MP Biomedicals (Solon, OH). Indomethacin (53-86-1) was purchased from
Sigma-Aldrich (St. Louis, MO). Cimetidine (51481-61-9) and nifedipine (21829-25-4) were
purchased from TCI Chemicals (Tokyo, Japan). PVPva was obtained from BASF (25086-89-9,
Kollidon VA 64 Fine).

7.2.1.

Cryomilling

API and PVPva were weighed and transferred directly into polycarbonate cryomilling
tubes containing a steel rod. The target total weight ranged from 0.75-1.00 g to permit efficient
grinding and sufficient sample size for analysis. Closed tubes were placed into a SPEX SamplePrep
6770 cryogenic impact mill, and the milling chamber was pre-cooled with liquid N2 for a minimum
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of 2 min. Milling occurred at a frequency of 10 Hz in cycles consisting of 2 min of active milling
followed by 2 min of cool-down. Reported milling durations refer to the total active milling time,
exclusive of cooling periods. The milling chamber was periodically replenished with liquid N2 to
ensure complete tube immersion and rapid removal of heat generated during milling.
The total milling time ranged from 4 to 30 min, and at least 3 different cryomilling
durations were performed for each sample. Samples were determined to have been sufficiently
cryomilled when no significant changes (ΔTend ≲ 0.5 °C) were observed in the measurement of
end-point dissolution. Immediately after milling, the sample tubes were transferred to a desiccator
containing P2O5 and allowed to equilibrate to room temperature before opening to minimize water
vapor condensation. Once at ambient temperature, powders were transferred to scintillation vials
and stored in the desiccator until needed for thermal analysis.
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Figure 47: Experimental setup for dissolution end-point experiments. Cryomilling was performed
for multiple durations and an optimal duration was identified using both PXRD and DSC. PXRD
was used to qualitatively confirm that crystals remain. DSC was used to measure Tend. The optimal
cryomilling duration was identified by comparison of changes in Tend (ΔTend ≲ 0.5 °C). The
optimal milling duration was then replicated to obtain n = 5-9 measurements of Tend.

7.2.2.

Differential Scanning Calorimetry (DSC)

A model Q100 DSC (TA instruments, New Castle, DE) was used for these experiments.
The instrument was calibrated using o-terphenyl, In, and Sn (three-point temperature calibration)
and In was used for the enthalpy calibration. N2 was used as the purge gas during all experiments,
at a constant purge rate of 50 mL/min. Milled samples were weighed (3-7 mg) into Al hermetic
pans with pin-holed lids, which were subsequently crimped. Samples were subjected to a 1 °C/min
heating ramp through the melting point of the API. It is important to note that the dissolution
endpoint (Tend) method, as described by Tao et al.,203 involved determining Tend at a number of
DSC ramp rates and extrapolating to zero-heating rate. However, since the ultimate goal of this
work was to obtain a rank-order of solubility for comparison with R3m values for library API, a
ramp rate of 1 °C/min was selected to balance sufficient in situ mixing with experiment duration.
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Additionally, the validity of the extrapolation to zero-heating rate has not been confirmed,92 while
a heating rate of 1 °C/min was previously applied by Marsac et al.85 for the determination of
melting point depression using DSC.
Samples from each cryomilling experiment were analyzed for Tend in duplicate, at a
minimum. Once the cryomilling duration was selected for an API, then samples for Tend
experiments were replicated and analyzed in triplicate (n=5-9). The Tend value for mixtures was
determined as the intersection of a tangent line drawn from the baseline after the drug had
completed dissolution in the polymer, and a tangent line drawn from before the inflection point of
the endotherm as it approached the baseline, where peak inflection was identified using the first
derivative of heat flow with respect to temperature.

7.2.3.

Powder X-ray Diffraction (PXRD)

Cryomilled powders were back-filled into stainless steel sample holders having a sample
well depth of 2.4 mm and diameter of 16 mm. Diffraction data were collected using an X’Pert Pro
MPD system (PANalytical B.V., Almelo, Netherlands) in Bragg-Brentano geometry, equipped
with a Cu anode (λ = 1.5406° Å), 10 mm beam mask, 0.04 soller slits, 2° divergence slit, Ni Kβ
filter, and X’Celerator™ detector. The operating voltage and amperage were set to 45 kV and 40
mA, respectively. Samples were rotated at 7.5 rpm during data collection to minimize effects of
preferred orientation. Irradiation time was set to 76.24 s per step with an angular step size of 0.017°
2θ over a range of 4.5 to 60° 2θ. PXRD data were used to qualitatively verify the presence of
crystallinity in the sample. This was done to ensure that milling did not reduce sample crystallinity
to the extent that a melting endotherm was either undetectable or too small to reliably identify Tend
in subsequent DSC experiments, which would prevent determination of the dissolution endpoint.
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Correspondingly, cryomilling was controlled to facilitate simultaneous mixing and particle size
reduction of the API and polymer, while maintaining crystallinity at least detectable by PXRD
(<10% crystallinity206). Additionally, PXRD data were used to monitor induction of solid-state
conversions to different crystalline polymorphs, which was observed for chlorpropamide, where
milling induced a partial conversion from the alpha (low-temperature stable) to epsilon (hightemperature stable) enantiotrope. In the case of chlorpropamide, the percent solubility reported
corresponds to the high-temperature epsilon polymorph, since conversion to the high-temperature
form occurs over the low ramp rate applied in DSC.

7.3. Results & Discussion
7.3.1.

Solubility Parameter

The initial indication that a relationship between solubility and R3m may exist was inferred
from an observed relationship between R3m and the Hansen partial solubility parameters. Data for
these parameters were collected from the literature for 10 of the 15 library API87 and PVPva, the
values for which are shown in Table 11 .
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Table 11: Solubility parameter data for select library API.
Compound

δd

δp

δh

δt

δv

Δδ

R3m

Cimetidine
Nifedipine
Propranolol
Quinidine
Sulfanilamide
Chlorpropamide
Indomethacin
Itraconazole
Ketoconazole
Tolbutamide

19.38
19.6
19.52
20.72
20.87
20.7
22.19
21.66
21.55
19.53

10.87
5.84
3.35
5.37
9.61
8.04
5.97
10.94
9.63
6.97

10.77
8.59
11.04
11.97
14.19
9.78
9.42
10.64
10.2
9.13

24.69
22.19
22.72
24.52
27
24.31
24.84
26.5
25.72
22.61

22.22
20.45
19.81
21.40
22.98
22.21
22.98
24.27
23.60
20.74

1.14
5.43
7.92
6.40
5.05
3.44
5.97
2.62
2.82
4.23

0.403
0.568
0.342
0.593
0.595
0.927
0.737
0.872
0.814
0.687

Experimental
Observation
(melt-quench)
0
0
0
0
0
1
1
1
1
1

PVPva

19.23

11.15

9.67

24.37

22.23

N/A

N/A

N/A

All API Hansen partial solubility parameters were obtained from Thakral et al.87
PVPva Hansen partial solubility parameters were obtained from Kitak et al.207
0 = Failed to Disperse, 1 = Successfully Dispersed
δd, δv, δh: Hansen partial solubility parameters (dispersion, polar, hydrogen-bond, respectively),
δv = volume dependent solubility parameter, δt = Hildebrand total solubility parameter
Solubility Parameter units: (J/cm3)1/2

Plots of the Hansen partial solubility parameters are shown in Figure 48a, b, and c. In Figure 48c,
the API that successfully dispersed are closest to the PVPva value for the Hansen partial solubility
parameter for hydrogen bonding (δh), as indicated by the green shaded area. All compounds with
R3m <0.65 failed to disperse in PVPva. This corresponded with the same compounds having a
difference in δh relative to PVPva greater than approximately 1 (J/cm3)1/2. Those API outside this
box, and therefore, having a greater difference in δh, failed to form an ASD in PVPva by melt
quenching.
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Figure 48: The relationship between the Hansen Partial Solubility Parameters and R3m. (a) The
dispersion Hansen partial solubility parameter, (b) the polar Hansen partial solubility parameter,
(c) the hydrogen-bond Hansen partial solubility parameter, and (d) the 3-D solubility parameter,
where the Euclidean distance between PVPva and the selected drugs is determined (0 is PVPva).

Additionally, there appeared to be a potential inverse correlation between R3m and the 3D
solubility parameter (Δδ), as seen in Figure 48d. The 3D solubility parameter is the Euclidean
distance between all three partial solubility parameters and the values for PVPva (Equation (25)).

2

(25)

Δδ = √((δd API − δd polymer ) + (δp

API

− δp

2

polymer

2

) + (δh API − δh polymer ) )

While the observed potential relationship between the Hansen partial hydrogen bonding
solubility parameter and R3m was promising, it is important to note that the application of
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solubility parameters for the prediction of solubility and miscibility has several limitations (see
Chapter 2, section 2.2.3. ). To further investigate the potential relationship between R3m and
solubility, the dissolution end point method was applied for a select number of API which spanned
the range of R3m.

7.3.2.

Dissolution End-Point (Tend) Method

The ultimate goal of this research was to relate the solubility of API in PVPva to temperatures
of interest in order to assess the relationship between solubility and the molecular descriptor R3m.
It was hypothesized that if a correlation was found between the descriptor and experimentally
determined solubility of API in PVPva, this could indicate that R3m captures useful
thermodynamic information. This could help to explain why R3m appears to be particularly useful
for predicting ASD formation with this specific polymer.
Representative experimental results for the determination of the optimal milling duration and
the dissolution end-point is shown in Figure 49 and Figure 50 . The temperature at which the
extrapolated solubility curve intersects with the Tg of the API-polymer mixture was of interest.
This temperature is expected to be useful since it is the temperature corresponding to the
equilibrium solubility at which thermodynamic forces are theoretically overcome by kinetics
owing to the significant change in molecular mobility. The solubility of the API in polymer at
room temperature is also of interest because this is the temperature at which the co-solidified
mixtures were stored and characterized. However, extrapolation to room temperature is tenuous
due to the significant change in mobility that is expected for all of the drugs examined as part of
our library. At Tg, the mobility is expected to change significantly, which will subsequently shift
the factors important to ASD formation from thermodynamics to kinetics. Specifically, below Tg,
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thermodynamics will no longer be as important due to the reduced mobility of the system. Even if
the solidified mixture is thermodynamically driven to phase separate at these lower temperatures,
the reduced mobility will significantly extend the timescale of phase separation. This significant
increase in the impact of kinetics below Tg is expected to result in increased uncertainty in
solubility predictions as the extrapolation continues significantly below the glass transition
temperature.
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Figure 49: Example data collected during optimization of cryomilling duration. Ketoconazole: PVPva 50:50% w/w. (a) PXRD data, (b)
DSC data, (c) a bar plot of replicate Tend measurements at different milling durations. No significant changes in the experimentally
determined dissolution end point are observed after 16 minutes of cryomilling.
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Figure 50: Example data collected during optimization of cryomilling duration. Indomethacin: PVPva 50:50% w/w. (a) PXRD data, (b)
DSC data, (c) a bar plot of replicate Tend measurements at different milling durations. The optimal milling duration was identified as 12
minutes in this case. After 12 minutes, the endotherm became more difficult to analyze, and at 24 minutes of milling the endotherm was
essentially absent, and therefore Tend could not be determined.

A limitation of the dissolution end-point method is the increased kinetic inhibition to
mixing as the temperature of interest approaches the Tg of the polymer. It is assumed that mixing
will occur on the timescale of the experiment, however, polymer viscosity will limit mixing near
its Tg. As a result, the range of temperatures over which Tend data can be collected is limited by the
viscosity of the polymer. In order to determine the solubility at the temperatures of interest, it is,
therefore, necessary to extrapolate the data. In this study, the extrapolation was performed using a
linear fit of the natural log of the mole fraction solubility of the API (ln) vs. the inverse of the
dissolution end-point temperature (i.e., a van’t Hoff plot).
At its Tm, the API will be in equilibrium between its crystalline and liquid states. The
presence of an impurity (polymer) will result in a change in entropy and enthalpy impacting the
chemical potential of the API relative to the pure state. This shifts the API solid-liquid equilibrium
and subsequently depresses the observed melting point. Experimental observations of melting
point depression can be used to reveal the specific relationship between API mole fraction and
temperature (Equation (26)), where a plot of the natural log of mole fraction solubility (X) vs. the
reciprocal temperature (1/T) is expected to yield a linear relationship.

ln(X) = −

(26)

ΔHmix
RT

+

ΔSmix
R

A linear fit of this relationship can then be applied to extrapolate to temperatures for which
experimental data cannot be obtained owing to kinetic factors, which inhibit API-polymer mixing
(e.g., those approaching the Tg).
The experimental results for the 5 API of interest are given in Figure 51, below, where a
van’t Hoff plot and a linear fit of data is applied. In general, the fit was good (R2 > 0.94 for all API
modeled). The slope and intercept obtained from linear fits was used to extrapolate the solubility
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to lower temperatures. Figure 52 shows the application of the van’t Hoff fit, and the subsequent
extrapolation to lower temperature.

Figure 51: Experimental data for the determination of API solubility in PVPva at different
temperature using the Van’t Hoff equation. API plotted as triangles are those API which failed to
disperse in PVPva by melt-quenching, while circles indicate API that successfully formed ASDs
by melt-quenching.

209

Figure 52: Experimental data for the determination of API solubility in PVPva at different
temperatures. The dotted lines show the Van’t Hoff extrapolation to lower temperature. Triangles
are used for API which had previously been show to fail to form an ASD in PVPva by meltquenching, while circles indicate API that had successfully formed an ASD in PVPva. Plots of the
predicted Tg for each API determined using the Couchman-Karasz equation are shown as solid
and dot-dash lines.
The van’t Hoff extrapolation and the predicted Tg values were then used to determine the
percent solubility at the temperature of interest. This is illustrated in Figure 76 in the appendix.
Figure 53 shows the percent weight solubility of the specified drug in PVPva as determined by
extrapolation at the predicted Tg. Drug loadings are indicated as circles for 15% w/w API and
squares for 75% w/w API preparations. Points above the blue and red lines indicate supersaturation
at 15% and 75% w/w API drug loading, respectively. The difference in solubility between these
concentrations is a result of the change in predicted Tg caused by changes in the concentration of
drug present. For example, the predicted solubility for all preparations at 75% w/w drug loading
is lower because the Tg of the API, which is the primary ingredient in these mixtures, will plasticize
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the mixture, resulting in a lower predicted Tg. This results in the solubility curve being extrapolated
to a greater extent to the identified lower temperature, and, therefore, a lower solubility relative to
the respective 15:85% w/w API:polymer mixtures. As noted previously, the extrapolated solubility
at the predicted Tg is of interest because this is the temperature at which the impact of
thermodynamics is expected to be overcome by kinetic effects as the mixture solidifies.

Figure 53: Weight percent solubility at the predicted glass transition temperature for 15% (circles)
and 75% (squares) drug loading vs. R3m. The horizontal blue and red lines are included to
reference the drug loading of interest (15 and 75% API). The vertical dashed line shows the
previously established R3m boundary (R3m = 0.65).
It was posited that, if the R3m value for an API correlated with that drug’s solubility in
PVPva, then it was expected that API having R3m values below 0.65 (cimetidine and nifedipine)
would have lower solubility in PVPva relative to the API with R3m > 0.65 (indomethacin,
ketoconazole, and chlorpropamide). This pattern was observed for 4/5 API investigated, with
ketoconazole being the exception. Cimetidine and nifedipine both had lower solubilities in PVPva
at the mixed Tg, relative to indomethacin and chlorpropamide. Correspondingly, the driving force
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to recrystallize as they cooled during quenching should be greater for cimetidine and nifedipine,
which was consistent with the observation that 24 h after preparation these samples had evidence
of crystallization, and were categorized as not dispersable in PVPva. In contrast, the indomethacin
and chlorpropamide both were more soluble in PVPva at the mixed Tg, suggesting that during
preparation, the driving force for recrystallization should be lower than for cimetidine and
nifedipine. Again, this was consistent with the categorization of indomethacin and chlorpropamide
as dispersable in PVPva, given persistence as an ASD without evidence of recrystallization at the
time of characterization.
Taken together, these data might suggest that compounds having R3m<0.65 (not
dispersable in PVPva) should have poorer solubility in the polymer relative to compounds having
R3m>0.65. Instead, ketoconazole, stands as an exception, having the lowest solubility in PVPva
among the 5 compounds studied, and according to the results, was supersaturated at Tg even at the
lower 15% drug loading. This was unexpected because ketoconazole was observed to successfully
form an ASD in PVPva by melt-quenching at both 15% and 75% drug loadings, and had an R3m
= 0.814. Currently, it is hypothesized that the large molecular weight and overall size of
ketoconazole molecules relative to the other compounds tested may have contributed to a lower
molecular mobility and diffusivity in the PVPva matrix. Given experimental controls to facilitate
mixing of molten ketoconazole and PVPva above the melting temperature of the drug, the
contributions of its relative size and mass likely help to kinetically inhibit crystallization as the
mixture is cooled. Despite having the poorest solubility in the polymer, these observations are still
consistent with the categorization of ketoconazole as “dispersable” in PVPva, as all its preparations
persisted as an ASD, without evidence of recrystallization within 24 h, at the time of initial
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characterization. This premise is the focus of future research, in which the solubility of other API
in the library will be investigated to determine if this trend is general.
Following a comparison of trends in R3m magnitude, dispersability observations, and
solubility in PVPva, it appears that solubility of drug in polymer alone could not fully explain the
successful formation of ASDs, and serve as a more physically intuitive surrogate for predictions
using R3m. This result supports the distinction between dispersability and solubility, where kinetic
factors such as the contribution of molecular mobility to nucleation in the solid state are also
expected to contribute to persistence as an ASD, and categorizations as dispersable. The
ketoconazole exception to the trends with respect to API solubility in PVPva and dispersability
predictions suggest that, as a complex molecular descriptor, R3m may better encapsulate the
physicochemical information (potentially both thermodynamic and kinetic) important for ASD
formation in this specific polymer, which solubility (a strictly thermodynamic quantity) alone is
unable to capture. Future work will focus on the expansion of the solubility dataset for the API
library, as well as the determination of miscibility of the library API in PVPva by determination
of the Flory-Huggins interaction parameter.

7.4. Conclusions
The results described in this chapter confirm that solubility alone cannot fully explain the
successful formation of ASDs. This supports the idea that dispersability and solubility are distinct.
While solubility is a thermodynamic quantity, dispersability is expected to be impacted by both
thermodynamic and kinetic factors. The relationship between R3m and dispersability in PVPva
indicate that the complexity of R3m is more useful for the prediction of ASD formation than
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solubility due to its ability to better capture physicochemical information that is important for ASD
formation.
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Chapter 8. Summary
The central hypothesis of this work has been that there exists a combination of materials
properties that correlates with the probability that an ASD will form in PVPva. Since molecular
descriptors are mathematical representations of properties of a molecule, it was hypothesized that
they can be successfully applied to predict the formation of amorphous solid dispersions. The
research described in the preceding chapters has supported this hypothesis, and points toward the
application of R3m as a useful tool for formulation development. Successful future development
of ASDs is dependent on continued research to better understand the applicability of these
predictive methods, as replacements for the experimental trial-and-error methods of the past.
Ultimately, methods that can rapidly direct scientists toward formulations having greater
probability of success will prove beneficial to both pharmaceutical development and human health.
R3m was shown to have statistically significant performance for the prediction of
dispersability of a library of up to 18 API in PVPva, prepared at two different concentrations, using
two different preparation methods. Dispersability predictions using the R3m model were 100%
accurate for dispersions prepared by melt-quenching. All API having an R3m > 0.65 were
dispersable in PVPva, at concentrations of both 15% w/w and 75% w/w, while API having an R3m
< 0.65 failed to disperse in this polymer. R3m predictions were less accurate for dispersions
prepared using a solvent-evaporation method, however, the prediction accuracy remained high and
models showed statistical significance (p-value < 0.05). A fixed R3m boundary of 0.65 resulted in
an overall prediction accuracy of 87.5%. These data suggest that R3m is useful for the prediction
of ASD formation, and prompted an investigation into the meaning of R3m in order to improve
model interpretability, and to advance scientific understanding of the formation of ASDs.
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The subsequent investigation into the physicochemical interpretation of R3m concluded
that the descriptor contains information about the size and shape of an API molecule, the number
and relative positions of intramolecular atoms in 3D space (with increasing significance for heavier
atoms), and increasing topological connectivity which indicates increased branching. In general,
large molecules, having increased topological connectivity (reflective of increased branching),
molecules having more heavy atoms (higher molecular density), and with heavy atoms furthest
from the geometric center (on the periphery of the 3D conformation of the molecule) have higher
R3m values, suggesting these attributes conform to R3m>0.65, which corresponds to API which
are dispersable in PVPva. This interpretation of the descriptor was further supported by multiple
linear regression of R3m against simpler, more intuitive descriptors and properties. A moderate
correlation was observed between MW, molecular density, and R3m. The size and shape of API
molecules is believed to be important to the kinetics of ASD formation. The relative location of
heavy atoms is expected to increase the likelihood of non-covalent interactions with the polymer,
since the atoms heavier than carbon in the API library considered are more electronegative. Heavy
atoms which are far from the geometric center of the molecule, and close to each other in Euclidean
space, are more likely to result in a larger R3m value, and also increase the likelihood of an
increased dipole moment in that molecule. This is expected to increase the likelihood of noncovalent interactions (i.e., dipole-dipole interactions), and thereby impact thermodynamic
parameters such as the enthalpy of mixing. The formation of ASDs is a complex phenomenon that
involves thermodynamics and kinetics. As a result, individual parameters are generally insufficient
to capture sufficient information for the prediction of ASD formation. In contrast, R3m is more
useful despite also being a single parameter because it contains more information as a result of its
derivation from several matrices which contain physically and chemically relevant data.
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Ultimately, the argument that R3m captured useful geometric information about the API
was further supported via comparisons between 3D conformations obtained using the CORINA
algorithm, crystal structure data, and MD simulations. Results showed that the variations in R3m
between these conformations was generally low for each API. A large majority (86%) of an
expanded dataset of API had a difference in R3m≤0.1, with a maximum difference in R3m equal
to 0.28. The average absolute difference between CORINA and both the mean and median MD
R3m values was 0.03, and the largest difference between median MD R3m and CORINA R3m
values was 0.11. Ultimately, these results showed that the predicted 3D conformation originally
used to calculate R3m is sufficiently representative of the geometry of an API in its amorphous
conformation as it forms an ASD in PVPva. However, the potential for large conformational
changes to impact the R3m value should not be ignored, since these large variations, although less
common, can have significant impact on predictions of ASD formation, particularly if the
calculated R3m value lies near the model boundary. Ultimately, this study further supported the
idea that R3m captures relevant 3D information about the API. The incorporation of additional
conformational variability into the model has improved confidence in the model boundary, and
inclusion of this variability helped to capture a more realistic distribution of R3m values, and will
likely improve future predictions.
The successful formation of an ASD is dependent on both thermodynamic and kinetic
factors. Solubility is an important aspect of ASD formation because it gives a measure of the
thermodynamic driving force for phase separation and recrystallization. Attempts to correlate R3m
with solubility were unsuccessful, suggesting that solubility alone cannot fully explain the
successful formation of ASDs. This supports the idea that dispersability and solubility are distinct.
While solubility is a thermodynamic quantity, dispersability is expected to be impacted by both
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thermodynamic and kinetic factors. The relationship between R3m and dispersability in PVPva
indicate that the complexity of R3m may better encapsulate physicochemical information
important for ASD formation which solubility alone is unable to capture.
Ultimately, the application of the R3m model may help to speed formulation development
for ASDs containing PVPva. This model also points toward the potential application of molecular
descriptors in similar models for other polymers. This work builds toward a future research goal
of building a formulation development tool for ASDs. Such a tool (envisioned in Figure 2) could
be used to rapidly identify an appropriate polymer for a new chemical entity with minimal
experimentation, and thereby aid ASD development by reducing experimental burden, time to
market, and development costs.
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Appendix

Figure 54: Evidence of Terfenadine polymorphs. DSC method adapted from Leitǎo et al.154
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Figure 55: Tolbutamide polymorphs. (a) Tolbutamide was received as the Form I polymorph, as
evident when comparing the experimental PXRD pattern with the reference pattern (CSDZZZPUS02).155, 156 (b) After several months of storage, Tolbutamide appears to recrystallize as the
Form II polymorph, as shown by comparison of the experimental PXRD pattern to the reference
pattern (CSD-ZZZPUS15).156, 208
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Table 12: Results Summary – Melt Quench 75:25% w/w (API: PVPva). The final inferences are
made based on observations made from the suite of analytical techniques.
Melt Quench 75:25 %w/w
PXRD
Diffraction
PDF
Combined Inference
Peaks (API)
Propranolol HCl
Not definitive
Yes
N/A
Failed to Disperse
Melatonin
Not definitive
No
Phase Separated
Failed to Disperse
Cimetidine
Not definitive
No
Phase Separated
Failed to Disperse
Terfenadine
Not definitive
Yes (1/3)
Phase Separated
Failed to Disperse
Cloperastine HCl
Not definitive
Yes
N/A
Failed to Disperse
Nifedipine
Miscible
Yes (2/3)
Phase Separated
Failed to Disperse
Sulfanilamide
Immiscible
Yes
N/A
Failed to Disperse
Quinidine
Immiscible
No
Phase Separated
Failed to Disperse
Tolbutamide
Miscible
No
Dispersed
Dispersed
Indomethacin
Miscible
No
Dispersed
Dispersed
Miscible
No
Dispersed
Dispersed
Felodipine
Itraconazole
Miscible
No
N/A
Dispersed
Ketoconazole
Not definitive
No
Dispersed
Dispersed
Chlorpropamide
Miscible
No
Dispersed
Dispersed
Bicalutamide
Not definitive
No
Dispersed
Dispersed
N/A: Not applicable. Amorphous API could not be prepared with sufficient physical stability.
API

DSC

Table 13: Results Summary – Melt Quench 15:85% w/w (API: PVPva). The final inferences are
made based on observations made from the suite of analytical techniques.
API

DSC

Propranolol HCl
Cimetidine
Melatonin
Terfenadine
Cloperastine HCl
Nifedipine
Quinidine
Sulfanilamide
Tolbutamide
Indomethacin
Ketoconazole
Itraconazole
Chlorpropamide
Felodipine
Bicalutamide

Partially Miscible
Partially Miscible
Partially Miscible
Partially Miscible
Partially Miscible
Partially Miscible
Partially Miscible
Partially Miscible
Miscible
Miscible
Miscible
Miscible
Miscible
Miscible
Miscible

Melt Quench 15:85 %w/w
PXRD
HSM
Diffraction
(birefringence)
Y/N (API)
ND
N
Trace
N
ND
N
ND
N
Trace
N
ND
N
Trace
N
Trace
N
ND
N
ND
N
ND
N
ND
N
ND
N
ND
N
ND
N

PDF

Failed to Disperse
Failed to Disperse
Failed to Disperse
Failed to Disperse
Failed to Disperse
Failed to Disperse
Failed to Disperse
Failed to Disperse
Dispersed
Dispersed
Dispersed
Dispersed
Dispersed
Dispersed
Dispersed
ND: None Detected.
N/A: Not applicable. Amorphous API could not be prepared with sufficient physical stability.
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N/A
Dispersed
Phase Separated
Dispersed
Dispersed
Dispersed
N/A
N/A
Dispersed
Dispersed
Dispersed
Dispersed
Dispersed
Dispersed
Dispersed

Combined
Inference

Table 14: Results Summary – Solvent Evaporation 75:25% w/w (API: PVPva). The final
inferences are made based on observations made from the suite of analytical techniques.
Solvent Evaporation 75:25 %w/w
API

DSC

HSM
(birefringence)

PXRD
Diffraction Y/N
(API)

PDF

Propranolol HCl
Cimetidine
Melatonin
ABT-102
Terfenadine
Cloperastine HCl
Nifedipine
Quinidine
Sulfanilamide
ABT-072
Tolbutamide
Indomethacin
Ketoconazole
Chlorpropamide
Felodipine
Bicalutamide

Immiscible
Partially Misc.
Partially Misc.
Immiscible
Miscible
Immiscible
Miscible (2/3)
Immiscible
Immiscible
Partially Misc.
Partially Misc.
Miscible
Miscible
Miscible
Miscible
Miscible

Yes
None Detected
Yes (minor)
Yes
None Detected
Yes
Yes
Yes
Yes
Yes (minor)
Yes (2/3)
None Detected
None Detected
None Detected
None Detected
None Detected

Yes
No
Yes (2/2, minor)
Yes
No
Yes
Yes
Yes
Yes
No
No (2/3)
No
No
No
No
No

N/A
Dispersed
N/A
N/A
Dispersed
N/A
N/A
N/A
N/A
N/A
N/A
Dispersed
Dispersed
Dispersed
Dispersed
Dispersed

Combined
Inference

Failed to Disperse
Failed to Disperse
Failed to Disperse
Failed to Disperse
Dispersed
Failed to Disperse
Failed to Disperse
Failed to Disperse
Failed to Disperse
Failed to Disperse
Failed to Disperse
Dispersed
Dispersed
Dispersed
Dispersed
Dispersed
ND: None Detected.
N/A: Not applicable. Amorphous API could not be prepared with sufficient physical stability.
Note: Itraconazole and ABT-348 had insufficient solubility in methanol for preparation at this concentration.
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Table 15: Results Summary – Solvent Evaporation 15:85% w/w (API:PVPva). The final inferences
are made based on observations made from the suite of analytical techniques.
API

DSC

Propranolol HCl
Cimetidine
Melatonin
ABT-102
Terfenadine
Cloperastine HCl
Nifedipine
Quinidine
Sulfanilamide
ABT-072
Tolbutamide
ABT-348 †
Indomethacin
Itraconazole †
Ketoconazole
Chlorpropamide
Felodpine
Bicalutamide

Immiscible
Immiscible
Immiscible
Miscible
Miscible
Immiscible
Miscible
Immiscible
Immiscible
Miscible
Miscible
Immiscible
Miscible
Immiscible
Miscible
Miscible
Miscible
Miscible

Solvent Evaporation 15:85 %w/w
PXRD
HSM
Diffraction
PDF
(birefringence)
Y/N (API)
ND
No
N/A
ND
No
Dispersed
ND
No
Dispersed
ND
No
N/A
ND
No
Dispersed
ND
No
Dispersed
ND
No
Dispersed
Yes (2/3)
Yes (2/3)
N/A
ND
No
N/A
ND
No
N/A
ND
No
Dispersed
Yes
Yes (3/3)
N/A
ND
No
Dispersed
Yes (1/3)
No
Phase Separated
ND
No
Dispersed
ND
No
Dispersed
ND
No
Dispersed
ND
No
Dispersed

Combined
Inference

Failed to Disperse
Failed to Disperse
Failed to Disperse
Dispersed
Dispersed
Failed to Disperse
Dispersed
Failed to Disperse
Failed to Disperse
Dispersed
Dispersed
Failed to Disperse
Dispersed
Failed to Disperse
Dispersed
Dispersed
Dispersed
Dispersed
ND: None Detected.
N/A: Not applicable. Amorphous API could not be prepared with sufficient physical stability.
† Lowest Solubility in MeOH.
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Table 16: (a) Solubility rankings were assigned based on the classifications proposed in USP 34.
(b) Solubility rankings are shown for the library compounds. ABT-348 and Itraconazole had the
lowest solubility in methanol.
(a)
Description
Very Soluble
Freely Soluble
Soluble
Sparingly Soluble
Slightly Soluble
Very Slightly Soluble
Practically Insoluble

Category
1
2
3
4
5
6
7

Approx. Volume (ml) of Solvent
Needed to Dissolve 1g of Solute
Less than 1
1 to 10
10 to 30
30 to 100
100 to 1000
1000 to 10,000
Greater than 10,000

(b)
API
Terfenadine
Quinidine
Indomethacin
Propranolol HCl
Cimetidine
Tolbutamide
Melatonin
Cloperastine HCl
Felodipine
Ketoconazole
Chlorpropamide
ABT-102
Nifedipine
Sulfanilamide
ABT-072
Bicalutamide
ABT-348
Itraconazole

Solubility Group
Very Soluble
Very Soluble
Very Soluble
Freely Soluble
Freely Soluble
Freely Soluble
Soluble
Soluble
Soluble
Soluble
Soluble
Sparingly Soluble
Sparingly Soluble
Sparingly Soluble
Slightly Soluble
Slightly Soluble
Very Slightly Soluble
Very Slightly Soluble
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Category
1
1
1
2
2
2
3
3
3
3
3
4
4
4
5
5
6
6

Table 17: Modeling statistics for solvent evaporation R3m models. The abbreviation LR refers to
the likelihood ratio. Removing the most poorly soluble compounds (Itraconazole and ABT-348)
resulted in an increased likelihood ratio, and therefore, lower p-value. However, removal of these
compounds from the model is inadvisable due to the potential for bias.
Method
SE (15:85)
SE (75:25)
SE (15:85) - exclusions

LR (χ²)
4.65*
12.36‡
10.11†

Regression Equation
logit P(Y) = -3.96 + 6.48(R3m)
logit P(Y) = -12.47 + 18.16(R3m)
logit P(Y) = -10.99 + 19.59(R3m)

Misclassification Rate
27.8% (n = 18)
6.3% (n=16)
18.8% (n = 16)
* p-value < 0.05
p-value < 0.005
‡
p-value < 0.0005
†

Table 18: Statistical assessment of solvent evaporation models with solubility rank as an additional
covariate. The drop in deviance tests indicated that adding solubility rank had no statistically
significant improvement over R3m alone.
Method

Regression Equation

SE (15:85)

logit P(Y) = -3.49 - 0.458(SolubilityRank) +
8.102(R3m)
logit P(Y) = -12.61 - 1.68(SolubilityRank) +
23.64(R3m)

SE (75:25)

LR
(χ²)
6.2*

Misclassification
Rate
22.2% (n = 18)

Drop in
Deviance (χ²)
1.56

15.01†

6.3% (n=16)

2.65
*p-value < 0.05
< 0.001

†p-value
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Figure 56: Multiple logistic regression model of 15% w/w API in PVPva with R3m and solubility
ranking as covariates. (a) A 3-D plot showing the logistic regression surface that results from
inclusion of solubility ranking as a covariate. (b) Comparison of univariate (R3m only) and
multivariate (R3m and solubility ranking) model statistics. AUC (ROC) = area under the receiver
operating characteristic curve.

Figure 57: Multiple logistic regression model of 75% w/w API in PVPva with R3m and solubility
ranking as covariates. (a) A 3-D plot showing the logistic regression surface that results from
inclusion of solubility ranking as a covariate. (b) Comparison of univariate (R3m only) and
multivariate (R3m and solubility ranking) model statistics. AUC (ROC) = area under the receiver
operating characteristic curve.
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Figure 58: Modeling of dichotomous classifications of API dispersability in PVPva for cosolidified mixtures prepared by (a) melt quenching and (b) solvent evaporation, against the
molecular descriptor R3m. Separation is observed in the melt quench models; all API having R3m
> 0.65 were dispersable in PVPva. Logistic regression was used to model solvent evaporation
behavior. Labels have been added to compounds having: variations between preparation methods,
outcomes which vary with concentration, and/or relatively low solubility in methanol. See section
4 (discussion) for additional details.
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Table 19: List of all 176 drugs used for multiple linear regression of molecular descriptors. Library API are indicated in bold.
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ABT-072
agomelatine
aspirin

ABT-102
albendazole
atorvastin

ABT-348
allopurinol
azathioprine

aceclofenac
alprazolam
azithromycin

acetaminophen
amitriptyline
benidipine

acetazolamide
amoxicillin
bicalutamide

acyclovir
aripiprazole
bisacodyl

cabergoline
cefixime
chlorpropamide
cloperastine
diclofenac
eprosartan

caffeine
cefotiam
cilostazol
clopidogrel
diloxanide
erythromycin

candesartan cilexetil
cefpodoxime
cimetidine
clozapine
diovan
esomeprazole

carbemazepine
cefuroxime axetil
ciprofloxacin
curcumin
duloxetine
ethyl icosapentate

carvedilol
celecoxib
clarithromycin
dapsone
ebastine
ezetimibe

cefdinir
chloroquine
clofazimine
dexamethasone
efavirenz
famotidine

cefditoren
chlorpromazine
clomipramine
diazepam
epalrestat
felodipine

fenofibrate
gliclazide
ibuprofen
isotretinoin
lisdexamfetamine
medroxyprogesterone

flurbiprofen
glimepiride
imatinib
itraconazole
lopinavir
melatonin

fluvoxamine
glipizide
imipramine
ketoconazole
loratadine
meloxicam

folic acid
griseofulvin
indapamide
ketoprofen
lorazepam
menatretrenone

furosemide
haloperidol
indinavir
lamotrigine
lovastatin
mesalamine

gefitinib
hydrochlorothiazide
indomethacin
levodopa
manidipine
metaxalone

glibenclamide
hydroxyzine
irbesartan
linezolid
mebendazole
methylphenidate

metoclopramide
naproxen
nimesulide
phenobarbital
propylthiouracil
rebamipide

metronidazole
nelfinavir
nitrofurantoin
phenytoin
pyrantel
retinol

modafinil
nevirapine
olanzapine
pioglitazone
pyrimethamine
risperidone

mosapride
nicergoline
orlistat
pranlukast
quetiapine
ritonavir

mycophenolate mofetil
niclosamide
oxcarbazepine
praziquantel
quinidine
rofecoxib

nabumetone
nifedipine
oxycodone
pregabalin
raloxifene
rosuvastatin

nalidixic acid
nilvadipine
phenacetin
propranolol
ramelteon
salbutamol

salmeterol
sulfasalazine
teprenone
triflusal
zaltoprofen

serotonin
sulpiride
terfenadine
trimethoprim

simvastatin
sultamicillin
theophylline
ursodeoxycholic acid

spironolactone
tacrine
ticlopidine
valproic acid

sulfadiazine
tacrolimus
tocopherol nicotinate
valsartan

sulfamethoxazole
tamoxifen
tolbutamide
verapamil

sulfanilamide
telmisartan
tosufloxacin
warfarin

Figure 59: Bicalutamide. (a) 2D structure with atom numbers labeled. Visual representation
(matrices and bar plots) of data relevant to the calculation of R3m: (b) molecular matrix, (c)
topology matrix, (d) geometry matrix, (e) influence/distance matrix, (f) bar plot of weighted mass,
(g) contribution to R3m, (h) bar plot of leverages.
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Figure 60: Chlorpropamide. (a) 2D structure with atom numbers labeled. Visual representation
(matrices and bar plots) of data relevant to the calculation of R3m: (b) molecular matrix, (c)
topology matrix, (d) geometry matrix, (e) influence/distance matrix, (f) bar plot of weighted mass,
(g) contribution to R3m, (h) bar plot of leverages.
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Figure 61: Cimetidine. (a) 2D structure with atom numbers labeled. Visual representation
(matrices and bar plots) of data relevant to the calculation of R3m: (b) molecular matrix, (c)
topology matrix, (d) geometry matrix, (e) influence/distance matrix, (f) bar plot of weighted mass,
(g) contribution to R3m, (h) bar plot of leverages.
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Figure 62: Cloperastine. (a) 2D structure with atom numbers labeled. Visual representation
(matrices and bar plots) of data relevant to the calculation of R3m: (b) molecular matrix, (c)
topology matrix, (d) geometry matrix, (e) influence/distance matrix, (f) bar plot of weighted mass,
(g) contribution to R3m, (h) bar plot of leverages.
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Figure 63: Felodipine. (a) 2D structure with atom numbers labeled. Visual representation (matrices
and bar plots) of data relevant to the calculation of R3m: (b) molecular matrix, (c) topology matrix,
(d) geometry matrix, (e) influence/distance matrix, (f) bar plot of weighted mass, (g) contribution
to R3m, (h) bar plot of leverages.
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Figure 64: Indomethacin. (a) 2D structure with atom numbers labeled. Visual representation
(matrices and bar plots) of data relevant to the calculation of R3m: (b) molecular matrix, (c)
topology matrix, (d) geometry matrix, (e) influence/distance matrix, (f) bar plot of weighted mass,
(g) contribution to R3m, (h) bar plot of leverages.
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Figure 65: Itraconazole. (a) 2D structure with atom numbers labeled. Visual representation
(matrices and bar plots) of data relevant to the calculation of R3m: (b) molecular matrix, (c)
topology matrix, (d) geometry matrix, (e) influence/distance matrix, (f) bar plot of weighted mass,
(g) contribution to R3m, (h) bar plot of leverages.
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Figure 66: Ketoconazole. (a) 2D structure with atom numbers labeled. Visual representation
(matrices and bar plots) of data relevant to the calculation of R3m: (b) molecular matrix, (c)
topology matrix, (d) geometry matrix, (e) influence/distance matrix, (f) bar plot of weighted mass,
(g) contribution to R3m, (h) bar plot of leverages.
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Figure 67: Melatonin. (a) 2D structure with atom numbers labeled. Visual representation (matrices
and bar plots) of data relevant to the calculation of R3m: (b) molecular matrix, (c) topology matrix,
(d) geometry matrix, (e) influence/distance matrix, (f) bar plot of weighted mass, (g) contribution
to R3m, (h) bar plot of leverages.
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Figure 68: Nifedipine. (a) 2D structure with atom numbers labeled. Visual representation (matrices
and bar plots) of data relevant to the calculation of R3m: (b) molecular matrix, (c) topology matrix,
(d) geometry matrix, (e) influence/distance matrix, (f) bar plot of weighted mass, (g) contribution
to R3m, (h) bar plot of leverages.
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Figure 69: Propranolol. (a) 2D structure with atom numbers labeled. Visual representation
(matrices and bar plots) of data relevant to the calculation of R3m: (b) molecular matrix, (c)
topology matrix, (d) geometry matrix, (e) influence/distance matrix, (f) bar plot of weighted mass,
(g) contribution to R3m, (h) bar plot of leverages.
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Figure 70: Quinidine. (a) 2D structure with atom numbers labeled. Visual representation (matrices
and bar plots) of data relevant to the calculation of R3m: (b) molecular matrix, (c) topology matrix,
(d) geometry matrix, (e) influence/distance matrix, (f) bar plot of weighted mass, (g) contribution
to R3m, (h) bar plot of leverages.
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Figure 71: Sulfanilamide. (a) 2D structure with atom numbers labeled. Visual representation
(matrices and bar plots) of data relevant to the calculation of R3m: (b) molecular matrix, (c)
topology matrix, (d) geometry matrix, (e) influence/distance matrix, (f) bar plot of weighted mass,
(g) contribution to R3m, (h) bar plot of leverages.
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Figure 72: Terfenadine. (a) 2D structure with atom numbers labeled. Visual representation
(matrices and bar plots) of data relevant to the calculation of R3m: (b) molecular matrix, (c)
topology matrix, (d) geometry matrix, (e) influence/distance matrix, (f) bar plot of weighted mass,
(g) contribution to R3m, (h) bar plot of leverages.
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Figure 73: Tolbutamide. (a) 2D structure with atom numbers labeled. Visual representation
(matrices and bar plots) of data relevant to the calculation of R3m: (b) molecular matrix, (c)
topology matrix, (d) geometry matrix, (e) influence/distance matrix, (f) bar plot of weighted mass,
(g) contribution to R3m, (h) bar plot of leverages.
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Table 20: List of all 80 API used to examine the relationship between R3m calculated by CORINA generated 3D structures and 3D
structures obtained from the CCDC. CCDC refcodes are given in parentheses.
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acyclovir (MECWIC, MECWIC03)

diclofenac (MISBEW)

indinavir (DIJWOJ)

acetaminophen (HXACAN12)
agomelatine (WENOW, 01, 02)
albendazole (BOGFUZ, SUTWIO)
allopurinol (ALOPUR)

diloxanide (DEMDIJ)
efavirenz (AJEYAQ02, 03, 04)
epalrestat (ZIPKOA01, 02, 03)
eprosartan (SUJXUR)

linezolid (TIYQAU01, 02)
lorazepam (BEQGIN)
lovastatin (CPHAZO01)
medroxyprogesterone (MACXPR10)

phenobarbital (PHBARB07, 08, 09,
11, 12, 13)
praziquantel (TELCEU)
pyrimethamine (MUFMAB01)
raloxifene (SAQYIR)
rebamipide (ILUPEM)

alprazolam (MENMIB, MENMIB01)
amitriptyline (YOVZEO)
aripiprazole (MELFIT, 01, 03, 04,
06, 07, 08, 09)
aspirin (ACSALA14, 20)
cabergoline (SUPBEK, 01, 03)
caffeine (NIWFEED03, 04)
carvedilol (GIVJUQ, 01, 02)

erythromycin (QIFKEX, 01)
ezetimibe (QUWYIR01)

metaloxone (AXOGAW, 01)
metoclopramide (AMBZCL)

risperidone (WASTEP, 01)
ritonavir (YIGPIO02, 03)

famotidine (FOGVIG06, 07)

metronidazole (MINMET02)

rofecoxib (CAXMUJ)

fenofibrate (TADLIU01, 02)
furosemide (FURSEM13, 14, 16)
gefitinib (FARRUM02, 03)
gilbenclamide (DUNXAL01)

mosapride (ZEHSEK)
mycophenolate (WAJYUC)
nabutemone (XOCUI03, 04)
nalidixic (NALIDX01)

celecoxib (DIBBUL)

gliclazide (SUVGUL)

naproxen (COYRUD13)

clarithromycin (NAVSUY01, 02)
clofazimine (DAKXUI, 01, 02, 03)

glimepiride (TOHBUN01, 02)
glipizide (SAXFED)

nevirapine (PABHIJ01)
niclosamide (HEBFUR01)

salbutamol (BHHPHE)
simvastatin (EJEQAL, 01, 02)
spironolactone (ATPRCL01, 10)
sulfadiazine (SULDAZ07)
sulfamethoxazole (SLFNMB05, 06,
07, 08)
sulpiride (PYMSBZ11)
telmisartan (XUYHOO, 01)

clozapine (FUQMOU01)
curcumin (BINMEQ08, 09)
dapsone (DAPSUO05, 12, 15)
dexamethasone (DEXMET11)
diazepam (DIZPAM11)

griseofulvin (GRISFL10, 11)
haloperidol (HALDOL02)
hydrochlorothiazide (BANPAK)
ibuprofen (IBPRAC19)
imipramine (IMIPRC)

nimesulide (WINWOL, 02)
nitrofurantoin (LABJON01, 02)
olanzapine (UNOGIN02, 03, 04)
oxcarbazepine (CANDUR01, 02)
phenacetin (PYRAZB21)

theophylline (BAPLOT05, 06)
trimethoprim (AMXBPM12, 13)
valsartan (KIPLIG)
verapamil (CURHOM)
warfarin (BEFZES)

Figure 74: The impact of the size of the amorphous cell on the results of molecular dynamics
calculations. (a) An amorphous cell containing 40 ketoconazole molecules, (b) an amorphous cell
containing 200 ketoconazole molecules, (c) the resulting distributions of R3m after a molecular
dynamics simulation. The blue bars are for the 200 molecule simulation, resulting in 1400 R3m
values, while the orange bars are for the simulations containing 40 molecules (3 replicates for a
total of 840 R3m values).
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Figure 75: A comparison of R3m values calculated from 3-D conformations generated from the
CORINA algorithm, obtained from crystal structure data, and generated by molecular dynamic
simulations. R3m values calculated using CORINA and CCDC structures fall within the range of
values determined using molecular dynamics.

Table 21: Relevant MATLAB functions
MATLAB Function Name
R3mCalculate

Purpose
Calculate the value of R3m from an .sdf file

GetAtomCoords

Extract the 3D molecule conformations from
Materials Studio .xsd files
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Link
https://www.mathworks.com/matlabcent
ral/fileexchange/69891-r3mcalculate
https://www.mathworks.com/matlabcent
ral/fileexchange/70004-getatomcoords

Figure 76: A plot of predicted % solubility vs. Temperature. The solid lines correspond to the van’t
Hoff extrapolation. The dotted lines correspond to the Couchman-Karasz predicted Tg values. The
gray dotted lines illustrate the determination of the solubility at the temperature of interest. The
predicted glass transition temperature corresponding to the concentration of the prepared
dispersion was used to identify the relevant % solubility. These values were then used for the plot
shown in Figure 53.
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